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Abstract 
 Initial predictions of drug response and drug-drug interactions (DDIs) are made 
following high-throughput in vitro screening. Such assays are indispensible in the 
pharmaceutical industry to determine the metabolism, transport and pharmacokinetics 
of new chemical entities. However, they often fail when extrapolated to in vivo 
response due to unsuitable pharmacokinetic or pharmacodynamic prediction. The 
primary aim of this thesis was to investigate and understand the differences in the 
expression profiles of drug disposition genes, between transformed hepatic cell lines 
and primary human hepatocytes. Primary human hepatocytes were also analysed to 
determine uptake contribution, induction and genotype of key drug disposition-
relevant genes. 
 The loss of hepatic phenotype in HepG2 and Huh7 cells is partly due to the 
altered expression of transcriptional regulators including; chaperones, co-chaperones, 
co-activators and co-repressors. Indeed, Chapter 2 of this thesis shows lower levels of 
the Gadd45β and PGC1α gene expression in HepG2 cells corresponds to a deficient 
expression and activity of cytochrome P450 3A4 (CYP3A4), with the levels reducing 
further as cell passage increases, in comparison to primary human hepatocytes. HepG2 
cells were transfected with a novel complex transfection of Gadd45β and PGC1α with 
the aim to improve CYP3A4 activity in Chapter 3. CYP3A4 activity was improved by 
54% and induction response was enhanced in comparison to control cells with no off-
target effects. 
 Over the last decade it has become apparent that transporters can play a 
significant role in the disposition of many drugs. Organic anion transporting 
polypeptide (OATP) transporters have received considerable recent attention since 
they mediate sodium-independent uptake of a broad array of xenobiotics. A method to 
determine the specific contribution of OATP1B1 in the hepatic uptake was 
successfully optimised and applied for 5 therapeutic drugs in Chapter 4. Future 
application of this strategy is likely to have broad importance in determining relative 
contribution that individual transporters play in drug disposition. 
 To prevent accumulation and toxicity of xenobiotics, biotransformation and 
transport of foreign compounds occurs. However, these processes can be altered by 
induction or inhibition mechanisms. Rifampicin is a first line drug in tuberculosis (TB) 
treatment but it is a potent inducer of CYPs and transporters. DDIs during TB 
treatment are common but the induction potential of different rifamycins has not been 
comprehensively ranked. Chapter 5 investigated the induction potential of rifampicin, 
rifapentine and rifabutin. Rifampicin significantly induced CYP3A4, ABCB1, 
OATP1B1 and ABCC2 in primary human hepatocytes. Induction by rifabutin was 
observed for CYP3A4, OATP1B3 whilst rifapentine only significantly induced 
OATP1B1. This work serves as a basis for further study into the extent to which 
rifamycins induce key metabolism and transporter genes. 
 Nuclear receptors (NR) regulate the expression of CYPs and drug transporters 
influencing pharmacokinetics. PXR and VDR have been found to synergistically 
increase CYP3A4 expression and activity in intestinal cell lines. This effect has been 
observed in vivo with seasonal variations apparent for CYP3A4 substrates. In Chapter 
6, novel associations between vitamin D receptor polymorphisms and expression of it 
and its target genes involved in drug disposition were shown in D2 intestinal biopsies. 
 This thesis reports generation of model systems and their application to enable 
many questions to be answered relating to pharmacokinetics and DDIs. The thesis 
forms a solid platform from which to further investigate these issues in future studies. 
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CHAPTER 1 
 
General Introduction 
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1.0 Introduction 
For a drug to be effective at its site of action, adequate concentrations must reach the 
systemic circulation, following oral administration. Intestinal absorption, drug 
transport, and phase I metabolism in the liver, are considered to be the primary factors 
influencing the systemic bioavailability of xenobiotics (1). Cytochrome P450 (CYPs) 
metabolism enzymes (2), ATP-binding cassette (ABC) efflux proteins (3) and organic 
anion transporting polypeptides (OATPs), are abundantly expressed in the liver and 
intestine, and regulate the pharmacokinetics (PKs) of many drugs (4). These 
fundamental proteins are regulated by nuclear receptor (NR) transcription factors, 
which are subsequently induced or inhibited by endogenous compounds and 
xenobiotics. The complex and overlapping mechanisms involved contribute to inter-
individual variability in responses observed in the clinic.  
 
PK, is the science of how the body breaks down an active drug into metabolites or 
more simply, the effect the body has on a drug (5). Understanding the PK of a drug is 
crucial to identify potential adverse drug effects (ADRs) or drug-drug interactions 
(DDIs), but requires accurate in vitro/in vivo correlations to ensure strength in 
predictions (6). Drug absorption, distribution, metabolism and elimination (ADME) 
can be estimated and accurate doses of drug prescribed by applying mathematical 
models (7). In 2010, the American Food and Drug Administration (FDA) noted over 
900,000 hospital admissions caused by DDIs or ADRs (8).  
 
 
 
 
 11 
1.1 Pharmacokinetics 
1.1.1 ADME 
To clearly define ADME, the velocity at which a reaction occurs (rate of reaction) 
must be determined (9). Assuming clearance of a drug (A) from the body is directly 
proportional to its concentration remaining in the body, the rate of reaction is 
described as first-order (5): 
 
Equation 1.1 First order rate of reaction (k = rate constant first order) 
 
If the concentration of a drug is increased the clearance will increase accordingly. 
First order rates of reaction are used to describe the ADME of most therapeutically 
administered drugs, but not all follow this pattern. Clearance of phenytoin 
(antiepileptic) and aspirin (analgesic) are independent of concentrations administered 
(10, 11). This rate of reaction is described as zero order rate of reaction (5). For 
example, the clearance of drug (A) occurs at a constant rate: 
 
 
Equation 1.2 Zero order rate of reaction (k0 = rate constant zero order) 
 
During an overdose, a first order drug can change to a zero order process due to 
limiting factors such as, saturation of metabolism enzymes, co-factors or drug 
transporters (12).  
 
 12 
1.1.2 Pharmacokinetic models 
Animal models or primary cell assays used to study drug metabolism aim to define 
the effects that will be observed by the parent drug and/or the metabolites formed in 
humans (13). Fundamental parameters that are correlated to drug action include: 
concentration of the drug at its site of action and the duration this remains above the 
effective concentration (5). However, measuring the drug concentration at its site of 
action is difficult (e.g. practicality of access to tissue, number of tissue samples 
required and ethical constraints) and, plasma drug concentrations are frequently used 
as a surrogate (14). Understanding the PK of a drug is vital to determine the optimum 
dose and dosing frequency of a drug, and is of particular importance for drugs with a 
narrow therapeutic range (e.g. warfarin) (15). Figure 1.1 highlights some specific 
factors that may influence drug PK. 
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Figure 1.1 Mechanisms that may influence PK parameters of some clinically 
administered drugs (adapted from Lentz et al., 2013, Part I). Multiple mechanisms 
may apply for an individual drug but not all mechanisms are relevant for all drugs.
 
The impact of the body and its processes on PK is complex and dynamic. Thus, 
analysis requires models to simplify the complexity into specific 
sections/compartments to describe the fate of a drug.  
 
The one-compartment model assumes all compartments are in equilibrium with the 
central blood compartment and the drug (D) is instantly distributed throughout the 
body (Ka), with the rate of excretion equal in all tissues (kel) (16) (Figure 1.2). 
Orally	
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Figure 1.2 One-compartment model (adapted from Dhillon et al., 2006) 
 
Therefore, drug concentration (D) can be calculated if the volume of distribution (Vd) 
(17) in the compartment (whole body) is known as the drug enters the systemic 
circulation (time zero; T0). 
 
Equation 1.3 Drug concentration calculated from one compartment model 
 
Consequently, the clearance of the drug from the compartment can be determined by 
the elimination rate constant (kel), which is normally directly proportional to the 
concentration of the drug. Hence, the time taken for the drug to halve in concentration 
(t1/2) is always the same. Primary factors that are directly influenced by physiology 
can be calculated using a first order, one compartment model: 
 
 
Equation 1.4 Elimination rate constant at time zero 
 
Taking into consideration the simplicity of the one compartment model, the results 
generated for Vd, Kel and t1/2 provide a relatively useful insight into the movement, 
duration and intensity of drug action (18, 19). 
	D 		= 	T0	
Vd	
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The two compartment model adds one more layer of complexity to generate a 
hypothesis. Whilst the one compartment model assumes elimination is equal for each 
tissue, the two compartment model encompasses a central (highly perfused organs e.g. 
heart, liver, etc.) and peripheral compartment (less well perfused tissues e.g. fat) and 
estimates the elimination of a drug from each compartment (18) (Figure 1.3). 
 
  Ka1 = rate constant from central to peripheral compartment 
      Ka2 = rate constant from peripheral to central compartment 
 
Figure 1.3 Two compartment model (adapted from Dhillon et al., 2006) 
 
Although the compartments are a poor representation of the human anatomy they are 
kinetically distinct. It is assumed the central compartment represents organs that are 
highly perfused, such as, the lungs, heart, kidneys, liver and brain, whilst the 
peripheral accounts for tissues that are less well perfused (and frequently cannot 
directly eliminate drugs), such as, muscle, skin and fat. Thus, analysis must consider 
the distribution of the drug from the central to the peripheral compartment, drug 
concentration throughout and elimination of the drug (20). In contrast to the one 
compartment model, this model does not assume instant equilibrium of the drug 
between both compartments and clearance (CL) is dependent on the rate constant for 
each compartment (21). 
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The two-compartment model can be applied to generate the Vd, Kel and t1/2. However, 
since the model is more complex it is used to determine the total amount of drug in 
the body over time (area under the concentration-time curve; AUC). This 
measurement can predict the fraction of the dose reaching the systemic circulation 
(bioavailability; F) (22), assuming CL remains constant. Representative equations of 
the two-compartment model include: 
 
 A      B  
 
Equation 1.5 Two compartment model use to determine the total amount of dug in 
the body over time (A) and clearance of the drug (B)  
 
 
1.2 Drug absorption, distribution, and elimination 
1.2.1 Biopharmaceutics drug disposition classification system 
The biopharmaceutics classification system (BCS) (Figure 1.4a) is a guidance for the 
classification of drug compounds based upon their solubility and intestinal 
permeability at which point the rate limiting step can be defined (e.g. gastric clearance 
or permeability) and drugs that may be eligible for a waiver in in vivo bioequivalence 
studies can be identified (23). Following dissolution of the drug product, the BCS can 
be used to predict the rate and extent of drug absorption and elimination from the 
solid dose form (23). The BCS classifies drug substances based on solubility and 
permeability. A compound is considered highly soluble if the highest therapeutic 
concentration is dissolvable in ≤250 ml of aqueous media from pH 1-7.5 and highly 
permeable if ≥90% of the administered dose is absorbed (17). 
	D 		= 	AUC	
CL	
kel 		= 	CL	
Vd1	
	D 		= 	AUC	
CL	
kel 		= 	CL	
Vd1	
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The FDA approved application of the BCS with set boundaries to waiver in vivo 
bioequivalence assays for immediate release drugs in 2000 (24). Much controversy 
exists regarding the policy with some authorities suggesting the biowaiver should be 
extended whilst others argue it should be stopped. In 2010, the European Medicines 
Agency (EMA) extended the waiver to include class 3 compounds provided they 
dissolved very rapidly (25). Whilst the World Health Organisation (WHO) embraces 
the FDA and EMA concepts, it has further extended the waiver to include weakly 
acidic, highly permeable and highly soluble compounds at pH 6.8 (e.g. class 2) (26, 
27). 
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Figure 1.4 Diagram of; Biopharmaceutics Classification System (adapted from 
Amidon et al., 1995) (A), Biopharmaceutics Drug Disposition Classification System 
(adapted from Benet et al., 2005) (B) and manipulation of the Biopharmaceutics Drug 
Disposition Classification System to ascertain the effects of drug transporters for each 
class (C) 
 
In contrast, the biopharmaceutics drug disposition classification system (BDDCS) 
(Figure 1.4b) developed by Wu and Benet (17) is used to classify compounds into 
four groups according to characteristics that affect drug disposition and potential 
DDIs, such as the route of elimination and solubility. In contrast to the BCS (28), 
phase I and II metabolism are regarded as appropriate markers of drug permeability 
(29). 
 
Drugs metabolised ≥ 90% are characterised as class 1 or 2 depending on their 
solubility according to the BDDCS. Ambiguity arises when comparing compounds 
classified under the BCS or BDDCS (30). Tallinolol for example, is highly absorbed 
by the body and is categorised as a class 2 compound according to the BCS (31). 
However, it is poorly metabolised, thus when applying the BDDCS the drug is a class 
4 compound and transport across the membrane is fundamental (31). By applying 
either method, drug absorption can be predicted. Nonetheless, the FDA (32, 33) 
requires absorption to be estimated as a product of metabolism and not permeability. 
Hence, the BDDCS must be applied. The BDDCS predicts the extent of metabolism 
but does not give an insight into the magnitude of absorption or elimination; instead it 
implies drug transporters are key factors. The effects of drug transporters can be 
predicted following oral administration (Figure 1.4c) (34).  
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Although the classification may not be suitable for every drug, the majority can be 
fitted to the BDDCS (17). According to Figure 1.4b and 1.4c, a drug that is 
extensively metabolised, membrane permeable and has high solubility, crosses the gut 
relatively independently, therefore effects of drug transporters will be minimal (class 
1). Class 2 compounds are extensively metabolised, membrane permeable but have 
low solubility suggesting influx transporter effects are minimal in comparison to 
efflux transporters that may play a significant role. However, Fagerholm et al., 2008, 
describes how varying intensities of ‘high’ permeability may determine whether a 
drug is a transporter substrate even though it is extensively metabolised (35). Class 3 
and 4 compounds are poorly metabolised and have varying levels of solubility, 
suggesting both influx and efflux transporters play a major role in the absorption 
distribution, and elimination of the drug (28). 
 
Whilst the BCS is part of the legal framework in waiving bioequivalence studies, 
there is no consensus with the BDDCS. However, they are regarded as complimentary 
classification systems that aid in improving drug disposition and DDI predictions to 
simplify and speed up the drug development process. 
 
1.2.2 Transport 
The route of administration, dose, physiochemical properties (lipophilicity, size, pH) 
and formulation of a drug all influence its absorption and subsequent distribution and 
elimination (22). A drug (unless administered intravenously) must cross numerous 
cell membranes by passive or facilitated diffusion, active transport or pinocytosis (36) 
before it reaches the systemic circulation.  
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The majority of drugs are weak organic acids or bases but lipophilicity varies 
depending on their charge. Lipophilic compounds flow across the cell membrane with 
ease down a concentration gradient in contrast to hydrophilic compounds that do not 
penetrate the lipid bilayer with ease (37). However, glucose does not demonstrate the 
same difficulties (38). Although glucose has poor lipid solubility it rapidly passes the 
cell membrane and facilitated diffusion is thought to be the mechanism responsible. 
Facilitated passive diffusion involves a chaperone that binds to a compound to aid the 
movement through the cell membrane after which the chaperone dissociates to carry 
the next molecule (37). The process does not require energy expenditure but the 
number of carriers and compound structure limits the process. Pinocytosis is 
dependent on energy and plays a minor role in the transport of non-protein 
compounds (39, 40). The lipid bilayer creates a crevasse, traps molecules and re-fuses 
to form interior vesicles that are released allowing the molecule to penetrate the cell. 
Lastly, active transport involves the energy dependent movement of endogenous 
molecules such as, vitamins, minerals, amino acids, drugs and xenobiotics against a 
concentration gradient (37). 
 
1.2.3 Role of drug transporters 
For a drug to reach the systemic circulation it must pass liver and intestinal 
transporters, which dictate drug concentrations that undergo, first pass metabolism 
(30, 41). By controlling bioavailability and absorption of drugs, uptake and efflux 
transporters regulate the disposition and efficacy profiles of orally administered drugs 
(42). The characterisation of the efflux transporter, ATP-binding cassette sub-family 
B member 1 (ABCB1; p-glycoprotein) in 1976 (43), highlighted the need for an 
improved understanding of transporters in influencing PK (30).  
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To date, over 400 membrane bound transport proteins have been identified in the 
human genome (42). In particular, the two transporter groups outlined below have 
been found to be influential in the safety, efficacy and disposition of many drugs 
(predominantly, but not exclusively, in the liver and intestine) (44, 45). As described 
later in chapter 4, to further understand the effects these proteins have on PK, some 
transporters have been cloned, transfected or knocked-down to characterise them in 
different models. Clinical DDI studies have suggested the PK of a drug is linked to 
the cross-talk between drug transporters and metabolism enzymes, rather than the 
proteins exerting their effects independently (46). 
 
The solute carrier superfamilies, SLC and SLCO have been identified as the main 
uptake transporters involved in hepatic and intestinal drug transport of type I organic 
ions, zwitterions and cations, and type II organic anions, respectively (47). 
Transporter activity is not energy dependent, rather ion movement over the membrane 
creates a chemiosmotic gradient, which the proteins utilise to transport xenobiotics or 
endobiotics (4, 41, 48). The SLC superfamily comprises numerous proteins including, 
the organic anion transporters (OAT1; SLC22A6), organic cation transporters (OCT1; 
SLC22A1), the electroneutral cation transporters (OCTN1; SLC22A4), the 
equilibrative nucleoside transporters (ENT; SLC29) and the apical sodium dependent 
bile salt transporter (ABST; SLC10A1) (47). In contrast, the SLCO superfamily 
includes the organic anion transporting polypeptides (OATP) such as the main drug 
transporters, SLCO1B1 (OATP1B1) and SLCO1B3 (OATP1B3) (13). These 
sinusoidal membrane bound proteins transport many substrates including the 
angiotensin receptor antagonists, the HMG-CoA reductase inhibitors and protease 
inhibitors (49, 50). 
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The ATP-dependent binding cassette superfamily (ABC) constitutes a major group of 
hepatic and intestinal transporters involved in drug efflux (51). The superfamily 
comprises 49 large membrane bound proteins split into 7 main groups with all ATP-
binding cassette members (ABC), including ABCB1 (p-glycoprotein), ABCCs 
(multidrug resistance proteins; MRPs) and ABCG2 (breast cancer resistance protein; 
BCRP) (51). The utilisation of ATP equips the transporters with a key energy source 
for the movement of compounds against a concentration gradient (52). Figure 1.7a 
and b illustrates selected drug transporters present in the liver and intestine, 
respectively. 
 
Factors affecting the expression and activity of drug transporters such as, single 
nucleotide polymorphisms (SNPs), inhibitors, inducers and protein regulatory 
elements are crucial factors influencing drug absorption and distribution and will be 
discussed in more detail later (section 1.5). 
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Figure 1.7 Selected transporters expressed on the membranes of human 
hepatocytes (A) and enterocytes (B). ABC, ATP-binding cassette protein; ASBT, apical 
sodium dependent bile acid transporter; BCRP, breast cancer resistance protein; BSEP, bile 
salt export port; MATE, multidrug and toxin extrusion protein; NTCP, sodium/taurocholate 
co-transporting polypeptide; OAT, organic anion transporter; OATP, organic anion 
transporting polypeptide; OCT, organic cation transporter; OST, organic solute transporter.  
 
1.2.4 DDIs and drug transporters 
Transporters can be major determinants of PK, efficacy and safety of compounds and 
can play an important role in DDIs (53). In the context of this chapter, Table 1.1 
includes drug transporters with clinical influence and practical considerations required 
in drug development. 
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Table 1.1. Examples of human drug transporters with associated substrates and 
inhibitors involved in DDIs (data obtained from the literature, see references (4, 41, 
54-63)). 
 
Although less well recognised in comparison to CYPs, due to extent of transporter 
based DDIs, the FDA now requires investigation of drugs in vitro to determine their 
potential as substrates for the transporters outlined in Table 1.1 (64). In 2012, the 
International Transporter Consortium (ITC) gathered to collate their opinions on 
which transporters should be studied in vitro, in vivo and in clinical studies based on 
their clinical significance in determining drug absorption and distribution (ITC White 
Paper) (33, 64). The FDA updated their requirements in February 2012, stating 7 key 
transporters should be analysed. Further to the White Paper published in 2012, the 
ITC recommendations have now been updated. The ITC suggest 11 drug transporters 
should be considered for all NCEs (42). The emphasis of drug transporter analysis is 
the significance of their role on PKs. For example, inhibition of OATP1B1 by 
cyclosporine increases the AUC of pravastatin, pitavastatin and rosuvastatin, 10-fold, 
5-fold and 7-fold, respectively (4). Inhibition of ABCB1 by quinidine results in 50% 
OATP1B1 OATP1B3 OAT1 MATE1 ABCB1 ABCC2 ABCG2
Atorvastatin Rifampicin Probenecid Quinidine Cyclosporine	A Cyclosporine Estrone
Saquinavir Cyclosporine	A Novobiocin Cimetidine Quinidine Delaviridine 17β-	oestradiol
Ritonavir Ritonavir Procainamide Tariquidor Efavirenz Fomitremorgin	C
Lopinavir Lopinavir Verapamil Emtricitabine
Rifampicin
OATP1B1 OATP1B3 OAT1 MATE1 ABCB1 ABCC2 ABCG2
Estrone-3-sulfate Cholecystokinin	8 Adefovir Metformin Digoxin Glutathione	conjugates Mitoxantrone
Olmesartan Fexofenadine Zidovudine Tetraethylammonium Loperimide Methotrexate Topotecan
Valsartan Telmisartan Methotrexate N-methylpyridinium Irinotecan Etoposide Methotrexate
Pitavastatin Valsartan Ciprofloxacin Vinblastine Valsartan Irinotecan
Bromosulphophthalein Digoxin Paclitaxel Olmesartan
Fexofenadine
Selected	Drug	Transporter	Inhibitors
Selected	Drug	Transporter	Substrates
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less clearance of digoxin and an 86% increase in AUC of ritonavir (59). Similar to 
CYPs, drug transporter expression can be induced mediating effects on many victim 
drugs. For example, efavirenz and oltipraz upregulate the expression of ABCB1, 
ABCC2 and ABCG2 (63, 65). Drug transporters and DDIs are discussed further in 
Chapter 4 and 5. 
 
 
1.3 Metabolism 
1.3.1 Cytochrome P450 enzymes 
In 1947, Williams et al., identified detoxification mechanisms of the human body 
upon xenobiotic insult (66). Metabolism was categorised into 2 distinct phases: phase 
I including oxidation, reduction and hydrolysis and phase II: conjugation reactions 
(66). Williams et al., 1947, proposed the liver was the main organ responsible for first 
past metabolism and posed as a major obstacle when regulating therapeutic drug 
concentrations. The human genome codes for a superfamily of over 50 membrane-
bound, haem-containing cytochrome P450 genes (CYP) that are responsible for 
xenobiotic and endogenous compound metabolism (67). The superfamily is classified 
according to structure (>40% identical) (CYP1, CYP2, CYP3, etc.) and sub-classified 
with group members >55% identical (CYP2B, CYP2D etc.). Finally, an Arabic 
numeral is used to identify each individual enzyme (CYP1A2, CYP2D6, CYP2B2, 
etc.).  Key members of this specialised xenobiotic metabolism group include 
CYP2C9, CYP2C19, CYP1A2, CYP2B6, CYP2D6, CYP3A5 and CYP3A4 (68) 
(Table 1.2). Although CYPs are located in the majority of organs their primary 
locations are the liver and intestine (69).  
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Table 1.2. Relative liver content of selected cytochrome P450 enzymes and their 
quantitative role in drug metabolism (data obtained from the literature, see references 
(70-79)). 
 
As Williams et al., 1947 described, metabolism can occur via a number of processes; 
oxidation, reduction, hydroxylation and dealkylation. Generally, in order for drug 
oxidation to be achieved, the CYPs utilise the mono-oxygenase redox system 
(NADPH-P450 reductase) (80). The mechanism by which the NADPH-P450 
reductase provides electrons for drug oxidation and how the redox cycle is maintained 
is highly complex (81). However, drug oxidation can be achieved efficiently by the 
transfer of one molecular oxygen atom to the drug, creating a more polar hydroxyl 
containing metabolite, with the other oxygen atom forming a water molecule (81). 
 
1.3.2 CYP induction and inhibition 
Over 80% of clinically administered drugs are metabolised by CYPs, therefore their 
involvement in DDIs are common (69). Induction or inhibition of CYP expression 
and activity (CYP1A1, CYP1A2, CYP2B6, CYP2C8, CYP3A4) can alter an 
Enzyme
Abundance	of	CYP	enzyme	in	
the	liver	(%	of	total	CYP	genes)
Contribution	to	the	metabolism	of	
therapeutic	drugs	(%)	
CYP1A2 12	-	13 4	-	6
CYP2A6 1	-	10	 -
CYP2B6 3	-	5 25
CYP2C8 7 -
CYP2C9 12	-	17 10	-	11
CYP2C19 0.2	-	3 4
CYP2D6 4 25
CYP2E1 7	-	15 21	-	52
CYP3A4 30 >50
CYP3A5 29 -
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individual’s PK by as much as 5-200 fold (76). Induction is usually a result of NR-
mediated transcriptional activation where mRNA and protein expression are increased 
leading to the production of new CYP protein, which may take several days (2). 
Induction can significantly reduce the efficacy of the mediating drug (perpetrator) 
through autoinduction or of a coadministered drug (victim) by increasing their 
metabolism, resulting in decreased absorption, increased clearance and treatment 
failure (2). In contrast to induction, CYP inhibition is immediate and drug plasma 
concentrations may be increased by competitive inhibition (e.g. ketoconazole is a 
CYP3A4 substrate also) or by non-competitive inhibition (e.g. quinidine is a CYP2D6 
inhibitor but not a substrate) (82). Inhibition of CYPs generally results in supra-
therapeutic concentrations of a victim drug by a perpetrator drug, which can result in 
a higher incidence of concentration-dependent toxicities. However, most inhibition-
mediated DDIs are rapidly reversible.  
 
Levels of CYP expression and activity can also be modified by SNPs (see section 1.5 
below) and functional variants have been noted for CYP1A2, CYP2C9, CYP2D6, 
CYP2B6 and CYP3A4 (75, 83). Inhibition, induction and SNPs result in large inter-
individual variability in PK and drug response. Table 1.3 includes examples of the 
main human CYP substrates, inhibitors and inducers. 
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Table 1.3. Examples of the main human CYPs with associated substrates, inhibitors 
and inducers involved in drug metabolism (data obtained from the literature, see 
references (2, 46, 55, 68, 70, 73, 74, 78, 81, 82, 84-109)). 
 
   
1.4 Regulation of transporter and CYP expression 
1.4.1 Nuclear receptors 
Xenobiotic insult can have a profound effect on human health. Metabolism and 
transport mechanisms are regulated through the nuclear receptor (NR) superfamily of 
transcription factors (110). The superfamily recognises toxic byproducts acting as 
1A2 2B6 2C8 2C9 2D6 2E1 3A4/5
Omeprazole Rifampicin Rifampicin Rifampicin Rifampicin Ethanol Rifampicin
Tobacco Phenobarbitol Verapimil Secobarbital Dexamethasone Isoniazid Carbamazepine
Insulin Carbamazepine Rosiglitazone DehydroepiandrosteroneGlutethimide Tabacco Efavirenz
Broccoli Phenytoin Paclitaxel Dexamethasone Phenobarbitol
Bok	Choy Phenytoin
Cabbage Nevirapine
Glucocorticoids
St	Johns	Wort
Bile	acids
Vitamin	D
1A2 2B6 2C8 2C9 2D6 2E1 3A4/5
Ciprofloxacin Orphenadrine Deferasirox Valproic	acid Ritonavir Disulfiram Ritonavir
Verapamil Curcumin Gemfibrozil Amiodarone Cimetidine Diethyldithiocarbamate Clarithromycin
Cannabis Ticlopidine Lapatinib Fluconazole Haloperidol Nefazodone
Peppermint	tea ThioTEPA Trimethoprim Sulfaphenazole Quinidine Ketoconazole
Fluvoxamine Montelukast Cyclizine Bupropion Erythromycin
Cimetidine Quercetin Quercetin Histamine	H1 Saquinavir
Grapefruit	 Lovastatin Doxorubicin Indinavir
Cumin St	Johns	Wort Fluoxetine Nelfinavir
Celecoxib Fluconazole
Cimetidine
1A2 2B6 2C8 2C9 2D6 2E1 3A4/5
Haloperidol Bupropion Amiodarone Celecoxib Codeine Benzene Cyclosporine
Amitriptyline Efavirenz Carbamazepine Tolbutamide Metoprolol Theophylline Paclitaxel
Caffeine Tamoxifen Chloroquine Losartan Chlorpromazine Ethanol Ketoconazole
Tamoxifen Valproic	acid Diclofenac S-warfarin Fluoxetine Paracetamol Dapsone
Erlotinib Nevirapine Ibuprofen Phenytoin Imipramine Halothane Amitriptyline
Naproxen Methadone Paclitaxel Rosiglitazone Amitriptyline Sevoflurane Citalopram
Estradiol Cyclophosphamide Torsemide Ketamine Encainide Chlorzoxazone Haloperidol
Phenacetin Propofol Cerivastatin Suprofen Phenacetin Codeine
Warfarin Rosiglitazone Atorvastatin
Ritonavir
Selected	CYP	Inducers
Selected	CYP	Inhibitors
Selected	CYP	Substrates
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xenosensors to modulate gene transcription through a variety of processes, depending 
on their classification (111).  Although derived from one common ancestor (112), 
NRs are grouped into 6 categories according to their mechanism of action and 
distribution within a cell (Table 1.4).  
 
Table 1.4 Classification of nuclear receptors 
Class Number Nuclear receptors
Thyroid hormone receptors (TRs)
Retinoic acid receptors (RARs)
Vitamin D receptors (VDRs)
Peroxisome proliferator-activated receptor (PPARs)
Numerous orphan receptors - (Pregnane X receptor (PXR), constitutive androstane receptor (CAR))
Retinoid X receptor (RXR)
Hepatocyte nuclear factor 4 (HNF4)
Testicular receptor (TLX)
Steroid receptors (progestins, glucocorticoids (GR), mineralcorticoids (MR))
Oestrogen receptor (ER) and homologs (oestrogen related receptor (ERR))
Nerve growth factor 1B-like (NGF1B)
Nuclear receptor related 1 (NURR1)
5 Steroidogenic factor like-1 (SF1)
6 Germ cell nuclear factor (GCNF)	
1
2
3
4
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The general mechanism of NR activation is illustrated in Figure 1.8. NR substrates 
(endogenous or exogenous) cross the cell membrane and bind to the receptor. Two 
main ligand binding processes proceed: 1) the NR, (for example CAR) may be bound 
to chaperones and co-chaperones, such as, heat shock proteins (Hsp) in the cytoplasm. 
Upon ligand binding, the chaperone/co-chaperone complex dissociates allowing the 
receptor to translocate to the nucleus, forming a homo- or hetero-dimer and binding at 
upstream regulatory sites of target genes. NR co-activators, such as, the p160 family, 
are then recruited and transcriptional activation occurs (Figure 1.8a). However, if NR 
co-repressors such as, NR co-repressor 1 (NCOR1) are recruited, DNA binding and 
subsequent DNA transcription can be repressed. For some NRs an alternative pathway 
occurs (Figure 1.8b). Specifically, some NRs (PXR, TR, VDR) may already be 
located in the nucleus of the cell bound to their response elements as a homo- or 
hetero-dimer in the presence or absence of a substrate. The dimeric complex does not 
require chaperones or co-chaperones to translocate, rather co-repressors such as, 
NCOR1 suppress transcription. Upon ligand binding, the co-repressor dissociates and 
co-activator proteins are recruited, initiating gene transcription. The roles of NR co-
regulators are discussed in more detail in section 1.4.7. 
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Figure 1.8 Activation of NR upon ligand binding via dissociation of 
chaperone/co-chaperone complex (A) or co-repressor dissociation (B) 
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1.4.2 Structure of nuclear receptors 
NRs are composed of 5 distinct regions (Figure 1.9), originally defined by Krust et 
al., 1986 (113): 
 
1. The A/B region (N-terminal domain), contains transcriptional activation 
function (AF-1) primarily responsible for activation. A range of signaling cascades 
mediate the post translational phosphorylation of the region, resulting in variable 
activity (114). The A/B region varies considerably in length between NRs; for 
example, VDR has 23 amino acids compared to GR that has 550 amino acids. The 
NH2 group also differs between NRs and the region is highly susceptible to SNPs, 
thus structure definition is yet to be complete (111). However, the region 
demonstrates cell and promoter selectivity, specific to cell action and AF-1 activity 
(115). 
 
2. The DNA binding domain (DBD) contains the peptide sequence that 
specifically recognises and binds to the response elements in the target genes of the 
NR. It is a highly conserved domain comprising 2 zinc finger motifs, a C-terminal 
motif and an N-terminal motif; each motif contains 2 cysteine residues that chelate 1 
zinc ion. The C-terminal sequence elements (P, D, T, A boxes) are key for identifying 
specific response elements contributing to DNA backbone binding and acting as an 
interface for dimerisation in the DBD (116). The major groove of DNA is bound to an 
α helix located in the core of the DBD (recognition helix) to ensure specific base 
binding. In addition, a second α helix of the DBD core intertwines the carboxyl group 
of the zinc finger forming a right angle with the recognition helix (117). 
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3. The hinge region allows rotation of the NR between the DBD and the LBD. 
Without causing any steric hindrance, the hinge allows surrounding domains to alter 
their conformational structure. The region is not well conserved between NRs, 
although most contain nuclear localisation signals (NLS) or elements that contribute 
to NR localisation from cytoplasm to nucleus (118). Polymorphisms are also 
common, many of which contribute to structure alterations and may modulate co-
repressor interactions (119). 
 
4. The ligand binding domain (LBD) is formed of 12 highly conserved α helices 
(H1-H12) split into 2 regions; a COOH-terminal comprising an activation function 
motif (AF-2) that acts as an interface for ligand-dependent transcription and a 
signature motif (120). The LBD is immensely flexible in shape and size allowing the 
binding of a range of diverse chemical structures. It is responsible for Hsp interaction, 
NR dimerisation and ligand dependent transcription and upon ligand binding a 
conformational change is evident (121). 
 
5. The F region (C-terminal) is not present in all NRs and poorly conserved. The 
function of the C-terminal is not fully understood but it is thought to be responsible 
for co-activator recruitment to the LBD and ‘fine tunes’ NR activation (122). 
 
 Figure 1.9 Schematic representation of a typical nuclear receptor sequence 
COOH	NH2	
A/B	region	
(N-terminal)	
DNA	binding	
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Hinge	
region	
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(LBD)	
F	region	
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1.4.2.1 NR hormone response elements 
Hormone response elements (HREs) are specific DNA sequences in target genes that 
NRs bind to mediate transcription (123). They are commonly found in regulatory 
sequences in the 5’-flanking region of the target gene, close to the promoter core but 
can also be found several kilobases (kb) upstream of the transcription activation site 
in the enhancer region (124). Copious analysis of endogenous and synthetic HREs, 
have determined that the core recognition motif is comprised of 6 base pairs (bp) 
(125). Further investigation has identified 2 consensus motifs: 1) a palindromic 
sequence of AGAACA that is separated by 3 nucleotides and preferentially 
recognised by class 3 NRs and 2) the remaining NRs recognise the direct repeat 
consensus motif AGG/TTCA (126). Although the consensus motifs represent ideal 
sequences, naturally occurring HREs show variation to those detailed above. Whilst 
most receptors bind as homo- or heterodimers to HREs composed of 2 core hexameric 
motifs, monomeric NRs are able to bind to a single hexameric motif. The half sites for 
dimeric HREs can be arranged as direct repeats (DR), inverted palindromes (IP) or 
palindromes (Pal) (127). A Pal is a nucleotide sequence with one strand that reads in 
the reverse order to the complimentary strand (the sequence is same whether it is read 
5’-3’ or 3’-5’). An IP is a nucleotide sequence that is the reversed compliment to 
another further downstream. A DR is a similar nucleotide sequence that is repeated in 
the same orientation within one strand (123). 
 
1.4.2.2 NR binding – monomers, homodimers, heterodimers 
Monomeric binding of orphan NRs to DNA can be achieved with high affinity. The 
monomeric NRs recognise the sequence by utilising the C-terminal extension (CTE) 
of the LBD, whilst recognition of specific amino acids is ensured by the DBD A box. 
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Extensive DNA receptor contacts, ensure affinity and specificity are achieved when 
the CTE binds the minor groove of DNA, extending the DBD connection further than 
the recognition sequence consensus half site.  
 
Whilst the majority of non-steroidal NRs bind as heterodimers, some can bind to 
DNA as homodimers. Thyroid hormone receptor (TR), vitamin D receptor (VDR) and 
retinoic acid receptor (RAR) can bind as homodimers but DNA binding and 
transcriptional efficacy are significantly improved following heterodimerisation with 
RXR (a promiscuous partner) (128). In addition, monomeric and homodimeric 
receptors such as NGF1B and RAR, can form heterodimers with RXR. NGF1B/RXR 
heterodimers recognise the DRs rather than monomeric sequences whilst RAR/RXR 
heterodimers bind to Pal or IP.  
 
DRs are asymmetric, hence heterodimers bind with 2 definitive polarities. RXR 
occupies the upstream half site on the DR3, 4 and 5 and the heterodimeric partner 
(e.g. TR, VDR, RAR) is present on the downstream half site (129). 
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Figure 1.10 Examples of NR binding to their hormone response elements (Adapted 
from Aranda et al., 2001) 
 
Post-translational modifications (PTM) including methylation, phosphorylation, 
acetylation, ubiquitination and sumoylation regulate the functions of NRs (130). 
Furthermore, these PTMs can be subdivided into 2 groups: 1) alterations through the 
addition of other proteins (e.g. sumoylation, ubiquitination); or 2) the reversible 
addition or removal of functional groups on specific target proteins (e.g. 
phosphorylation). PTMs subtly alter NR functions, modulating the activity (positively 
or negatively) through steric hindrance, reducing the stability of the protein as well as 
manipulating the localisation of the intracellular proteins (131). Recently, it has been 
Pal	
A/T	
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found PTMs of NRs are fundamental in the pathophysiological formation of 
numerous diseases including diabetes, cancer and obesity (130). 
 
1.4.3 Key NRs; PXR and CAR 
The most widely studied NRs in terms of drug disposition are PXR and CAR. Both of 
these NRs exhibit promiscuous xenobiotic sensitivity although PXR appears to be 
more promiscuous than CAR. Mechanistically, these 2 fundamental NRs regulate the 
transcription of a broad range of drug metabolising enzymes and transporters often in 
a concerted manner (132, 133). 
 
1.4.3.1 PXR 
The ‘adopted’ orphan NR, PXR (NR1I2), is highly expressed in the liver and 
intestine, was initially named steroid X receptor (SXR) or pregnane-activated receptor 
(PAR) as a reflection of its versatility in substrate recognition (134). The 434 amino 
acid, 50 kDa protein located on chromosome 3, locus 3q12-q13.3 was isolated and 
cloned in 1998 (135). The promiscuity of PXR is deemed to be as a result of a large 
and flexible LBD that is able to accommodate a wide range of structures in contrast to 
other NRs (136). Human PXR (hPXR) and mouse PXR (mPXR) share approximately 
90% structure similarity but the LBDs share less sequence homology. In addition, 
although they are activated by numerous ligands including, glucocorticoids, 
antifungals, macrolide antibiotics, pregnane derivatives and herbal remedies, they 
display different profiles (137). For example, species-specific differences are 
observed with rifampicin (RIF) and pregnenolone-16α-carbonitrile (PCN) (138). 
Whilst RIF is a potent inducer of hPXR, only a weak effect is prevalent for mPXR 
with the converse true for PCN, which is a weak activator of hPXR and a potent 
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activator of mPXR (138). The difference in species specificity poses a challenge when 
extrapolating pre-clinical models to analyse human drugs (139). Investigations into 
the binding characteristics and structure of PXR have been extensive (140). Identified 
upon RIF and hyperforin binding, in contrast to other NRs, the LBD of PXR can 
change shape and structure as well as vary significantly in its volume capacity (141). 
 
1.4.3.2 Regulation of drug metabolism and transport by PXR 
Upon ligand binding, PXR binds as a heterodimer with RXR to direct or everted 
repeats ((A/G)G(G/T)TCA) separated by 3 (DR3) or 6 (ER6) base pairs present on the 
enhancer region or proximal promoter region of CYP3A4, respectively (142). In 
addition to CYP3A4 induction, it has been demonstrated the basal expression of the 
enzyme is highly dependent on PXR (108). Indeed, a correlation between PXR and 
CYP3A4 expression has been reported in many tissues in the absence of enzyme 
inducers (61, 111, 143, 144). The most common DDI occurrence is observed in 
patients with complex drug regimens including, tuberculosis, human 
immunodeficiency virus, cancer or cardiovascular diseases. In particular, the 
macrolide antibiotic, rifampicin (RIF), a PXR substrate used in tuberculosis treatment, 
is associated with over 100 CYP3A4 substrate DDIs (137). Mechanistically, RIF 
binds 18 amino acid side residues of the PXR LBD, inducing CYP3A4 and resulting 
in decreased plasma drug concentrations due to an upregulation of clearance (145).  
 
Another widely reported PXR agonist is the herbal medicine, St John’s Wort. The 
herb contains many PXR ligands including hyperforin (146). Hyperforin does not 
bind directly to the α helix in the LBD, instead it induces a unique conformational 
change in 2 loops opposite the LBD to activate gene transcription (147). In addition to 
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CYP3A4, other CYPs and drug transporters activated by PXR include, CYP2B6, 
CYP2C8, CYP2C9, CYP2C19, ABCB1, OATP1B1, OATP1B3 and ABCC2 (132). 
Recent studies have shown PXR activation of genes is not dependent on the location 
of the attachment. CYP4F12, responsible for metabolising arachidonic acid, contains 
PXR binding sites located on the intron rather than the upstream promoter region 
(148). Paclitaxel, a mitotic inhibitor used in the treatment of ovarian or breast cancer 
is metabolised by CYP3A4 and CYP2C8, and removed from the hepatic cell by 
ABCB1 (149). Importantly, paclitaxel activates PXR, inducing gene transcription of 
CYP3A4, CYP2C8 and ABCB1; thus, efficacy is reduced with an increased incidence 
of development of drug resistance.  
 
Over the last decade it has become more apparent PXR is responsible for coordinating 
the efflux, and, influx of compounds rather than just metabolic processes (38). The 
main transporters responsible for preventing therapeutic concentration are the efflux 
transporters hence they are more commonly studied. The PXR ligand, RIF, induces 
NR binding to the distal DR4 HRE 8kb upstream of the ABCB1 initiation site (150, 
151). As described earlier, PXR CYP binding also occurs at the distal region, 
indicating the maximum induction of target genes is achieved through the distal 
enhancer regions (133). The use of PXR knock-out mice has demonstrated ABCC2 is 
regulated by PXR upon PCN or dexamethasone (DEX) exposure (152). In contrast to 
the CYPs, ABCB1 and ABCC2 bind to PXR/RXR and CAR/RXR heterodimers at the 
ER8 HRE on the upstream proximal promoter region. Pharmacokinetics is 
additionally influenced by influx transporters OATP1B1, OATP1B3 and NTCP all of 
which are also regulated by PXR (144, 150). Other regulatory targets of PXR include, 
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sulfotransferases (153), carboxylesterases (154), aldo-keto reductases (155) and 
uridine-5’-diphosphate glucuronosyl transferases (UGTs) (156). 
 
1.4.3.3 CAR 
Similar to PXR, CAR (NR1I3) is highly expressed in the liver and intestine. The 
8.5kb NR located on chromosome 1, locus 1q23 was first identified in 1994 following 
cDNA screening of the conserved NR DBD using degenerate oligonucleotides (157). 
In the absence of a ligand, the NR can be constitutively active, bound as a 
heterodimer to RXR at DR5 HREs, as well as RARs and CYP2B, although it is 
largely sequestered inactive in the cytoplasm (158). Forman et al., 1998, identified the 
first CAR ligands, androstenol and androstanol but rather than activating the NR, the 
compounds suppress the basal activity of CAR in vitro. However, the androstane 
metabolite binding still results in the dissociation of co-activators therefore, they are 
classed as inverse agonists rather than antagonists (159).  
 
Activation of CAR was fully characterised using knock-out mice (107). CAR binding 
motifs within the proximal HRE consists of 2 DR hexamers separated by 4 amino 
acids (DR4), with complimentary DR4 binding motifs able to bind CAR (160). 
Phenobarbital (PB) was shown to reverse the suppression of the androstane 
metabolites on the proximal promoter region of CYP2B6 (161). Recently, activation 
of CAR by PB has been studied in greater detail. Shizu et al., 2012, found PB 
mediates the down regulation of micro-RNA-122 (miR-122) (an intergenic miRNA, 
regulated through its own promoter) early in the activation-signaling cascade of CAR.  
The reduction in miR-122 results in 5’-adenosine monophosphate-activated protein 
kinase (AMPK) dependent activation of CAR, suggesting miRNA changes may be 
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connected to DDIs but further work is required to understand the relationship between 
miR-122 and AMPK (162). 
 
X-ray crystallography shows CAR has a smaller ligand binding pocket compared to 
PXR, as well as a unique structural conformation change upon ligand binding (163). 
Ligand activation of CAR is also species specific; 1,4-bis[2-(3,5-
dichloropyridyloxy)]benzene (TCPOBOP) is highly inducible of mouse CAR 
(mCAR) but not human CAR (hCAR), whilst 6-(4-chlorophenyl)imidazole[2,1-
b]thiazole-5-carbaldehyde-O-(3,4-dichlorobenzyl)oxime (CITCO) is a potent agonist 
of hCAR but not mCAR (164). Despite possessing a relatively small ligand binding 
pocket, CAR mediates the transcription of a broad array of xenobiotic metabolism and 
transporter genes (133), sharing many target genes with PXR. Cross-talk of 
overlapping HRE binding suggests CAR and PXR coordinately regulate gene 
expression. Nonetheless, the NRs are activated by ligands in 2 distinct ways. PXR is 
exclusively dependent on ligand binding whereas CAR can be activated indirectly or 
by direct ligand binding (133). CAR is sequestered in the cytoplasm in vivo prior to 
ligand activation and subsequent translocation to the nucleus. However, in 
immortalised cell lines, CAR spontaneously accumulates in the nucleus (165). Ligand 
independent activation of CAR poses as a major obstacle for investigating drug 
activation in vitro but distinguishes it from other NRs.    
 
1.4.3.4 Regulation of drug metabolism and transport by CAR 
Transfection of CAR into HepG2 cells results in an increase of CYP3A4 mRNA 
implying crosstalk between CAR and PXR is a key factor to be considered (132). 
Phenobarbital (PB) is highly documented as an inducer of the CYP2B family but until 
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recently the mechanism of action was subject to debate. Of particular prominence is 
CYP2B6 as it metabolises approximately 25% of drugs (Figure 1.7). With the aid of 
CAR knock-out mice, induction of Cyp2b10 was absent when treated with PB (107). 
More so, it has been found that CAR HREs are present on the promoter region of 
CYP2B6 similar to mouse Cyp2b10 (107). During in vitro screening of CYP2B6 and 
CAR mRNA expression in 12 hepatocyte donors, Chang et al found a 278 fold and 
240 fold increase in CYP2B6 and CAR mRNA expression, respectively, when treated 
with PB (166). In addition to CYP2B genes, aryl hydrocarbon (AhR) knockout mice 
have been used to dissect the activation mechanisms of CYP1A1 and CYP1A2. 
Located on the cis-ER8 element of both enzymes, this HRE is a CAR binding site, 
indicating their expression is regulated through this NR (167).  
 
The CYP3A4 and CYP2B6 substrates carbamazepine and phenytoin (antiepileptics), 
are also CAR ligands (99). Activation of CAR by 100 μM phenytoin has been shown 
to increase CYP3A4 mRNA levels in human hepatocyte donors by 707%, as well as 
significant upregulation of CYP2C9, drastically reducing its efficacy through 
autoinduction. In addition, the systemic concentration of carbamazepine is 
significantly reduced due to an increase in the metabolism of the drug by CYP3A4 
and CYP2C9, which are regulated through CAR (168).  
 
In addition to CYPs, drug transporters have been identified as targets for CAR, 
although most are shared with PXR including, ABCB1, ABCC2, OATP1B1 and 
OATP1B3 (62, 169, 170). In contrast to PXR, contradictory data is reported for 
transcriptional regulation of drug transporters by CAR. Some groups report ABCC3 
as a target for CAR (171) whereas others found no mRNA correlation (172). 
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Accordingly, it is crucial that data attained from target gene identification assays are 
accurately interpreted, given over 50% of genes induced by PB are not regulated 
through CAR (173). Other regulatory targets of CAR include, sulfotransferases (174), 
UGTs (175) and glutathione-s-transferases (176). Recent studies suggest although 
CAR plays a key role in induction, it is capable of repressing activation or 
suppressing transcriptional induction (111). 
 
1.4.4 Indirect DDIs mediated through generation of toxic metabolites 
In addition to DDIs affecting plasma exposure of the victim drug, PXR and CAR 
activation can result in an increase in drug metabolism leading to toxicity through 
overproduction of toxic metabolites. Paracetamol, an analgesic, is primarily 
metabolised in the liver into metabolically inactive sulfate and glucuronide 
metabolites (145). However, paracetamol is also metabolised by CYP2E1 into N-
acetyl-p-benzo-quinone imine (NAPQI), a toxic metabolite. Induction of CYP2E1, 
CYP3A11 or CYP1A2 increases the production of NAPQI, resulting in an increased 
incidence of hepatotoxicity. Androstanol administration following paracetamol has 
been shown to inhibit CAR activity and reduce paracetamol hepatotoxicity in mice 
(177). It is conceivable that research and development into PXR and CAR antagonists 
may provide useful mechanisms to prevent DDIs (178). Studies have shown 
antagonists target their binding to the AF-2 domain of the C-terminal, altering the NR 
tertiary structure, hindering the binding/release of co-activators/co-repressors (136). 
Known PXR and CAR antagonists include ketoconazole (46), coumestrol (179), 
androstanol (180) and androstanol (178). 
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1.4.5 Cross-talk of HNF4α with PXR and CAR in regulation of metabolism and 
transport 
Recently, HNF4α has been identified as a key determinant in CAR and PXR mediated 
expression of CYP3A4 (69). In the absence of HNF4α, induction of CYP3A4 is 
absent or significantly repressed, which is correlated to the lack of HNF4α binding on 
the CAR and PXR upstream HREs in the CYP3A4 enhancer region, indicating it is a 
fundamental mediator of CAR and PXR action (132). It has also been reported 
HNF4α null mice express significantly less mRNA of OATP1B1, OATP2B1 and 
ABCC2. However, PXR is positively upregulated in the null mice, demonstrating 
adaptive activation through NR cross-talk (181).  
 
1.4.6 NR co-regulators 
As described earlier, NRs are crucial for gene regulation but they lack the properties 
required for chromatin re-structuring or direct interaction with the polymerase. 
Transcriptional modulation involves a complex process of ligand binding, binding of 
the NR to target HREs, co-regulator recruitment, binding of the RNA polymerase II 
holocomplex (Pol II), chromatin condensation and activation of gene transcription 
(182). To directly mediate induction, NR co-regulators are recruited upon ligand 
binding (183) and a substantial number of co-regulator complexes are required for 
gene transcription. Functioning as mediators these complexes are capable of 
interpreting xenobiotic activation. Central to the discussion here, co-regulators are 
classified as, chaperones, co-chaperones, co-activators and co-repressors (184). 
Expression of proteins is dependent upon the interaction of Pol II (a constitutive 
group of 30 general transcription factors) with human DNA (185), in addition to non-
constitutive co-regulator complexes that interact directly with the NRs (182). Further 
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to solely ‘bridging’ complexes, co-regulators possess many functions and contribute 
to transcriptional elongation, mRNA trafficking and RNA splicing (186). Currently, 
over 300 co-regulators have been reported, the majority of which are not restricted in 
their selectivity between NRs. Table 1.4 includes a literature based search of PXR and 
CAR co-regulators that have been shown to contribute to drug disposition and NR 
interactions.  
 
1.4.6.1 NR chaperones and co-chaperones 
Chaperones and their associated co-chaperones are proteins that assist in the non-
covalent folding and assembly of nuclear receptor complexes in the cytosol. The 
general mechanism is initiated through the exposure of NR hydrophobic residues, 
which heat shock protein 70 (Hsp70) binds to. As the NR begins to fold, heat shock 
protein 90 (Hsp90) binds allowing completion of the folding and priming the LBD in 
a hormone binding state (187). The LBD is unstable in the absence of a ligand thus it 
cycles through an ATP-dependent chaperone complex reaction preparing the LBD for 
activation. Co-chaperones such as, stress induced phosphoprotein 1 (STIP1) and 
cytoplasmic CAR retention protein (CCRP) are involved in this ATP-dependent 
reaction by controlling the ATPase activity of chaperones, or by contributing directly 
to the NR folding. CCRP is over expressed in HepG2 cells stabilising CAR in the 
cytosol thus, upon TCPOBOP treatment, nuclear translocation is significantly 
enhanced (188). Ligand binding and NR heterodimerisation requires translocation to 
the nucleus which is aided by this chaperone/co-chaperone complex. 
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1.4.6.2 NR co-activators and co-repressors 
Co-activators are described as proteins that are recruited through direct signals from 
NRs (sometimes when bound or unbound to ligands) to activate/enhance gene 
transcription (189). Although all co-activators contribute to gene expression, they can 
be split into 2 groups: primary co-activators interact directly with NRs whereas 
secondary co-activators do not bind to the receptor, rather they are members of a 
subunit complex (182). Some co-activators possess intrinsic histone acetylase (HAT) 
and methyltransferase activity, or, alternatively act as docking sites for such enzymes 
implicating them in chromatin relaxation (61). They are capable of modifying histone 
tails, protein kinases, SUMO ligases, ubiquitin and protein phosphatases (190). 
 
Co-repressors bind to NRs that are inactive either through the absence of a ligand 
(e.g. nuclear receptor co-repressor 1; NCOR1) or in the presence of an antagonist or 
inverse agonist (e.g. ligand dependent co-repressor 1; LCOR, nuclear receptor 
interacting protein 1; RIP140) (184). In contrast to co-activators, co-repressors can 
recruit histone deacetylase enzymes (HDACs) to condense chromatin and repress 
gene expression. Co-activators and co-repressors play an integral role in the gene 
transcription pathway (191). 
 
1.4.6.3 Activation mechanisms involving co-regulator proteins 
Co-regulators are involved in coordinating the regulation of xenobiotic metabolism 
and transport, cell growth, differentiation and metabolic processes (186). Intensity of 
activation is influenced by PTMs including methylation, phosphorylation or 
acetylation (192). One important co-regulator is the nuclear receptor co-activator 1 
(NCOA1). NCOA1 is a member of the p160 superfamily of co-activators that bind to 
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NR leucine repeats in the AF-2 region co-activator binding cleft that is produced upon 
ligand binding (192). CAR and PXR recruit other members of the p160 family 
including nuclear receptor co-activator 2 (NCOA2) and nuclear receptor co-activator 
3 (NCOA3) (193). Binding of these co-activators recruits HAT and 3’-5’-cyclic 
adenosine monophosphate (cAMP) to enhance gene transcription (194). In the liver 
NCOA1 is phosphorylated at serine/threonine residues by kinases, the potency of this 
phosphorylation then regulates NR activation (17). 
 
Co-repressors are also regulated by phosphorylation, which determines their 
localisation within the cell. Stimulation of phosphorylation reactions, initiates the 
transfer of co-repressors such as NCOR1 and nuclear receptor co-repressor 2 
(NCOR2) to the cytoplasm, inhibiting their ability to repress mRNA transcription 
(195). Hence, kinase signaling cascades, co-regulators and NRs work in concert to 
regulate gene transcription. 
 
In humans, the majority of co-regulators are constitutively expressed and their basal 
mRNA expression is subject to dynamic stimuli (except peroxisome proliferator-
activated receptor gamma co-activator 1 alpha (PGC1α)). However, this is not always 
true in transformed cell lines (90). Co-regulators add another layer of complexity to 
NR activation and can sometimes contribute to human disease. For example, co-
activator-associated arginine methyltransferase 1 (CARM1) over expression inhibits 
tumour suppressor protein 53 (p53) and induces antiapoptotic genes resulting in 
uncontrolled cell proliferation and prostate cancer (196). A lack of PGC1α expression 
contributes to reduced mitochondrial function, and may result in diabetes, 
Huntington’s disease or cholesterol cholelithiasis (197-199). Similarly, upregulation 
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of NCOR1 is associated with embryonic mortality, CNS development defects and 
erythrocyte defects (200). Heat shock protein 90kDa (Hsp90) is correlated to 
expression levels of oncogenic proteins (201) and growth arrest DNA damage 
inducible 45 beta (Gadd45β) is linked with Alzheimer’s disease and hepatic 
hypertrophy (202-204). 
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Gene Description Alias
Chromosomal 
location
Reference 
sequence
Regulatory 
activity/function
Gene ID
HSPA4 Heat shock 70kDa protein 4 Hsp70 5q31.1 NM_002154.3 Chaperone 3312
HSP90AA1
Heat shock protein 90α, cytosolic, 
class A, member 1
Hsp90 14q32.33 NM_005348.3 Chaperone 3320
PIH1D1 PIH1 domain containing 1 NOP17 19q13.33 NM_017916.2 Chaperone 55011
HSPA8 Heat shock 70kDa protein 8 HSC70, LAP1 11q24.1 NM_006597.4 Chaperone 3312
DNAJB1
DnaJ (Hsp40) homolog, subfamily 
B, member 1
Hsp40, HSPF1 19p13.2 NM_006145.1 Co-chaperone 3337
PTGES3
Prostaglandin E synthase 3 
(cytosolic)
p23/TEBP 12q13.13 NM_006601.5 Co-chaperone 10728
REG3A Regenerating islet-derived 3 alpha Hip, PAP 2p12 NM_002580 .2 Co-chaperone 5068
DNAJC4
DnaJ (Hsp40) homolog, subfamily 
C, member 4
Hsp40 11q13 NM_005528.3 Co-chaperone 3338
VCP Valosin-containing protein p97 9p13.3 NM_007126.3 Co-chaperone 7415
CDC37 Cell division cycle 37 P50, CDC37 19p13.2 NM_007065.3 Co-chaperone 11140
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Gene Description Alias
Chromosomal 
location
Reference 
sequence
Regulatory 
activity/function
Gene ID
PPID Peptidylprolyl isomerase D CYP-40 4q31.3 NM_005038.2 Co-chaperone 5481
STIP1 Stress-induced-phosphoprotein 1 HOP, P60 11q13 NM_006819.2 Co-chaperone 10963
PPP5C
Protein phosphatase 5, catalytic 
subunit
PP5 19q13.3 NM_006247.3 Co-chaperone 5536
DNAJA1
DnaJ (Hsp40) homolog, subfamily 
A, member 1
HSDJ, DJ-2 9p13.3 NM_001539.2 Co-chaperone 3301
DNAJC7
DnaJ (Hsp40) homolog, subfamily 
C, member 7
TPR2, DJC7 17q11.2 NM_003315.3 Co-chaperone 7266
FKBP4 FK506 binding protein 4, 59kDa FKBP52, Hsp56 12q13.33 NM_002014.3 Co-chaperone 2288
FKBP5 FK506 binding protein 5 FKBP51, P54 6p21.31 NM_004117.3 Co-chaperone 2289
STUB1
STIP1 homology and U-box 
containing protein 1
CHIP, UBOX1 16p13.3 NM_005861.2 Co-chaperone 10273
NCOR1 Nuclear receptor co-repressor 1 N-CoR, TRAC1 17p11.2 NM_006311.3 Co-repressor 9611
Sin3A
SIN3 transcriptional regulator 
homolog A
SIN3 homolog A 15q24.2 NM_015477.2  Co-repressor 25942
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Gene Description Alias
Chromosomal 
location
Reference 
sequence
Regulatory 
activity/function
Gene ID
NRIP1
Nuclear receptor interacting protein 
1
RIP140 21q11.2 NM_003489.3 Co-repressor 8204
HDAC1 Histone deacteylase 1 HD1, RPD3 1p34 NM_004964.2 Co-repressor 3065
HDAC2 Histone deacteylase 2 HD2, YAF1 6q21 NM_001527.3 Co-repressor 3066
NR0B2
Nuclear receptor subfamily 0, group 
B, member 2
SHP, SHP1, DAX1 1p36.1 NM_021969.2 Co-repressor 8431
SREBF1
Sterol regulatory element binding 
transcription factor 1
SREBP1 17p11.2 NM_004176.4 Co-repressor 6720
NCOR2 Nuclear receptor co-repressor 2 SMRT, N-CoR2 12q24 NM_006312.5 Co-repressor 9612
LCOR
Ligand dependent nuclear receptor 
corepressor
MLR2 10q24 NM_032440.3 Co-repressor 84458
CARD16
Caspase recruitment domain family, 
member 16
COP, COP1 11q23 NM_052889.2 Co-repressor 114769
TMTC3
Transmembrane and 
tetratricopeptide repeat containing 3
SMILE 12q21.32 NM_181783.3 Co-repressor 160418
NRBF2 Nuclear receptor binding factor 2 COPR1 10q22.1 NM_030759.3 Co-activator 29982
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Gene Description Alias
Chromosomal 
location
Reference 
sequence
Regulatory 
activity/function
Gene ID
MED1 Mediator complex subunit 1 TRAP220, TRIP2 17q12 NM_004774.3 Co-activator 5469
PSMC5
Proteasome (prosome, macropain) 
26S subunit, ATPase, 5
SUG1, p45 17q23.3 NM_002805.5 Co-activator 5705
CARM-1
Coactivator-associated arginine 
methyltransferase 1
PRMT4 19p13.2 NM_199141.1 Co-activator 10498
Gadd45β
Growth arrest and DNA-damage-
inducible, beta
GADD45BETA 19p13.3 NM_015675.3 Co-activator 4616
SMC1A
Structural maintenance of 
chromosomes 1A
CDLS2, SMC1 Xp11.22-p11.21NM_006306.2 Co-activator 8243
CITED1
Cbp/p300-interacting transactivator, 
with Glu/Asp-rich carboxy-terminal 
domain, 1
MSG1 Xq13.1 NM_004143.3 Co-activator 12705
NCOA3 Nuclear receptor coactivator 3 AIB1, ACTR 20q12 NM_006534.3 Co-activator 8202
KAT2B K(lysine) acetyltransferase 2B CAF, P/CAF 3p24 NM_003884.4 Co-activator 8850
NCOA6 Nuclear receptor coactivator 6 ASC2, PRIP 20q11 NM_014071.3 Co-activator 23054
NCOA1 Nuclear receptor coactivator 1 RIP160, SRC1 2p23 NM_147223.2 Co-activator 8648
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Table 1.5 Selected co-regulators associated with PXR and CAR function 
 
Gene Description Alias
Chromosomal 
location
Reference 
sequence
Regulatory 
activity/function
Gene ID
NCOA2 Nuclear receptor coactivator 2 GRIP1, SRC2 8q13.3 NM_006540.2 Co-activator 10499
PGC1α
Peroxisome proliferator-activated 
receptor gamma co-activator 1
PGC1, PPARGC1 4p15.1 NM_013261.3 Co-activator 10891
CREBBP CREB binding protein CBP/KAT3A 16p13.3 NM_004380.2 Co-activator 1387
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1.4.6.4 NR co-regulators and CYP regulation 
Although many interactions can occur with the co-regulators included in Table 1.5, 
the following section details examples of their interactions with PXR and CAR in the 
regulation of CYP3A4. Key chaperones Hsp90 and co-chaperones cytoplasmic CAR 
retention protein (CCRP), FK506 binding protein 4 (FKBP4) and 5 (FKBP5) 
expression levels are linked to CAR and PXR activation (205). 
 
Studies have shown that induction of CYP3A4 by RIF requires the binding of PXR, 
PGC1α and NCOA1 following the dissociation of NCOR1 (206). Transfection of 
PGC1α and to a lesser extent NCOA1 is correlated to dose-dependent increases in 
CYP2C9, CYP1A1, CYP3A4, CYP3A5 and ABCB1 of which all are PXR and CAR 
target genes. Whilst the effect is increased upon RIF binding, these data also 
demonstrate that PGC1α and NCOA1 are required for CYP3A4 basal expression 
(207).  
 
Sterol regulatory element binding protein (SREBP1) is a NR co-repressor of the basic 
helix-loop-helix family (208). The co-repressor is membrane bound to the 
endoplasmic reticulum with its amino acid carboxy-terminals protruding into the 
cytoplasm. SREBP1 binds to the promoter regions of lipogenic genes inducing fatty 
acid and triglyceride production (208). A decrease in lipid metabolism in the liver is 
correlated to a decrease in drug metabolism through SREBP1 binding to PXR and 
CAR, inhibiting co-activator recruitment and preventing CYP3A4 production (209). 
Although the majority of CAR is sequestered in the cytoplasm, it is also found in the 
nucleus where it interacts with members of the p160 co-activator family (137). Small 
heterodimer partner (SHP) and the nuclear receptor protein, dosage-sensitive sex 
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reversal adrenal hypoplasia congenital critical region on X chromosome, gene 1 
(NR0B1) binds to CAR inhibiting transactivation through preventing binding of the 
p160 family (210). In addition, complete repression of the NR is achieved due to the 
presence of an intrinsic repression domain on the C terminal of SHP. The co-repressor 
recruits additional proteins to a complex achieving this effect (211). Small 
heterodimer partner interacting protein leucine zipper protein (SMILE) is a novel co-
repressor of CAR (212). SMILE recruits HDACs, binds to the AF-2 domain and 
hinders the interaction of the NR with co-activators thus repressing transcription and 
decreasing drug clearance (212).  
 
1.4.7 NRs, co-regulators and drug discovery 
In depth analysis of NRs is now applied during the drug discovery and development 
process, which has aided understanding of the mechanisms that underpin DDIs. As 
described earlier, PXR is thought to be involved in over 60% of unwanted DDIs 
(132). The promiscuity and uniqueness of CAR and PXR have lead pharmaceutical 
companies to conduct NR induction assays before advancing into clinical trials. This 
increased interest has intensified the requirement for accurate in vitro and in vivo 
models to predict NR activation (111). Cell based reporter gene assays are ordinarily 
used in vitro to determine NR activation whereas expression of drug disposition genes 
is routinely analysed in primary human hepatocytes (99, 213).  
 
Co-regulators are emerging as critical factors for NR function and have therefore 
attracted interest as targets for modifying drug response and disease. Current targets 
include Hsp90, the chaperones inhibitor geldanamycin effectively prevents hormone 
dimerisation and enhances protein degradation making it a potentially useful 
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compound to treat breast cancer (205). Additionally, inhibitors for co-activators such 
as NCOA1 are being investigated as treatment strategies in breast cancer (214) and 
microRNAs of the co-repressor SMRT allow modulation of the transcription factor 
nuclear factor-kappaB (NF-κB) and interleukin 8 during the inflammatory response 
against microbial infection of innate immune cells (215). Species specific gene 
activation of NRs prevents accurate induction analysis in rodents but humanised 
rodent models exhibit responses closer to that of a human and are an invaluable tool 
in NR induction interactions (61).   
 
 
1.5 Pharmacogenetics in drug response 
Pharmacogenetics is the study of how genetic variants may result in altered responses 
to xenobiotics (216). With the application of genomic technology and analysis, 
pharmacogenetics can also be applied during drug discovery to analyse the complete 
target genome (111). Of particular clinical interest are single nucleotide 
polymorphisms (SNPs) in drug disposition genes.  
 
The interindividual variability observed in xenobiotic PK is in part a result of genetic 
polymorphisms in ADME genes (217). Drug plasma concentrations are a 
consequence of numerous processes regulated by several proteins rather than the 
direct and sole influence of SNPs. Subsequently, polymorphisms in multiple genes 
may contribute to variable PK and their consideration during drug discovery and 
development may be warranted. SNPs with particular relevance to this thesis are 
discussed below. 
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CYP3A4 polymorphisms have been identified and related to drug concentrations of 
immunosuppressants and alpha-blockers. Two haplotypes resulting from CYP3A4 
SNPs are CYP3A4*1B, rs52740574 and CYP3A4*22, rs35599367. CYP3A4*1B is a 
relatively newly identified haplotype associated with an increase in enzyme mRNA 
expression which is correlated to a decrease in the Cmax of silodosin (218), although 
conflicting data exist for this SNP (219, 220). In contrast, CYP3A4*22 is a SNP on 
intron 6 and is associated with an increase in tacrolimus exposure regulated through 
the presence of the C allele resulting in a defective enzyme (221, 222). 
 
Numerous sequence alterations and SNPs have been documented for the influx 
transporter SLCO1B1, many of which vary between populations (223). Two distinct 
SNPs in particular have been associated with the differences in xenobiotic 
pharmacokinetics. The 521T>C, rs4149056 and 388A>G, rs2306283 collectively 
define 4 haplotypes: SLCO1B1*1A, SLCO1B1*1B, SLCO1B1*5 and SLCO1B1*15. 
SLCO1B1*5 and SLCO1B1*15 contain the 521C allele and this SNP has a dominant 
effect, which is associated with a decreased activity (224). This decrease in 
transporter activity is correlated to a 144%, 221% and 110% increase in AUC of 
atorvastatin, simvastatin and pravastatin, respectively (225). Additionally, the Ctrough 
of the CCR5 antagonist, maraviroc is reduced by 53% (226) and the Cmax of the 
protease inhibitor, lopinavir is significantly increased (49).  
 
Efflux transporters are also subject to SNPs that can alter their activity and/or 
expression. The most commonly studied SNP in ABCB1 is 3435C>T, rs1045642 
which is associated with transporter expression and increased concentrations of 
sirolimus (227); however, data for this SNP is not very reproducible (104, 228). 
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Homozygous individuals with the C allele express 2-fold more ABCB1 than 
individuals homozygous for the T allele (heterozygotes have intermediate expression 
levels). The SNP is a synonymous silent mutation in the gene sequence therefore the 
mechanism governing expression is unknown (104, 229, 230). 
 
SNPs in the promoter, DBD and LBD have significant functional consequences for 
PXR (231, 232). Polymorphisms associated with a decrease in PXR gene expression 
resulting in a decrease of CYP3A4 activity are 698789A>G (G allele), rs763645 and 
44477T>C (T allele), rs1523130 (233). In contrast, an increase in PXR expression is 
associated with the T allele of the SNP 63396C>T, rs2472677 which significantly 
reduces the Cmax of CYP3A4 substrates (234). 
 
Similar to PXR, nonsynonymous SNPs in CAR are rare but those localised to the LBD 
have been shown to alter ligand binding as well as dimerisation with RXR, co-
activator binding and nuclear localisation of the receptor (233). A significant decrease 
in basal and induced CYP3A4 and CYP2B6 activation is associated with the CAR 
SNP located on exon 5, 246A>G (allele), rs2307424 (60, 109). The 246A>G SNP is 
associated with early discontinuation of efavirenz containing regimens due to toxicity 
(109). It has been reported this SNP influences the PK significantly of efavirenz in 
Chilean patients (235). In contrast, a polymorphism located on exon 7, 380T>C, 
rs437470 is associated with reduced constitutive CAR activity but response to CITCO 
is not affected (60, 232). 
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1.6 Organotypic liver models 
Regulatory and safety pressures to understand and accurately predict human response 
upon compound exposure are becoming increasingly more evident. As described in 
more detail below and in Chapter 2, in vitro strategies are currently applied to predict 
PK parameters, dose and DDIs. However, it is clear there is an urgency to improve 
current model systems.  
 
Although the majority of drugs are biotransformed and eliminated by the liver (236), 
the organ contains numerous cells that work in concert to perform a range of tasks, for 
example, protein and fat metabolism, secretion of bile products and localised immune 
responses (236). Table 1.6 details representative cell types of the liver, their 
overlapping roles and the effect they have on CYP gene expression. 
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Cell Type Form Function Gene	Expression
Hepatocyte Paraenchymal
Dependent	upon	growth	factors,	hormones	
and	extracellular	matrix
Liver	sinusoidal	
endothelial	cell
Non-parenchymal
Elongated	cell	possessing	high	
number	of	pinocytotic	vesicles
Dependent	upon	growth	factors,	hormones	
and	extracellular	matrix
Hepatic	stellate	
cell
Non-parenchymal
Influence	their	own	gene	expression	through	
production	of	growth	factors	and	cytokines
Xenobiotic	biotransformation	(Phase	I	and	II	
enzymes)	and	elimination,	Fat,	steroid	and	
protein	metabolism,	Sugar	and	vitamin	storage,	
Size	and	polyploid	number	increases	from	zone	1	
to	zone	3,	Efficient	influx	or	efflux	transport
Highly	differentiated	epithelial	cells,	
Comprise	cell	plates	of	the	liver	
lobule
Maintain	hepatic	homeostasis,	Function	as	
antigen	presenting	cells,	Improve	passive	
diffusion	-	contribute	to	hepatocyte	exposure	of	
soluble	components,	Xenobiotic	
biotransformation	(Phase	I	and	II	enzymes)	and	
elimination			
Involved	in	regulating	liver	injury,	Store	vitamin	
A,	Produce	a	network	of	fibrillar	collagens,	
elastin	and	heparan	sulfate	proteoglycans,	
Produce	cytokines	and	growth	factors	for	
intracellular	communications	
Reside	in	the	space	of	Disse,	
Extensive	dendrite-like	extensions	
that	wrap	around	the	sinusoids
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Table 1.6. Representative cell types of the liver, their role and effect of gene expression (Adapted from LeCluyse et al., (237)) 
 
Cell Type Form Function Gene	Expression
Kupffer	cell Non-parenchymal
Cholangiocyte Non-parenchymal
Form	the	cuboidal	epithelium	in	the	
small	interlobular	bile	ducts
Hepatic	
progenitor	cell
Non-parenchymal
Regulate	localised	hepatic	immune	response	
through	sectrion	of	cytokines,	Interact	directly	
with	immune	cells	through	adhesion	molecules,	
Involved	in	absorption	of	organic	anions/cations,	
lipids	and	in	the	regulation	of	bile	secretion,	
Regulation	of	GSH
Reside	in	the	compartment	within	
the	canals	of	Hering,	Bi-potential	
stem	cells
Activated	upon	hepatic	epithelial	cell	damage	
(>50%),	Migrate	from	zone	1	to	zone	3	to	form	
mature	hepatocytes	of	cholangiocytes,	Support	
stem	cell	populations	of	all	liver	cells,	Represent	
a	target	for	drug	induced	toxicty	that	controls	
liver	regeneration
Influence	gene	expression	of	Phase	I	and	II	
enzymes	and	transporters	in	hepatocytes	
through	production	of	growth	factors	and	
cytokines
Influence	gene	expression	of	Phase	I	and	II	
enzymes	and	transporters	in	hepatocytes	
through	production	of	growth	factors	and	
cytokines
Form	new,	mature	hepatocytes	that	posses	
Phase	I	and	phase	II	enzymes	and	
transporters
Mesenchymal	origins,	Localised	
within	the	sinusoidal	on	the	luminal	
side	of	endothelial	cells,	Long	
cytoplamsic	extensions
Resident	macrophages	in	the	liver	-	
endocytic/phagocytic	ability,	Induced	in	liver	
injury,	In	constant	contact	with	gut-derived	
material	that	are	eliminated	from	the	blood,	
Modulate	the	turn-over	and	metabolic	ability	of	
hepatocytes,	Large	and	more	active	in	zone	1,	
Zone	3	are	more	active	in	cytokine	production
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1.6.1 Current model systems 
Although in vitro analysis cannot replicate the complexity of a human, the simplicity 
of using isolated hepatocytes allows analysis of specific components. Nevertheless, 
the accuracy of this model varies considerably depending on the isolation and culture 
conditions used (238, 239). A physiologically-relevant phenotype including cell 
differentiation, metabolism and transporter protein expression and tight regulation of 
cellular processes can be partially maintained in isolated human hepatocytes, if the 
environment closely resembles that of the liver (239). However, the artificial 
environment results in the formation of significantly different phenotypes. Groups 
standardising their culture preparations and medium observe variability in drug 
metabolism, suggesting the inconsistency in vitro is a reflection of the donor 
phenotype (56), which may complicate extrapolation but may provide an early 
evaluation of inter-individual variability.  
 
1.6.1.1 Primary hepatocytes 
Efficient secretion of key liver proteins (collagen, fibrinogen, laminin) can be 
achieved in mono-cell cultures of hepatocytes in suspension. Hepatocytes form 
spheroids that utilise the secreted proteins to encapsulate themselves. Cell viability is 
improved and in vivo cell-cell connections are established (240). The main 
disadvantage of this model is sub-optimal oxygen levels due to the uncontrollable size 
of the spheroid aggregates that are produced. Hence, current research is focusing on 
the generation of scaffolds that restrict spheroid aggregate size but maintain liver 
specific protein secretion (241).  
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Factors affecting the profile of 2-dimensional mono-cultured hepatocytes include:  
- The quantity of fetal bovine serum (FBS) supplement (blood fraction containing low 
antibody content but high levels of growth factors). The serum is associated with an 
increase in hepatocyte surface attachment (242, 243) but a decrease in the formation 
of bile canaliculi (244).  
- Increased hepatocyte plating density (~100%) maintains hepatic morphology and 
phenotype (increasing production of bile canaliculi) for ~1-2 days more, in contrast to 
cells plated at ~80% confluence (245).  
- Specific individual donor genotypes can significantly alter the expression and/or 
activity of key drug disposition genes and hepatocyte architecture.  
- Supplements including growth hormones and dexamethasone (DEX) maintain 
structure identity, integrity and gene expression of the hepatocyte. However, over use 
results in significant fibroblast growth and abnormal gene expression profiles (244).  
- Whilst a matrigel/collagen matrix overlay increases the time in culture, hepatocytes 
take longer to produce a polygonal morphology and form cell-cell contacts (238). 
However, if a ‘sticky’ biomatrix is used, the hepatocyte spread across the culture plate 
is reduced and the cells are subject to extensive stress (238). 
- The use of plastic culture dishes can result in a rapid reduction depletion of 
hepatocyte cell membrane polarity as well as variable cell attachments (237). 
- A lack of relevant liver cell types in a mono-primary hepatocyte culture does not 
allow analysis of the concerted response upon xenobiotic exposure or accurate 
mechanisms to remove waste products making them more susceptible to toxicity 
(239). 
- Culturing cells with a constant perfusion flow replicates the blood flow and oxygen 
levels in the liver (237). 
 64 
1.6.1.2 Co-cultures 
As described earlier, co-cultures enhance cell-cell communications through organised 
production of inter-cellular junctions (246, 247). Co-culture of hepatocytes with 
kupffer cells has been pivotal in understanding the in vivo effects of IL-2 on CYP3A4 
metabolism (248). In addition, hepatocytes cultured with rat liver endothelial cells 
have allowed production of a robust assay to analyse the inflammatory cytokine 
production upon xenobiotic exposure (249). Nonetheless, co-cultures are still 
hindered by the lack of CYP expression, which is thought to be due to the absence of 
a hemodynamic environment (249). 
 
1.6.1.3 HepaRG cells 
Similar to HepG2 and Huh7 cells (described in more detail throughout Chapter 2), 
HepaRG cells are derived from hepatocellular carcinoma (249). In comparison to 
routinely used HepG2 and Huh7 cell lines, HepaRG cells are superior due to their 
ability to differentiate into hepatocyte-like cells. Grown to confluence, the mono-
culture produces two equally representative cell types; a flat cholangiocyte cell and a 
rounded hepatocyte-like cell. However, to achieve the required morphology, 
phenotype and gene expression profile, HepaRG cells must be treated with 1% 
DMSO (249). Functional phase I and II metabolism enzyme activity is restored along 
with NR pathways that regulate xenobiotic biotransformation (e.g. PXR, CAR, AhR) 
(250, 251). To date, HepaRG cells are the most representative cell line of the human 
liver. However, their main limitation for toxicity and xenobiotic analysis is the high 
concentration of DMSO required in culture. Whilst gene expression profiles are 
restored, the level of expression is significantly greater than those observed in vivo, 
hence response to prototypical inducers such as RIF is misrepresented (237).  
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1.6.1.4 Stem cells 
Numerous cell types, cell-cell communications, gene expression profiles and a 
constant hemodynamic environment are all examples of significant obstacles when 
producing a characteristic organotypic liver model. Despite ethical concerns, stem 
cells represent a promising alternative as a renewable cell source. For the purpose of 
the work herein, stem cells are discussed in two classes; adult stem cells and 
pluripotent stem cells. Pluripotent stem cells are capable of constant replication and 
differentiation to form all three layers of the liver (ectoderm, mesoderm, endoderm). 
To date, there are many established methods for the controlled differentiation of 
pluripotent stem cells into hepatocytes (115, 252, 253) but gene expression profiles 
closely relate those of fetal levels rather than adults. Similarly, adult stem cells self-
renew and are capable of differentiating into all liver cell types (described in Table 
1.6). Specific to the liver, hepatic progenitor cells (resident liver stem cells) are 
crucial in liver re-generation, which is initiated upon exposure to specific growth 
factors (254). Importantly, the main advantages of adult stem cells are availability and 
potential to generate donor panels for analysis of inter-individual variability and 
polymorphisms (237).  
 
1.6.2 Advanced technologies 
In addition to the models described above, throughout the last decade technological 
advances have enabled more complex liver models to be engineered, although the 
majority remain in optimisation. Examples of manufactured novel devices include: 
- Microfluidic perfusion array; the 96-well automated format system has a continuous 
perfusion across the plates that replicates liver blood flow. The hepatocytes are 
maintained in 3-dimensional (3-D) aggregates optimizing gas and nutrient transport 
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across the porous barrier. With the co-culture of numerous cell types, cell-cell 
contacts are maintained, replicating gene expression and liver protein profiles, 
induction/inhibition responses and cell viability for 3-4weeks (255). 
- Bioengineered micropatterned liver platform; hepatocytes are co-cultured with 
stromal cells to support the formation of hepatocyte colonies within a miniaturised 
multiwell system. Cells remain viable in culture for up to six weeks with accurate in 
vivo morphologies, functional bile canaliculi, phase I and II metabolism enzymes and 
transport functions (256). 
- Biochip dynamic flow system; living cells are inserted into microfluidic 
compartments that are connected by a circulating blood partition to simulate the effect 
in vivo. Co-culture of hepatocytes with non-parenchymal cells correlates significantly 
with the responses observed in vivo (257). 
- 3-D liver tissue culture scaffold; this multi-well plated model accommodates mono 
or co-cultures in addition to static or flow conditions. The cells remain differentiation 
for numerous weeks allowing the model to be characterised for use in induction 
assays and inflammatory responses (258).  
- 3-D scaffolds with dynamic flow; Silicon pores are utilised as scaffolds for 3-D co-
culture aggregates to form and ensure oxygen flow. Thus, histotypic morphology and 
cell organisation are optimised. The platform of the model is scalable to in vivo and 
replicates the different zones within the liver. Living cells used in the model retain 
gene expression profiles of transcription factors, CYPs, transporters and NRs for 
several weeks (259). 
Immortalised hepatic cells are discussed further in Chapter 2 but an advantage of 
hepatoma cells is their suitability as an alternative cell source during optimisation of 
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dynamic flow organotypic mechanical devices due to their low cost and availability 
(236). 
 
 
1.7 Thesis aims 
The primary aim of this thesis was to investigate and understand the differences and 
similarities in the expression profiles of drug disposition genes, between transformed 
hepatic cell lines and primary human hepatocytes. Primary human hepatocytes were 
also analysed to determine uptake contribution, induction and genotype of key drug 
disposition-relevant genes. This was achieved as follows: 
 
1. Comparison of the gene expression profiles of key drug transporters and 
metabolising enzymes between hepatoma cell lines and primary human hepatocytes. 
PXR and CAR co-regulators were identified and gene expression compared between 
the two cell types. Selected co-regulators were then chosen to determine any 
correlation with CYP3A4 expression and activity. 
 
2. Upon identification of Gadd45β and PGC1α correlation with CYP3A4, 
genetic manipulation was applied to determine if a more physiologically relevant 
phenotype could be achieved. The two co-activators were transiently transfected into 
HepG2 cells using Lipofectamine2000. Western blotting, HPLC and Taqman analyses 
were completed to determine protein expression, CYP3A4 activity and mRNA 
expression, respectively. Off-target effects were determined by microfluidic analysis. 
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3. Optimisation and application of a robust in vitro assay using AtuFect01 and 
specific oligomers to selectively inhibit OATP1B1 in primary human hepatocytes was 
developed to determine the role of OATP1B1 in the hepatic uptake of xenobiotics. 
OATP1B1 inhibition was analysed at the mRNA and activity level using Taqman 
expression assays and [
3
H] estrone 3 sulfate uptake, respectively. Atorvastatin was 
used to selectively inhibit the drug transporter and off-target effects were determined 
using microfluidic analysis. 
 
4. The impact of the prototypical inducer rifampicin, as well as, rifabutin and 
rifapentine on the mRNA expression of CYP3A4, ABCB1, ABCC1, ABCC2, 
OATP1B1 and OATP1B3 mRNA was determined. Primary human hepatocyte donors 
(6) were treated with 0, 0.5, 5 and 10 μM of drug for 24 hours and gene expression 
analysis used to analyse the effects on the drug disposition genes.  
 
5. The effect of VDR gene expression and VDR SNPs were analysed to 
determine if the NR contributed to differences in PXR, CYP3A4, ABCB1 or 
OATP1B1 mRNA expression in D2 intestinal biopsies. Gene expression and 
genotype analysis (of 5 VDR SNPs) were completed on 84 human intestinal samples 
and linear regression used to determine any correlations. 
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CHAPTER 2 
 
A comparison of key drug 
disposition gene expression including 
NRs and their co-regulators in 
primary human hepatocytes and 
hepatoma cell lines 
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2.1 Introduction 
Initial predictions of drug response and drug-drug interactions are made following 
high-throughput in vitro screening. Such assays are indispensible in the 
pharmaceutical industry to determine the mechanism and safety of new chemical 
entities (NCEs). However, they often fail when extrapolated to predict in vivo 
response due to unsuitable pharmacokinetic or poor pharmacodynamic prediction 
(260). 
 
As described in Chapter 1 (Section 1.2 and 1.3) cytochrome P450 3A4 (CYP3A4), 
ATP binding cassette transporters (ABC), organic anion transporting polypeptides 
(OATP) and nuclear receptors (NR) contribute to the detoxification of xenobiotics 
and endogenous compounds (53, 102, 261). The transcription of CYPs and 
transporters is regulated through PXR, CAR and their co-regulators (111). Previous 
reports have shown extensive correlations between NR expression and CYP activity 
(67, 111, 123, 137, 139, 261) but to date there is no comprehensive and simultaneous 
analysis on the expression of NR co-regulators and CYP3A4 in multiple hepatic 
models.  
 
Variable drug response between individuals is common (due to genotype, drug-drug 
interactions (DDIs), etc.), but advances in the laboratory investigating the complete 
metabolic profile and transport of a compound have improved in vitro predictions 
(244). Hence, in vitro analysis is vital, but limitations arise when predicting an in vivo 
response. In many cases, the models used are not representative of primary cells in 
intact organ systems and relying on over-expression systems does not completely 
avoid the problem. The majority of transfected systems do not generate 
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physiologically relevant expression levels of the protein of interest. 
 
To date, the main in vitro approaches used to investigate drug metabolism are liver 
microsomes or whole cell systems. Liver microsomes (subcellular fractions) 
efficiently retain their CYP function years after extraction from liver tissue. However, 
they only possess the uridine-5’-disphosphate glucuronosyltransferases (UGTs) from 
the phase II class of metabolism enzymes (67). Drug incubations with microsomes are 
limited to 2 hours and involve the assessment of metabolism in the absence of intact 
cells, significantly restricting their use.  
 
Metabolically active cell systems (primary human hepatocytes/transformed 
immortalised hepatic cell lines) are used as an alternative tool. Primary human 
hepatocytes are regarded as the 'gold standard' model of hepatic function and are 
therefore used widely to simulate drug metabolism, toxicity and transport in vitro to 
quantitatively predict the effect in vivo (13, 53, 244, 262). For example, hepatocyte 
studies of aceclofenac, an anti-inflammatory, directly match the metabolic profile 
observed in vivo (86, 244). In addition, current regulatory guidelines require all NCEs 
to be analysed in at least three human hepatocyte donors (46).  
 
Hepatoma cell lines, including Huh7 and HepG2 have the advantage of low cost, 
commercial availability and extensive use in in vitro investigations of hepatotoxicity 
(263), gene regulation in disease and drug response (264) and mechanisms of 
infection of certain pathogens (265). HepG2 and Huh7 cells were derived from 
hepatocellular carcinomas that were extracted from a 15-year old and 57-year old 
male, respectively. Studies have outlined fundamental differences in the gene 
 72 
expression profile of hepatoma cell lines, compared to primary human hepatocytes. 
When grown to confluence, CYP3A4 activity is induced in Huh7 cells (105) but the 
same effect has not been observed for HepG2 cells. Olvasky et al., 2010, found Huh7 
and HepG2 cells were unable to express specific liver function genes to mimic the 
biological response of the cell upon xenobiotic treatment (266). In addition, it has 
been well documented that hepatoma cell lines are unable to exhibit CYP3A4 
expression and activity that resemble primary human hepatocytes (101, 239, 267, 
268).  Consequently, recent studies have focussed on characterising the gene 
expression profiles of key drug transporters (261), NRs (105) and CYPs (105, 148, 
269) between different cell lines. Previous investigations have shown there is a 
significantly lower basal expression of CAR, PXR and their co-activators (SRC-1, 
TIF-2, GRIP) in contrast to an increase in basal levels of co-repressors (NCOR1, 
SMRT) when compared to primary human hepatocytes (270). Another factor for 
consideration when extrapolating from hepatoma cells is fluctuations in gene 
expression across passage number and culture conditions (271).  
 
The aim of this study was to understand the disparities in the gene expression profile 
of key drug disposition genes including CYP3A4, CYP2B6, ABCB1, ABCC1, 
ABCC2, SLCO1B1, SLCO1B3, SLCO1A2, SLCO3A1, NRs CAR and PXR and their 
co-regulators in hepatoma cells (HepG2 and Huh7 cells) versus primary human 
hepatocytes. From initial studies, two co-activators were selected using strict criteria 
to determine if their expression varied over passage number and was subsequently 
correlated to CYP3A4 activity in the HepG2 cell, to ultimately define the mechanisms 
in transcriptional regulation that underpin the levels of CYP3A4 activity.  
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2.2 Methods and Materials 
2.2.1 Materials.  
Vivid
®
 CYP screening kit assays, primary human hepatocytes, Williams E media, 
optiMEM media, cryopreserved hepatocyte recovery medium (CHRM
®
), CHRM
®
 
supplements, Hanks balanced salt solution (HBSS) and Dulbecco’s modified eagle 
medium (DMEM) were purchased from LifeTechnologies, Ltd (Paisley, Scotland). 
Fetal bovine serum (FBS) was purchased from BioSera Co, Ltd (East Sussex, UK). 
Taqman reagents and assays, reverse transcription products and real time-qPCR 
master mix were obtained from Applied Biosystems (Warrington, UK). HepG2 cells 
were purchased from American Tissue Culture Collection (ATCC, Ltd). Huh-7 cells 
were purchased from European Collection of Cell Cultures (ECCAC, HPA). 96-well 
plates pre-coated with collagen IV were purchased from BD Biosciences (Oxford, 
UK). All other reagents were of analytical grade and purchased from Sigma-Aldrich 
(Poole, UK). 
 
2.2.2 Cell Line Maintenance  
DMEM with the addition of 10% FBS (v/v) was used to maintain Huh7 and HepG2 
cells. Cells were seeded in T175 flasks and placed in a humidified incubator (37 
o
C, 
5% CO2). Cells were sub-cultured when approximately 75-85% confluent (~3 days) 
using the standard trypsin and centrifugation method. Previous investigations have 
shown optimum gene expression occurs at passage (p) 10 (271). Hence as a control, 
cells were passaged until p10, used for analysis and then removed to waste. For 
comparative passage analysis, cells were passaged 21 times and analysis completed at 
passage 5, 10, 15 and 20. 
 
 74 
2.2.3 Primary Hepatocytes 
Cryopreserved human hepatocytes from 3 donors (Table 2.1) were thawed in a 37 
o
C 
water bath for approximately 2 min. Once thawed, 50 ml of pre-warmed CHRM
®
 was 
added to the hepatocytes, centrifuged for 10 min at 100 x g and the supernatant 
fraction discarded. The hepatocytes were re-suspended in plating media prepared as 
Williams E media with phenol red (500 ml) supplemented with 1 μM dexamethasone, 
a 1% solution of penicillin-streptomycin, 4 μg/ml insulin, 5% FBS, 2 mM 
GlutaMAX™ and 15 mM HEPES (CHRM® supplement A). 
 
Table 2.1 Human donor demographics of the cryopreserved hepatocytes used in 
the study 
 
2.2.4 Cell viability 
Cell viability and density of primary human hepatocytes were calculated using trypan 
blue exclusion. A 0.4% solution of trypan blue was prepared in buffered isotonic salt 
solution to pH 7.2. 100 μl of cell solution was added to 100 μl of trypan blue stock, 
loaded onto a haemocytometer and counted under a light microscope. A cell viability 
of > 80% was required for all experiments. 
 
Cell viability (%)    =         Number of dead cells (blue)  x 100 
                                    Number of total cells  
Donor Viability Gender 
Donor Demographics 
Age/Race Characteristics 
Hu8089 91 % Male 36year old, Caucasian Alcohol abuse, smoking 
Hu8085 97 % Female 1 year old, Caucasian No alcohol abuse, no smoking 
Hu4244 89 % Male 3 year old, Caucasian No alcohol abuse, no smoking 
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Cell viability of Huh7 and HepG2 cells was calculated using a Countess™ automated 
cell counter (LifeTechnologies, UK). 10 μl of cell suspension was added to 10 μl of 
trypan blue and placed on a Countess™ slide. Using specific algorithms the 
Countess™ measured the approximate size, concentration and viability of the cells.  
 
2.2.5 Plating and maintaining primary human hepatocytes 
Cells were seeded in 96-well plates pre-coated with collagen at a density of 4.5 x 10
4
 
cells/well and incubated for 24 h at 37 ºC with 5% CO2 and 95% humidity. Plating 
media was replaced with 100 μl William’s E media supplemented with optiMEM 
media and a maintenance cocktail of 0.1 μM dexamethasone, a 0.5% solution of 
penicillin-streptomycin, 2 mM GlutaMAX™, 15 mM HEPES, 6.25 μg/ml human 
recombinant insulin, 6 μg/ml human transferrin, 6 μg/ml selenous acid, 1.25 μg/ml 
bovine serum albumin and 5.35 μg/ml linoleic acid (CHRM® supplement B) 
(LifeTechnologies, Ltd), 24 h prior to mRNA extraction (to allow formation of cell-
cell contacts and bile canaliculi).  
 
2.2.6 Extraction and Quantification of mRNA 
Trizol reagent (1 ml) was added to 2-5 x 10
6
 cells for lysis. The resulting sample was 
incubated for 5 min at 37 
o
C followed by centrifugation (12000 x g for 2 min at 2-
8
o
C). The supernatant fraction was then removed to a fresh eppendorf. Chloroform 
(200 l/1ml Tri) was added and the eppendorf shaken vigorously. Incubation at 37 oC 
for 3 min followed. Samples were centrifuged at 12000 x g for 15 min at 2-8 
o
C. The 
upper aqueous phase was transferred to a fresh eppendorf, isopropanol was added (500 
l/1ml Tri) and the solution incubated at 37 oC for 10 min. Centrifugation at 12000 x g 
for 10 min at 2-8 
o
C followed and the supernatant was discarded. Ethanol (75%; 
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1ml/1ml Tri) was added to the pellet, the solution was vortexed and centrifuged at 
7500 x g for 5 min at 2-8 
o
C. The supernatant fraction was removed and the pellet air-
dried for 5-10 min. RNase free water (20 l/1ml Tri) was used to re-dissolve the 
pellet, which was then incubated for 10 min at 58 
o
C. Samples were stored at -80
o
C. 
Quantification of mRNA was achieved by spectrophotometry using a Nanodrop1000. 
The absorbance of UV light at 260 nm determined the concentration (ng/µl) and the 
260:280 nm ratio was used to assess protein contamination (ratio >1.90 was required 
for all experiments). 
 
2.2.7 Synthesis of cDNA from mRNA 
Reverse transcription of mRNA to cDNA was completed using a Taqman

 reverse 
transcription (RT) assay. RT mixtures were made to 50 l volume with RNase free 
water. RT mixtures included; 10X Taqman

 RT buffer (5 l), MgCl2 (5.49 mM), 
reverse transcriptase (1.75 l), RNA (2 μg), dNTP (50 μM), random hexamers (2.5 
μM) and RNase inhibitor (1 M). A GeneAmp PCR 9700 (Applied Biosystems, UK) 
was used to run a thermal cycle of: 10 min at 25 
o
C, 30 min at 48 
o
C, 5 min at 95 
o
C 
and a hold phase at 4 
o
C. Concentrated cDNA was diluted with sigma water to 
produce a working stock of 20ng/µl. 
 
2.2.8 Quantitative real time-PCR  
A Chromo4™ real-time PCR (LifeTechnologies, UK) was used to determine the gene 
expression of selected genes. All samples were completed in triplicate for primary 
human hepatocytes, Huh7 and HepG2 cells. Real time-PCR solutions were prepared 
for each well as follows; 12.5 µl of 2X Taqman
®
 Master Mix, 1.25 l of 20X 
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Taqman
®
 custom assay, 9.25µl sigma water and 2 µl of 20ng/µl of cDNA. Table 2.2 
details the assays (Applied Biosystems) used for each gene with its ID. 
PCR conditions were 15 min at 95 
o
C (to activate polymerase, denature cDNA and 
initiate PCR) followed by 50 cycles of 15 sec at 94 
o
C (denaturation) and 60 seconds 
at 60 
o
C (annealing/extension of the product). Fluorescence was collected at the end of 
each cycle.  
No template controls and no reverse transcriptase controls were completed in 
duplicate to ensure no contamination, specific amplification and maximum 
amplification, respectively. For the custom array 4 housekeeping genes were analysed 
to determine the most constant expression throughout all samples (18s, GUSB, 
HPRT1, GAPDH). In all other experiments, GAPDH was used as a housekeeping 
gene (C(t) values were consistent in every sample). A geometric mean was calculated 
for the 4 housekeeping genes and the value used to normalise the expression data. For 
all other experiments, data were compared to GAPDH and normalised to the primary 
hepatocyte (or control) sample using the comparative threshold cycle (C(t)) method 
(Ct=2^
-∆∆C(t)
). To ensure only gene amplification was measured the C(t) was set to 
ignore any aberrant fluorescence such as that from primer-dimer formation.  
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Gene Description Alias
Chromosomal 
location
Reference 
sequence
Assay ID Gene ID
CYP3A4
Cytochrome P450, family 3, 
subfamily A, polypeptide 4
CP33, CYP3A 7q21.1 NM_017460.5 Hs00604506_m1 1576
CYP2B6
Cytochrome P450, family 2, 
subfamily B, polypeptide 6
CPB6, CYP2B 19q13.2 NM_000767.4 Hs04183483_g1 1555
ABCB1
ATP-binding cassette, subfamily B 
(MDR/TAP), member 1
ABC20, P-GP 7q21.12 NM_000927.4 Hs00184500_m1 5243
ABCC1
ATP-binding cassette, subfamily C 
(CFTR/MRP), member 1
MRP, ABCC 16p13.1 NM_004996.3 Hs01561502_m1 4363
ABCC2
ATP-binding cassette, subfamily C 
(CFTR/MRP), member 2
ABC30, MRP2 10q24 NM_000392.3 Hs00166123_m1 1244
SLCO1A2
Solute carrier organic anion 
transporter family, member 1A2
OATP1A2, 
OATP-A
12p12 NM_134431.3 Hs00203184_m1 6579
SLCO1B1
Solute carrier organic anion 
transporter family, member 1B1
OATP1B1, 
OATP2
12p NM_006446.4 Hs00272374_m1 10599
SLCO1B3
Solute carrier organic anion 
transporter family, member 1B3
OATP1B3, 
OATP8
12p12 NM_019844.3 Hs00251986_m1 28234
SLCO3A1
Solute carrier organic anion 
transporter family, member 3A1
OAPT3A1, 
OATPD
15q26 NM_013272.3 Hs00203184_m1 28232
HSPA4 Heat shock 70kDa protein 4 Hsp70 5q31.1 NM_002154.3 Hs00382884_m1 3312
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Gene Description Alias
Chromosomal 
location
Reference 
sequence
Assay ID Gene ID
HSP90AA1
Heat shock protein 90α, cytosolic, 
class A, member 1
Hsp90 14q32.33 NM_005348.3 Hs00743767_sH 3320
PIH1D1 PIH1 domain containing 1 NOP17 19q13.33 NM_017916.2 Hs00215579_m1 55011
DNAJB1
DnaJ (Hsp40) homolog, subfamily 
B, member 1
Hsp40, HSPF1 19p13.2 NM_006145.1 Hs00428680_m1 3337
HSPA8 Heat shock 70kDa protein 8 HSC70, LAP1 11q24.1 NM_006597.4 Hs00941880_m1 3312
PTGES3
Prostaglandin E synthase 3 
(cytosolic)
p23/TEBP 12q13.13 NM_006601.5 Hs00832847_gH 10728
DNAJC4
DnaJ (Hsp40) homolog, subfamily 
C, member 4
Hsp40 11q13 NM_005528.3 Hs00268602_m1 3338
VCP Valosin-containing protein p97 9p13.3 NM_007126.3 Hs00997642_m1 7415
CDC37 Cell division cycle 37 P50, CDC37 19p13.2 NM_007065.3 Hs00606477_m1 11140
PPID Peptidylprolyl isomerase D CYP-40 4q31.3 NM_005038.2 Hs00234593_m1 5481
STIP1 Stress-induced-phosphoprotein 1 HOP, P60 11q13 NM_006819.2 Hs00428979_m1 10963
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Gene Description Alias
Chromosomal 
location
Reference 
sequence
Assay ID Gene ID
PPP5C
Protein phosphatase 5, catalytic 
subunit
PP5 19q13.3 NM_006247.3 Hs00196577_m1 5536
DNAJA1
DnaJ (Hsp40) homolog, subfamily 
A, member 1
HSDJ, DJ-2 9p13.3 NM_001539.2 Hs00266011_m1 3301
DNAJC7
DnaJ (Hsp40) homolog, subfamily 
C, member 7
TPR2, DJC7 17q11.2 NM_003315.3 Hs00268602_m1 7266
FKBP4 FK506 binding protein 4, 59kDa FKBP52, Hsp56 12q13.33 NM_002014.3 Hs00427038_g1 2288
FKBP5 FK506 binding protein 5 FKBP51, P54 6p21.31 NM_004117.3 Hs01561006_m1 2289
STUB1
STIP1 homology and U-box 
containing protein 1
CHIP, UBOX1 16p13.3 NM_005861.2 Hs00195300_m1 10273
NCOR1 Nuclear receptor co-repressor 1 N-CoR, TRAC1 17p11.2 NM_006311.3 Hs01094540_m1 9611
Sin3A
SIN3 transcriptional regulator 
homolog A
SIN3 homolog A 15q24.2 NM_015477.2  Hs00292479_m1 25942
NRIP1
Nuclear receptor interacting protein 
1
RIP140 21q11.2 NM_003489.3 Hs00942766_s1 8204
HDAC1 Histone deacteylase 1 HD1, RPD3 1p34 NM_004964.2 Hs00606262_g1 3065
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Gene Description Alias
Chromosomal 
location
Reference 
sequence
Assay ID Gene ID
HDAC2 Histone deacteylase 2 HD2, YAF1 6q21 NM_001527.3 Hs00231032_m1 3066
NR0B2
Nuclear receptor subfamily 0, group 
B, member 2
SHP, SHP1, 
DAX1
1p36.1 NM_021969.2 Hs00222677_m1 8431
SREBF1
Sterol regulatory element binding 
transcription factor 1
SREBP1 17p11.2 NM_004176.4 Hs00231674_m1 6720
NCOR2 Nuclear receptor co-repressor 2 SMRT, N-CoR2 12q24 NM_006312.5 Hs00196955_m1 9612
LCOR
Ligand dependent nuclear receptor 
corepressor
MLR2 10q24 NM_032440.3 Hs00287120_m1 84458
CARD16
Caspase recruitment domain family, 
member 16
COP, COP1 11q23 NM_052889.2 Hs00430993_m1 114769
TMTC3
Transmembrane and 
tetratricopeptide repeat containing 3
SMILE 12q21.32 NM_181783.3 Hs00699202_m1 160418
NRBF2 Nuclear receptor binding factor 2 COPR1 10q22.1 NM_030759.3 Hs00852466_g1 29982
MED1 Mediator complex subunit 1 TRAP220, TRIP2 17q12 NM_004774.3 Hs00191130_m1 5469
PSMC5
Proteasome (prosome, macropain) 
26S subunit, ATPase, 5
SUG1, p45 17q23.3 NM_002805.5 Hs00267687_m1 5705
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Gene Description Alias
Chromosomal 
location
Reference 
sequence
Assay ID Gene ID
CARM-1
Coactivator-associated arginine 
methyltransferase 1
PRMT4 19p13.2 NM_199141.1 Hs00406354_m1 10498
Gadd45β
Growth arrest and DNA-damage-
inducible, beta
GADD45BETA 19p13.3 NM_015675.3 Hs00169587_m1 4616
SMC1A
Structural maintenance of 
chromosomes 1A
CDLS2, SMC1 Xp11.22-p11.21 NM_006306.2 Hs00196849_m1 8243
CITED1
Cbp/p300-interacting transactivator, 
with Glu/Asp-rich carboxy-terminal 
domain, 1
MSG1 Xq13.1 NM_004143.3 Hs00366310_m1 12705
NCOA3 Nuclear receptor coactivator 3 AIB1, ACTR 20q12 NM_006534.3 Hs01105251_m1 8202
NCOA5 Nuclear receptor coactivator 3 CIA 20q12-q13.12 NM_020967.2 Hs00253115_m1 57727
NCOA6 Nuclear receptor coactivator 6 ASC2, PRIP 20q11 NM_014071.3 Hs00204160_m1 23054
NCOA1 Nuclear receptor coactivator 1 RIP160, SRC1 2p23 NM_147223.2 Hs00186661_m1 8648
NCOA2 Nuclear receptor coactivator 2 GRIP1, SRC2 8q13.3 NM_006540.2 Hs00197990_m1 10499
PGC1α
Peroxisome proliferator-activated 
receptor gamma co-activator 1
PGC1, 
PPARGC1
4p15.1 NM_013261.3 Hs01016724_m1 10891
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Table 2.2 List of genes analysed using real-time PCR. Assay ID is the Applied Biosystems reference number and gene ID is the NCBI 
reference number. Dye - FAM: 6-carboxyfluorescein 
Gene Description Alias
Chromosomal 
location
Reference 
sequence
Assay ID Gene ID
CREBBP CREB binding protein CBP/KAT3A 16p13.3 NM_004380.2 Hs00231733_m1 1387
NR1I1
Nuclear receptor subfamily 1, group 
1, member 1
VDR 12q13.11 NM_000376.2 Hs00172113_m1 7421
NR1I2
Nuclear receptor subfamily 1, group 
1, member 2
PXR 3q12 NM_003889.3 Hs01114267_m1 8856
NR1I3
Nuclear receptor subfamily 1, group 
1, member 3
CAR 1q23.3 NM_005122.4 Hs00901571 9970
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2.2.9 Measurement of CYP3A4 enzyme activity 
Cells (4.5 x 10
4
/well) were seeded in a black 96-well plate and CYP3A4 activity 
assessed using a Vivid® CYP450 screening assay. The Vivid® substrate is 
metabolised specifically by the CYP3A4 enzyme into highly fluorescent products in 
aqueous solution. CYP450 baculosomes plus reagent (positive control), Vivid® 
regeneration system, Vivid® substrate and Vivid® NADP+ were placed at room 
temperature for 10 min until just thawed, mixed by inversion and then stored on ice 
until ready to use. Vivid® substrate was reconstituted in acetonitrile (2 mM stock 
solution, assay final concentration 3 μM). 2X Vivid® CYP450 reaction buffer was 
diluted in nanopure water (final concentration 100 mM). 40 μl of the 1X Vivid® 
CYP450 reaction buffer was dispensed into the selected wells in triplicate. A master 
pre-mix was prepared for the control wells by combining 1X Vivid® CYP450 
reaction buffer (50.52 μl/well), Vivid® regeneration system (1.04 μl/well) and 
CYP450 baculosomes plus reagent (0.52 μl/well). Final P450 concentration was 5 
nM. Two negative controls were included: one excluding the Vivid® regeneration 
system and one excluding the CYP450 baculosomes plus reagent (1X Vivid® 
CYP450 reaction buffer was used to ensure all volumes were equal). A master pre-
mix was prepared for the test wells by combining 1X Vivid® CYP450 reaction buffer 
(51.04 μl/well) and Vivid® regeneration system (1.04 μl/well). 50 μl of master pre-
mix was added to the selected wells and the plate incubated at 37 
o
C for 20 min. 
During this incubation a 10X Vivid® mix was prepared by combining 1X Vivid® 
CYP450 reaction buffer (9.22 μl/well), Vivid® substrate (0.16 μl/well) and Vivid® 
NADP+ (1.04μl/well). The reaction was initiated by adding 10 μl of the 10X Vivid® 
mix to the wells. 
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Fluorescent measurements were recorded every minute for 20 min at ambient 
temperature using a Tecan Magellan plate reader at 530 nm excitation, 605 nm 
emission and analysed using XFluor software. 
 
Activity endpoint assay calculation: 
CYP3A4 Activity (%) = 
          1  –    Relative fluorescence of hepatic cell line         x  100  
  Relative fluorescence of primary human hepatocytes 
 
 
2.2.10 Data Analysis.  
All data presented for the Huh7 and HepG2 cells is the mean of three independent 
isolations completed in triplicate. The primary hepatocyte data for the CYP3A4 
activity analysis and mRNA expression was mean of three donors completed in 
duplicate. Normality of all data was assessed using a Shapiro-Wilk test and for gene 
expression data statistical analysis conducted using paired t-test or Wilcoxon signed-
rank test for normally or non-normally distributed data, respectively. For comparison 
of CYP3A4 activity and co-activator expression, statistical analysis was conducted 
using Spearman’s or Pearson test for normally or non-normally distributed data, 
respectively. Statistical analyses were conducted using Stats Direct (Version 2.4.6 
Stats Direct Ltd). Results were considered significant if; *, p < 0.05; **, p < 0.01; 
***, p < 0.001. 
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2.3 Results 
2.3.1 Relative gene expression of key drug transporters and metabolism enzymes 
Previous work has shown differences in the expression of key drug transporters and 
metabolism enzymes between hepatic cells but significance varies between studies 
(261). Hence, initial work focused on assessing the gene expression of ABCC1, 
ABCC2, ABCB1, CYP3A4, CYP2B6, OATP1A2, OATP1B1, OATP1B3 and 
OATP3A1 in hepatoma cell lines (HepG2 and Huh7) compared to primary human 
hepatocytes. Figure 2.1, shows all of the genes analysed had a lower expression in 
hepatoma cells compared to primary human hepatocytes. In addition, excluding 
ABCB1 and CYP3A4, gene expression varied between HepG2 and Huh7 cells. As a 
whole, Figure 2.1 shows Huh7 cells express approximately 25% more of these genes 
than HepG2 cells and the majority of genes expressed in HepG2 cells were 
significantly less than the primary human hepatocytes. In agreement with the 
literature (105, 236, 270) CYP3A4 was expressed ~50% less in hepatoma cells 
compared to primary human hepatocytes (p=0.02). Expression of CYP2B6 was near 
absent in HepG2 cells compared to a 30% expression in Huh7 cells when compared to 
primary human hepatocytes.  
 
The efflux transporters ABCC1 and ABCC2 were expressed significantly less (~65%) 
in HepG2 cells compared to primary human hepatocytes and ~40% and 10% less in 
Huh7 cells. In contrast, both cell lines expressed significantly less ABCB1 (80%, 
p=0.005) compared to primary human hepatocytes. The expression of OATP influx 
transporters varied considerably between cell types. In comparison to OATP1A2 and 
OATP1B1, OATP1B3 and OATP3A1 had greater expression in HepG2 cells although 
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this was also significantly lower than that observed in the primary human hepatocytes 
(42% (p=0.001) and 92%, respectively). 
 
Figure 2.1 Relative gene expression of efflux / influx drug transporters and CYPs 
in Huh7 (◆) and HepG2 (◆) cells compared to primary human hepatocytes. Data are 
normalised to GAPDH house keeping gene and to a pool of 3 primary human 
hepatocyte donors using the comparative C(t) method (C(t)=2^
-ddC(t)
). Data are 
expressed as the mean of 3 independent isolations completed in duplicate ± standard 
deviation. p<0.05 *, p<0.01 **, p<0.0001 *** 
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2.3.2 PXR and CAR gene expression 
The expression of the key drug disposition genes analysed in Figure 2.1 are tightly 
regulated by xenobiotic sensors PXR and CAR (133). The expression of PXR and 
CAR was analysed in HepG2 and Huh7 cells at passage 10 (Figure 2.2). CAR 
expression was undetectable in Huh7 cells (p>0.0001) whereas HepG2 cells 
expressed 20% of CAR (p=0.004) in comparison to primary human hepatocytes. The 
expression of PXR was consistent in both cell lines, but expression was ~80% less 
when compared to primary human hepatocytes (p=0.007 and p=0.008 for Huh7 and 
HepG2 cells, respectively). 
 
Figure 2.2 Relative gene expression of NRs CAR and PXR in Huh7 and HepG2 
cells compared to primary human hepatocytes. Data were normalised to GAPDH 
house keeping gene and to a pool of 3 primary human hepatocyte donors using the 
comparative C(t) method (C(t)=2^
-ddC(t)
). Data are expressed as the mean of 3 
 89 
independent isolations completed in duplicate ± standard deviation. p<0.05 *, p<0.01 
**, p<0.0001 *** 
 
2.3.3 CYP3A4 activity versus cell passage number 
As shown in Figure 2.1, CYP3A4 gene expression was expressed ~50% less in 
HepG2 and Huh7 cells compared to primary human hepatocytes. The next step was to 
determine if the same effect was observed at the activity level and whether the activity 
of CYP3A4 varied as cell line passage number increased, comparing all data to 
primary human hepatocytes. A CYP3A4 Vivid® fluorescent assay was used to 
kinetically measure the activity of CYP3A4 in HepG2 cells (Figure 2.3). At passage 
5, CYP3A4 activity was 78% of the primary human hepatocyte but as passage number 
increased, CYP3A4 activity decreased. At passage 10, CYP3A4 activity was 49% 
(Figure 2.3), paralleled to 53% mRNA expression (Figure 2.1) both compared to 
primary human hepatocytes. At passage 20, CYP3A4 activity was reduced to 26% 
(p=0.0082). Furthermore, at passage 25 activity decreased to 17% (p=0.006) of the 
primary human hepatocyte activity. 
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Figure 2.3 Relative activity of CYP3A4 in HepG2 cells compared to primary 
human hepatocytes. Data are compared to 3 primary human hepatocyte donors and 
expressed as the mean of 3 independent isolations completed in duplicate ± standard 
deviation. p<0.05 *, p<0.01 **, p<0.0001 ***. 
 
2.3.4 PXR and CAR co-regulator gene expression array 
Chaperones retain NRs in complexes within the cytoplasm preventing/hindering their 
transcriptional activation. Along with a reduced expression of CAR and PXR, all 
chaperones were under-expressed in the cell lines compared to primary human 
hepatocytes (Figure 2.4a). Whilst there was a difference in expression of NR 
chaperones between Huh7 and HepG2 cells, the expression of all 4 chaperones was 
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consistent in each cell type. HSPA8, HSPA4 and HSP90AA1 were expressed 50% 
less compared to primary human hepatocytes in HepG2 cells in contrast to 10% in 
Huh7 cells (p=0.009, p=0.002, p=0.002 for HSPA4, HSP90AA1 and HSPA8, 
respectively). PIH1D1 basal expression was maintained in HepG2 cells when 
compared to primary human hepatocytes but 95% less in Huh7 cells (p=0.02). 
 
Co-chaperones are components of the binding complex retaining NRs in the 
cytoplasm. Similar basal levels of DNAJB1 was observed in HepG2 and Huh7 cells 
compared to primary human hepatocytes (Figure 2.4b) as well as PPP5C, STUB1, 
FKBP4 and DNAJC4 in HepG2 cells. Whilst FKBP5 and PTGE3S were found to be 
expressed ~80% less (p=0.004, p=0.003 for PTGE3S and p=0.002, p=0.002 for 
FKBP4 in Huh7 and HepG2 cells, respectively) compared to primary human 
hepatocytes, basal expression was comparable between cell lines. In contrast, VCP 
(p=0.04), STIP1 (p=0.05) and PPP5C (p=0.004) were significantly over-expressed in 
Huh7 cells and PPID (p=0.002), CDC37 (p=0.009), DNAJA1 (p=0.004), VCP 
(p=0.002) and DNAJC7 (p=0.002) were significantly under-expressed in HepG2 cells 
compared to primary human hepatocytes. 
 
Co-repressors involved in preventing gene transcription are shown in Figure 2.4c. The 
cell lines displayed very different gene expression profiles. All co-repressors were 
significantly under-expressed in Huh7 cells, excluding HDAC2 and HDAC1 when 
compared to primary human hepatocytes. In comparison, TMTC3 was expressed 
350% (p=0.007) more in Huh7 cells when compared to primary human hepatocytes 
and 429% more compared to HepG2 cells. In HepG2 cells, Sin3A, SREBF1, NCOR1 
 92 
and NRIP1 presented similar basal expression levels to the primary human 
hepatocytes. 
 
A similar trend was observed for co-activator expression (Figure 2.4d). Variable 
results were presented for each gene between cell types. However, HepG2 cells 
displayed basal levels comparable to primary human hepatocytes for NRBF2, 
CARM1, NCOA1, PSMC5, NCOA6 and SMC1A. Gadd45β and PGC1α exhibited 
similar expression in Huh7 and HepG2 cells when compared to primary human 
hepatocytes. Expression of PGC1α and Gadd45β in Huh7 cells was 8% (p=0.002) and 
2% (p=0.003), respectively and expression in HepG2 cells was 11% (p=0.0004) and 
8% (p=0.004), respectively. 
 
Throughout the NR co-regulator analysis, HepG2 cells were found to present gene 
expression closer to primary human hepatocytes when compared with Huh7 cells. 
Hence, further analysis was completed with HepG2 cells. 
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Figure 2.4 Relative gene expression of NR chaperones (A), NR co-chaperones 
(B), NR co-repressors (C) and NR co-activators (D) in Huh7 and HepG2 cells, 
compared to primary human hepatocytes. Data are normalised to a geometric mean of 
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4 house keeping genes and to a pool of 3 primary human hepatocyte donors using the 
comparative C(t) method (C(t)=2^
-ddC(t)
). Data are expressed as the mean of 3 
independent isolations completed in duplicate ± standard deviation. p<0.05 *, p<0.01 
**, p<0.001 *** 
 
 
2.3.5 Selection of Gadd45β and PGC1α 
To determine whether the decrease in CYP3A4 activity and mRNA expression in 
hepatoma cell lines was a result of altered NR co-regulator expression, a strict 
criterion was applied. The selection criteria included: 
- mRNA expression in the co-regulator assay (Figure 2.4) was <20% for both 
cell lines compared to primary human hepatocytes 
- there was evidence in the literature of CYP interactions 
- the co-regulators modulate the expression/activity of CAR and PXR 
- there was evidence in the literature of cell maintenance/growth regulation by 
the co-regulator 
 
Based on these selection criteria, Gadd45β and PGC1α were progressed for further 
analysis. 
 
 
2.3.6 Gadd45β and PGC1α gene expression versus HepG2 cell passage number 
The expression of Gadd45β and PGC1α was determined over 25 passages with results 
recorded every 5 passages (Figure 2.5). In agreement with Figure 2.4d, Gadd45β and 
PGC1α expression at passage 10 was found to be 14% (p=0.007) and 8% (p=0.004) 
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when compared with primary human hepatocytes. As cell passage increased the 
expression of both co-activators decreased, at passage 25 Gadd45β and PGC1α 
expression was 0.68% (p=0.001) and 1.69% (p=0.001) compared to primary human 
hepatocytes, respectively. 
 
 
 
Figure 2.5. Relative gene expression of Gadd45β and PGC1α in HepG2 cells over 
25 passages, compared to primary human hepatocytes. Data are normalised to 
GAPDH house-keeping gene and to a pool of 3 primary human hepatocyte donors 
using the comparative C(t) method (C(t)=2^
-ddC(t)
). Data are expressed as the mean of 
3 independent isolations completed in duplicate ± standard deviation. p<0.05 *, 
p<0.01 **, p<0.0001 *** 
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2.3.7 Correlation of CYP3A4 activity with cell passage and Gadd45β/PGC1α gene 
expression 
As shown in Figure 2.5 and 2.3, expression of Gadd45β and PGC1α and activity of 
CYP3A4 decreased significantly over cell passage, respectively. Linear regression 
analysis was used to determine the relationship between Gadd45β/PGC1α mRNA 
expression in HepG2 cells (compared to primary human hepatocytes) and the activity 
of CYP3A4 in primary human hepatocytes. A significant linear relationship was 
observed for Gadd45β and CYP3A4 activity (r2=0.88) (Figure 2.6a) as well as PGC1α 
gene expression and CYP3A4 activity (r
2
=0.93) (Figure 2.6b). 
 
 
 98 
 
 
Figure 2.6. Relative gene expression of Gadd45β (A) and PGC1α (B) with 
CYP3A4 activity in HepG2 cells across 20 passages (p5 (), p10 (), p15 (), p20 
(), p25 (). Expression data are normalised to GAPDH house keeping gene and to 
a pool of 3 primary human hepatocyte donors using the comparative C(t) method 
(C(t)=2^
-ddC(t)
). Activity data was calculated as relative fluorescent units/min as a 
percent of 3 primary human hepatocyte donors. Data are expressed as the mean of 3 
independent isolations completed in duplicate. 
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2.4 Discussion 
The bioavailability and disposition of a drug is largely governed by biotransformation 
mechanisms and transport. These mechanisms occur in the intestine but the liver is 
clearly a major organ for metabolic clearance. Traditional analyses are completed 
using established in vitro models but many more are in development and validation 
stages. Although hepatic cell lines are widely used as they retain many hepatic 
functions, they have limitations with numerous reports recording lower levels of drug 
transporters and CYPs (84, 105, 261, 272) than primary hepatic cells, which have 
very similar gene expression profiles to liver tissue (268, 273). Some studies have 
reported extremely low levels of CYP3A4 mRNA and protein in HepG2 cells that are 
not induced upon rifampicin (RIF) treatment (274). Nonetheless, cell lines have been 
pivotal in defining mechanisms for transcriptional regulation including, constitutive 
activation of CYP2B6 and CYP3A4 by CAR through its accumulation in the nucleus 
due to a lack of cytoplasmic CAR retention protein (CCRP, designated DNAJC7 in 
the NCBI database) (164, 165). Therefore, they provide tools for drug metabolism, 
toxicity and absorption studies. 
  
Primary human hepatocytes display common hepatic functions, similar levels of gene 
expression and metabolism observed in vitro and in vivo (271). Analysis can be 
completed on suspension hepatocytes that retain hepatic function for 4-6 hours (275) 
or on cultured hepatocytes that display hepatic capabilities for ~24 hours post plating 
(244), meaning both methods can be utilised in drug metabolism or toxicity studies. 
Interestingly, cryopreservation of primary human hepatocytes is linked with a 
selective decrease in gene expression, drug metabolism (275) and a loss of specific 
sub-types including diploid and tetraploid cells accompanied with decreased cell 
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viability (271). Although inter-individual variation between human hepatocyte donors 
is high, the greatest asset of using isolated hepatocytes is the ability to assess active 
drug transport, metabolism and response to metabolite formation. 
 
This chapter focussed on characterising the gene expression profiles of HepG2 and 
Huh7 cell lines in comparison with primary human hepatocytes to consequently 
determine any relationships between NR co-regulators and CYP3A4. It should be 
noted that the results and conclusions are based on mRNA expression data, which 
may not always correlate to protein expression or activity. However, strong 
correlations for efflux transporters and CYPs are well documented in the literature 
(261, 276). Protein expression analysis of all genes would be required to completely 
correlate data, but due to challenges in proteomic assessment of nuclear and 
membrane bound proteins (277) and the number of candidates selected, mRNA 
analysis was deemed to be the most appropriate alternative.  
 
Although clear similarities were found for some genes, variability was observed 
between cell lines and primary human hepatocytes. Initially, work focussed on 
assessing the quantitative differences of key drug transporter and metabolism enzyme 
gene expression (Figure 2.1). Of the 3 efflux transporters investigated (ABCB1, 
ABCC1, ABCC2), ABCC2 expression was found to be similar to primary human 
hepatocytes. The most abundantly expressed efflux transporter in the human liver is 
ABCC2 (261) suggesting analysis of this transporter may be completed with more 
confidence in Huh7 cell lines. However, the most abundantly expressed influx 
transporter of the liver, OATP1B1 was found to have significantly lower levels of 
expression in the cell lines (~1-20%). Synergistic transport by OATP1B1 and ABCC2 
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has been identified as a crucial mechanism of both proteins involved in the transport 
of substrates including, HMG-CoA reductase inhibitors (e.g. simvastatin, 
rosuvastatin, pravastatin) hence, biliary secretion should be analysed with caution in 
the two hepatic cell lines investigated. OATP1B1 is an important mediator of 
CYP3A4 metabolism due to the large overlap in substrate affinity as well as 
governing access of substrates to the enzyme (30, 278). Hence, it may be a 
contributing mechanism for the low CYP3A4 metabolic activity reported in these 
cells.  
 
ABCB1 has a low expression in the human liver but is significantly induced during 
regeneration and cholestasis (279). ABCB1 and CYP3A4 were significantly under 
expressed in both hepatic cell lines compared to primary human hepatocytes. In 
contrast, an up-regulation of CYP3A4 expression has been observed in confluent 
Huh7 cells but the mechanism by which this occurs is yet to be determined (105). 
CYP3A4 mRNA expression and activity in HepG2 cells were found to be a poor 
representation of primary human hepatocytes (Figure 2.1 and 2.3, respectively). 
Additionally, the passaging process correlated to a decrease in CYP3A4 activity 
(Figure 2.3), as previously observed (84, 280). CYP3A4 activity was comparable to 
values noted by others (101). The major drug disposition genes analysed in Figure 2.1 
are targets of the NRs CAR and PXR, which regulate their transcription thus it was 
also important to consider NR expression.  
 
NRs CAR and PXR are strict regulators of drug metabolism, cell growth, 
differentiation, apoptosis and cell migration. One would therefore predict variable NR 
expression in immortalised cells, as demonstrated in Figure 2.2. In agreement with 
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previous studies (111), relative to primary human hepatocytes, HepG2 and Huh7 cells 
expressed diminished levels of CAR and PXR. CAR and PXR control the expression 
of the genes analysed in Figure 2.1, hence their reduced expression in hepatoma cell 
lines (compared to primary human hepatocytes) is a likely consequence of 
significantly low levels of the NRs (94). Albeit minimal, detection of CYP3A4 and 
NR mRNA in HepG2 and Huh7 hepatoma cells implies gene expression is not fully 
eradicated by known molecular mechanisms such as methylation alterations and/or 
chromatin condensation. CAR and PXR are also regulated by a number of 
transcriptional modifiers (Table 1.4). Comparative analysis of these transcription 
factors between HepG2 and Huh7 hepatic cell lines and primary human hepatocytes 
showed significant disparities in gene expression profiles (Figure 2.4).  
 
The cellular chaperones are essential in coordinating the translocation of proteins. The 
major chaperone Hsp90 is responsible for not only positively folding DNA but 
supports and contributes to protein degradation (281), chromatin remodelling (282) 
and cytoskeleton movement (283). The mechanisms by which Hsp90 orchestrates 
these functions are currently under investigation. However, due to its diverse abilities 
and correlation with oncogenic proteins Hsp90 has the potential to be targeted for 
cancer and immunological dysfunction treatments (282, 284). The chaperones 
investigated herein (HSPA4, HSPA8, HSP90AA1, PHI1D1, Figure 2.4a) were under 
expressed in HepG2 cells and significantly under expressed in Huh7 cells when 
compared to primary human hepatocytes. Within the liver and primary human 
hepatocytes nuclear translocation of CAR predominantly occurs via activation 
cascades. However, it has been noted within transformed hepatic cell lines that CAR 
spontaneously accumulates in the nucleus (285). Hence, the low expression of 
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chaperones in hepatoma cell lines here may be a result of this spontaneous 
mechanism. 
 
In contrast to the chaperones, the majority of co-chaperones expressed in Huh7 cells 
were over-expressed when compared to primary human hepatocytes, whilst the 
majority were under expressed in HepG2 cells (Figure 2.4b). Co-chaperones serve to 
stabilise the chaperone conformation and extend the binding region to the NR (205). 
Inhibition of these co-chaperones (VCP, CDC37) has been shown to result in lethal 
perinatal outcomes in knockout mice (286). The dissociation of the chaperone/co-
chaperone complex from NRs in vivo is highly dependent upon hydrolysis of ATP. In 
vitro co-chaperones have been found to dynamically exchange on chaperones leading 
to many behavioural displays by the NR (205). Co-chaperones (FKBP4, FKBP5, 
PPP5C) primarily attenuate or potentiate receptor activity and binding of hormones 
involved in cell growth and survival. Therefore, the over-expression of these genes in 
immortalised cells is not surprising. In addition, the lack of chaperone expression may 
also contribute to the low expression observed in the HepG2 cells. In contrast to work 
herein, DNAJC7 has been reported to be significantly over-expressed in HepG2 cells 
compared to Huh7 cells or primary human hepatocytes and is associated with higher 
levels of CAR in the cytoplasm (188). Possible reasons for the discrepancy in co-
chaperone expression may be due to the maintenance buffer used, media supplements, 
cell passage number or if the cells have diverged. 
 
Co-repressors bind to unliganded, antagonist or inverse agonist bound NRs to prevent 
the interactions and actions of co-activators (184). Similar to all the co-regulators 
analysed, Huh7 cells poorly expressed co-repressors in comparison to HepG2 cells 
 104 
(Figure 2.4c). However, TMTC3 strongly competes with the co-activators NCOA2 
and PGC1α (212) and therefore, the significant over expression of TMTC3 in Huh7 
cells may contribute to the significantly reduced expression of the co-activators 
(Figure 2.4c and 2.4d). TMTC3 recruits HDAC1 and HDAC2, thus the expression of 
the co-repressors may be a consequence of this signalling cascade. The same trend 
was not observed for HepG2 cells. Expression of SREBF1 is associated with 
decreased xenobiotic clearance and regulation of cholesterol and triglyceride 
synthesis (208). Expression of this co-repressor was significantly lower in Huh7 cells 
but HepG2 cells expressed similar levels of the gene to primary human hepatocytes. 
Regulation of this gene is crucial to ensure optimum lipid metabolism suggesting 
HepG2 cells may be more reliable in this context.  
 
The NCOA family of co-activators function as intermediate signalling genes to 
enhance transcription and it has also been demonstrated they play a key part in 
general metabolism (287). Conflicting data exist for NR co-activator expression in 
hepatoma cell lines (192, 207). We found NCOA1, NCOA2, NCOA3, NCOA5 and 
NCOA6 were under expressed in both cell lines compared to primary human 
hepatocytes suggesting the transformed cell lines may utilise alternative pathways. To 
restore CYP3A4 activity and inducibility, studies have also found transfection of 
NCOA1 and PGC1α genes increases PXR, hepatocyte nuclear factor 4 α (HNF4α) 
and CYP3A4 gene expression in HepG2 cells. However, CYP3A4 activity and 
induction was not restored (96, 288). Gadd45β is known to mediate numerous cellular 
functions including: apoptosis, cell growth and DNA repair by interacting with cyclin 
and cyclin-dependent kinases (203). Hence, one may predict increased expression of 
the co-activator in immortalised cells but this was not apparent (Figure 2.4d). 
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Activation of PXR by Gadd45β has no effect on cell growth in vitro, rather HepG2 
cells have been found to differentiate into epithelial-mesenchyma (202). In addition, 
an over expression of CAR is correlated to an upregulation of Gadd45β (203); the 
converse may also be expected which is demonstrated herein (Figure 2.1 and 2.4d). 
PGC1α regulates adaptive thermogenesis, gluconeogenesis, mitochondrial activity 
and oxidative metabolism, making it a crucial hepatospecific transcription factor. In 
comparison to primary human hepatocytes, PGC1α was significantly under-expressed 
in Huh7 and HepG2 cell lines, as observed previously (207, 288). 
 
In comparison to the environment in vivo, cultured hepatoma cell lines experience 
different stimuli in terms of cell stress, growth factors, tissue specific functions and 
xenobiotic exposure which may contribute to the significantly altered phenotype 
observed here. It is feasible to hypothesise that the hepatoma cell may adapt to its 
artificial environment with its primary aim to preserve life in the most efficient way 
possible rather than preservation of hepatic functions, since selective pressures will be 
different. The analysis completed clearly outlines the extent of gene expression 
disparities between hepatoma cells and primary human hepatocytes and the caution 
that should be applied when utilising the cells for drug metabolism and transport 
studies.  
 
Cell passage can alter the phenotype and morphology of cell lines, which are 
particularly apparent at high passage number (67, 289). CYP3A4 activity (Figure 2.3) 
and NR co-activator Gadd45β and PGC1α expression were significantly reduced as 
HepG2 cell passage number increased (Figure 2.5). Linear correlations between 
Gadd45β/PGC1α expression and CYP3A4 activity in HepG2 cells were observed 
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(Figure 2.6). Whilst the correlation for Gadd45β and CYP3A4 is novel, the 
association of PGC1α and CYP3A4 is consistent with previous work (288).  
 
In summary, we have determined the extent of the disparities between hepatic cell 
lines (HepG2 and Huh7) and primary human hepatocytes by comprehensively 
analysing the expression of key drug disposition genes, PXR, CAR and their co-
regulators, which has not previously been assessed. Potential reasons for altered gene 
profiles in HepG2 and Huh7 cells were elucidated and Gadd45β and PGC1 were 
identified as potential mediators for the lack of CYP3A4 activity and expression in 
HepG2 cells and were therefore selected for work aimed at restoration of metabolic 
function in Chapter 3. 
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CHAPTER 3 
 
Determinants of transcriptional 
regulation of CYP3A4 activity in 
hepatoma cell lines 
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3.1 Introduction 
Primary human hepatocytes are extensively used in in vitro drug metabolism and 
toxicity screening (262). However, despite them being the current ‘gold standard’ 
(244), limitations are evident (246, 249) (see Chapter 2, Section 2.3 for more detail). 
 
Accuracy of predictions from early stage in vitro assays in drug discovery are often 
hindered by the use of cell lines due to their altered metabolic processes and lack of 
hepatospecific functions (105). Comparisons between cell lines and primary human 
hepatocytes are discussed in more detail in Chapter 2 but the mechanism of sustaining 
CYP levels by both cell types is achieved through the concerted role of tissue specific 
and ubiquitously expressed transcription factors (96). For example, the expression of 
CYP3A4 is directed by co-regulators, with co-activators representing the primary 
target of physiological signals (95, 96, 193). Furthermore, based on the significance 
between PGC1α, Gadd45β and CYP3A4 found in Chapter 2, it was deemed 
appropriate and beneficial to determine the impact on CYP3A4 upon upregulation of 
the 2 co-activators. 
 
NR co-activator, peroxisome proliferator-activated receptor-gamma co-activator 1-
alpha (PGC1α), is a member of the PGC1 family expressed in the cell nucleus on 
chromosome 4 (290). It is involved in mitochondrial biogenesis, drug metabolism 
(although levels are relatively low in the liver in comparison to the heart where 
mitochondria are abundant (291)), adaptive thermogenesis and gluconeogenesis (290). 
PGC1α binds the N-terminal regions of histone acetylase proteins (HAT) (e.g. p300, 
CBP, SRC-1) or forms a complex at its C-terminal region with protein mediator 
complex (TRAP/DRIP) (292, 293). This binding displaces any present co-repressor 
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proteins, allowing access of DNA to the transcriptional complex, subsequently 
initiating gene transcription (294). In contrast to other co-activators, PGC1α has a 
distinctive architecture, comprising a RNA recognition motif (RRM) at the C-terminal 
and a rich serine/arginine (RS) domain (252).  
 
The main mechanism of PGC1α binding is dependent upon cell type and nutritional 
status but primarily it forms a complex to 3’-5’-cyclic adenosine monophosphate 
(cAMP) at its proximal promoter region, inducing the cAMP signaling pathway (291). 
Previous studies have demonstrated PGC1α is key in the regulation of NRs including 
hepatocyte nuclear factor 4α (HNF4α) (295), constitutive androstane receptor (CAR) 
(252) and pregnane x receptor (PXR) (137), all of which are responsible for 
influencing the expression of cytochrome P450 enzymes (CYPs) and transporters 
(137). Martinez-Jimenez et al., 2006a, showed co-transfection of PGC1α and HNF4α 
increased the expression of CYP1A1, CYP1A2 and CYP2C9, but the same effect was 
not observed when the genes were transfected alone (207). In contrast, when PGC1α 
was transfected alone, Martinez-Jimenez et al., 2006b achieved a significant increase 
in CYP1A1, CYP1A2 and CYP2C9 as well as a moderate increase in CYP2D6, 
CYP3A4 and CYP3A5 (96). However, Novotna et al., 2012, succeeded in increasing 
HNF4α, PXR, aryl hydrocarbon receptor (AhR) and fibrinogen protein but did not 
observe any increase in CYP enzyme expression (288).   
 
Growth arrest and DNA damage inducible 45 beta (Gadd45β) is a NR co-activator 
that responds immediately to external stress including, inflammation (cytokines) and 
oxidative stress (296). Similar to PGC1α, Gadd45β modulates numerous processes 
that are cell specific. It is involved in DNA repair, apoptosis and cell cycle regulation 
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(297, 298). The main mechanism of Gadd45β is activation of the p38 mitogen-
activated protein kinase (MAPK) pathway (297), where MTK1/MEKK4 form a 
complex directly with Gadd45β, repressing apoptosis and enhancing cell proliferation 
(299, 300). One would therefore speculate that Gadd45β expression may be greater in 
hepatoma cells in comparison to primary human hepatocytes. However, unregulated 
growth observed in hepatoma cells has been shown to be associated with a negative 
correlation of Gadd45β expression (301). Qiu et al., (2007) and results from Chapter 
2 have demonstrated Gadd45β expression is significantly reduced in HepG2 and 
Huh7 cells compared to primary human hepatocytes. Upon activation of PXR and 
CAR, the DR4 promoter region of Gadd45β binds directly to the NRs, activating the 
p38 MAPK pathway altering cell morphology but not cell growth (203). Although 
current literature details no specific link between Gadd45β and CYP3A4, the 
activation pathway detailed above allows speculation that Gadd45β may contribute to 
xenobiotic activation of NRs (203). 
 
Having identified a positive correlation between the mRNA expression of Gadd45β or 
PGC1α and CYP3A4 activity in Chapter 2, the aim of this chapter was to determine 
whether manipulation of Gadd45β and PGC1α expression in hepatoma cells, can 
produce a more physiologically relevant phenotype.   
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3.2 Methods and Materials 
3.2.1 Materials.  
Primary human hepatocytes, Vivid
®
 CYP screening kit, Lipofectamine2000, Williams 
E media, optiMEM media, CHRM
®
, Hanks balanced salt solution (HBSS) and 
Dulbecco’s modified eagle medium (DMEM), OptiMEM media and western blotting 
reagents were purchased from LifeTechnologies, Ltd (Paisley, Scotland). β-Actin 
(Ab6276), PGC1α (Ab54481), Gadd45β (Ab105468) primary antibodies and 
secondary antibodies (Ab97240 and Ab6721) were sourced from AbCam (Cambridge, 
UK). Fetal bovine serum (FBS) was purchased from BioSera Co, Ltd (East Sussex, 
UK). Taqman reagents and assays, reverse transcription products and real-time qPCR 
master mix were obtained from Applied Biosystems (Warrington, UK). HepG2 cells 
were purchased from American Tissue Culture Collection (ATCC, USA). Purified 
plasmids were purchased from GeneCopoeia (MD, USA). Chemically competent 5α 
E.coli and BsaAI restriction digest enzyme were purchased from New England 
BioLabs (Herts, UK). HPLC grade acetonitrile (ACN), methanol (MeOH) and diethyl 
ether were purchased from Fisher Scientific (Loughborough, UK). A 3 µm C18, 100 x 
4.6 mm Fortis
®
 column was obtained from Fortis
®
 Technologies Ltd (Neston, UK).  
Plasmid midi-prep kits, CelLytic™ M, midazolam hydrochloride (MDZ), 1’-
hydrozymidazolam and all other products were of analytical grade and purchased from 
Sigma-Aldrich (Poole, UK). 
 
3.2.2 Cell Line Maintenance.  
HepG2 cells were passage and maintained as described in section 2.2.2. HepG2 cells 
were passaged until p10, used for analysis and then removed to waste. 
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3.2.3 Thawing and plating of cryopreserved primary human hepatocytes. 
Cryopreserved human hepatocytes were thawed as previously described in section 
2.2.3. Donor demographics are detailed in Table 2.1. 
 
3.2.4 Cell viability 
Cell viability and density of primary human hepatocytes were calculated using trypan 
blue exclusion as described in section 2.2.4. 
 
3.2.5 Plating and maintaining primary human hepatocytes 
24 h prior to midazolam (MDZ) treatment cells were seeded in 96-well plates pre-
coated with collagen at a density of 4.5 x 10
4
 cells/well and incubated for 24 h at 37 
ºC with 5% CO2 and 95% humidity as described in section 2.2.5. Plating media was 
replaced with 100 μl William’s E media supplemented with optiMEM media and 
CHRM
® 
supplement B (LifeTechnologies, Ltd).  
 
3.2.6 Cell treatment 
24 hours post plating, plating media was replaced with maintenance media (as 
described in section 2.2.5) for primary human hepatocytes or replaced with fresh 
DMEM/10% FBS for HepG2 cells containing rifampicin (RIF) at concentrations 
spanning the therapeutic range (0.5, 5 and 10 μM) for 24 hours. Following 24 h 
incubation with RIF, cells were washed twice in HBSS and incubated for 60 min with 
3.37 μM MDZ. 
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3.2.7 Transformation of chemically competent 5-α E. coli 
Purified pEZ-M02 vectors containing Gadd45β and PGC1α (Figure 3.1 and 3.2) were 
transformed separately into E. coli. Agar plates were produced containing 100 μg/ml 
ampicillin to select for positive colonies. One vial of DH 5-α chemically competent E. 
coli was defrosted per transformation. Plasmid DNA (10 pg) was added to a vial of E. 
coli and incubated on ice for 30 min, cells were heat shocked at 42 
o
C for exactly 30 
sec and then placed back on ice. Warmed SOC medium (950 μl, 37 oC) was added to 
the vial and the solution placed in an incubator at 37 
o
C and shaken at 250 rpm for 1 
hour. A range of culture dilutions (1:1, 1:10, 1:100) were streaked onto warmed agar 
plates whilst ensuring enough space was allowed for growth and separation and 
incubated at 37 
o
C overnight. Following incubation, single colonies were removed 
from the agar plate and added to Luria Bertani (LB) broth (4 ml) and incubated 
overnight at 37 
o
C and 250 rpm. 100 μl of the overnight incubation was added to 25 
ml of LB broth containing 100 μg/ml ampicillin to select for positive colonies and 
incubated at 37 
o
C overnight at 350 rpm. 
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Figure 3.1. Details, restriction sites within the pEZ-M02 plasmid containing 
Gadd45β (A) plasmid virtual digest results and (B) and the size of the digest products 
(C). 
 
Figure 3.2. Details, restriction sites within the pEZ-M02 plasmid containing 
PGC1α (A) plasmid virtual digest results and (B) the size of the digest products (C). 
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3.2.8 Restriction endonuclease analysis of DNA samples 
To ensure the gDNA of E. coli contained PGC1α and Gadd45β, restriction enzyme 
digest was completed. Using the vector information sheet and the NEB cutter 
software, BsaAI was shown to produce 3 distinct bands when the vector was cut to 
determine the correct insertion via virtual digest (see vector maps, Figure 3.1 and 3.2). 
The dsDNA was extracted using a Sigma Midiprep kit; overnight positive cultures (25 
ml) were centrifuged at 5000 x g for 10 min. Resuspension/RNase A solution (2 ml) 
was used to resuspend the pellet and lysis buffer (2 ml) added to lyse the cells. To 
neutralise the cell solution, neutralisation solution (2 ml) was added. To neutralise the 
lysate, 1.5 ml of binding solution was added to the solution and the cell lysate left to 
settle for 5 min. The cleared lysate was transferred to a column and centrifuged at 
3000 x g for 2min. The column was washed twice with wash solution 1 and 2, 
spinning the column at 3000 x g for 2 min after each wash. Finally, 0.5 ml of elution 
solution was added to the column, centrifuged at 3000 x g for 5 min and the dsDNA 
collected in a clean tube. Quality/quantity of the plasmid determined using a 
Nanodrop1000 spectrophotometer. Plasmid DNA (500 ng) was added to BsaAI for 1 
hour at 37 
o
C and resulting digest products pictured on an ethidium bromide 0.8% 
agarose gel. Following confirmation of the correct digest products, transformed E. 
coli were grown and extracted using the Midiprep kit as previously described. 
Quantification of the plasmid was again analysed using spectrophotometry and 
working aliquots (10 μg) frozen at -80 oC. 
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3.2.9 Transient transfection of PGC1α and Gadd45β into HepG2 cells using 
nucleofection 
Initially transfection was completed using nucleofection. To obtain maximum 
transfection efficiency 5 μg of purified plasmid DNA was combined to appropriate 
solutions as described by Amaxa. The cells were passaged 4 days before 
nucleofection in 10% FBS/DMEM culture medium to achieve a confluence of 80%. 
HepG2 cells (1 x 10
6
). Nucleofector V supplement (0.5 ml) and 2.25 ml of 
Nucleofector solution were combined with 1 x 10
6
 cells in a nucleofector cuvette. The 
cuvette was loaded into the Nucleofector and the program for high transfection 
efficiency selected (T28). Following nucleofection, the cuvette was rinsed with pre-
warmed culture medium (500 μl) and transferred to a 6 well plate containing culture 
medium (1.5 ml). The plates were then incubated (37 
o
C, 5% CO2) ready for analysis. 
However, due to significant cell death (>95%), nucleofection was deemed to be an 
inappropriate method in transfecting HepG2 cells. 
 
3.2.10 Transient transfection of PGC1α and Gadd45β into HepG2 cells using 
calcium chloride 
Due to significant cell death using the nucleofector, calcium chloride was 
subsequently used as a delivery method of the plasmid DNA. HepG2 cells were 
seeded in 24 well plates in 10% FBS/DMEM culture medium at a density of 4.5 x 10
5
, 
24 hours prior to transfection. On the day of transfection the culture medium was 
replaced. 20 μg of plasmid DNA was placed in a polypropylene tube, made to 450 μl 
with 0.1X TE buffer and 50 μl of 2.5 M CaCl2 added, vortexed and incubated at room 
temperature for 5 min. 500 μl of 2X HEBs buffer (280 mM NaCl, 50 mM Hepes, 1.5 
mM Na2HPO4, 10 mM KCl, 12 mM dextrose) was prepared and the DNA/CaCl2 
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solution added drop by drop whilst vortexing the HEBs buffer. The solution was left 
to equilibrate at room temperature for 30 min then added dropwise to the cells and 
placed back in the incubator for 4 hours. The media was aspirated off the cells and 
washed in 500 μl of fresh media, which was also removed. Cells were then glycerol 
shocked by adding 500 μl of HEBs/glycerol (25 ml 2X HEBs, 7.5 ml glycerol, 17.5 
ml distilled water) and left to incubate at room temperature for 3min. The solution 
was aspirated off the cells and again washed in fresh media. 500 μl of fresh media was 
added to each well and the cells incubated at 37 
o
C, 5% CO2 for 24, 48 and 72 hours, 
ready for mRNA, activity, toxicity and protein analysis. The calcium chloride method 
was successful in achieving significant upregulation of Gadd45β and PGC1α but 
efficiency was not very high so other methods were investigated. 
 
3.2.11 Transient transfection of PGC1α and Gadd45β into HepG2 cells using 
Lipofectamine2000 
A third attempt of transfecting HepG2 cells was completed using Lipofectamine2000. 
A range of Lipofectamine2000 volumes were analysed (0.4-1.1 µl) whilst maintaining 
plasmid DNA concentration at 0.2 µg. Additionally, a range of plasmid DNA 
concentrations (0.02 - 0.64 µg) were analysed whilst maintaining Lipofectamine2000 
volume at 0.8 µl. Optimum transfection conditions were deemed to be 0.6 µl 
Lipofectamine 2000 and 0.16 µg plasmid DNA incubated for 24 hours. Transfections 
were performed according to the manufacturer’s instructions. In brief, 24 hours prior 
to transfection 5 x10
4
 HepG2cells (~80% confluent, recommended by Invitrogen) 
were plated in 96-well plates in culture medium (10% FBS/DMEM, 100 µl) so that on 
the day of transfection they were ~95% confluent. Media was replaced in each well 
(50 µl) and incubated for 30 min. Plasmid DNA was then diluted in optiMEM media 
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(25 µl) and incubated at room temperature for 10 min whilst Lipofectamine2000 was 
diluted with optiMEM media (25 µl), vortexed and incubated for 5 min. Following 
incubation, the DNA and Lipofectamine2000 solutions were combined (50 µl) and 
incubated at room temperature for a further 20min. Transfection complexes were 
added directly to the media of appropriate wells and mixed gently by ‘criss-crossing’ 
the plate. Plates were then incubated (37 
o
C, 5% CO2) until ready for analysis. 
 
3.2.12 Assessment of cell viability   
Primary hepatocytes were seeded in a 96-well plate and cell viability was measured 
using a fluorometric assay. Mitochondrial activity was assessed by the cleavage of the 
tetrazolinium salt, 4-[3-(-4-Iodophenyl)-2-(4-nitrophenyl-2H-5-tetrazolio]-1,3-
benzene disulphonate (WST-1) by dehydrogenase (according to the manufacturer’s 
protocol). Maintenance media was aspirated to waste and cells were incubated with 
100 µl of WST-1 (1 mL WST-1 reagent/10 mL maintenance media) at 37 ºC, 5% 
CO2, 95% humidity, for 1 h. Each plate contained samples, blanks and controls with 
three replicates each and absorbance was measured at 450 nm using a SPECTRAmax 
v2.1.28 absorbance reader. Cells were assessed for toxicity using WST-1 reagent at 
all time points. 
 
3.2.13 mRNA and cDNA Quantification 
mRNA was extracted using Trizol reagent and reverse transcribed using standard 
methodology as described in section 2.2.6 and 2.2.7.  
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3.2.14 Quantitative real time-PCR  
Real time-PCR (Chromo4™) was used to determine the gene expression of two NR 
co-regulators (PGC1 and Gadd45β). All samples were completed in triplicate.  Real 
time-PCR solutions and PCR conditions were as described in section 2.2.8. Table 3.1 
details the assay sequence (Applied Biosystems) of each gene with its ID. 
Table 3.1. Applied Biosystems Assay ID and the gene sequence that was 
amplified by real-time PCR. Dye - FAM: 6-carboxyfluorescein 
 
No template controls and no reverse transcriptase controls were also completed in 
duplicate to ensure no contamination, specific amplification and maximum 
amplification, respectively. 2 house-keeping genes were analysed to determine the 
most constant expression throughout all samples (18s, GAPDH). All data were 
compared to the housekeeping gene GAPDH and normalised to the primary 
hepatocyte sample using the comparative threshold cycle (Ct) method (Ct=2^
-∆∆C(t)
). 
To ensure only gene amplification was measured the Ct was set to ignore any aberrant 
data such as primer degradation.  
 
3.2.15 Protein Extraction 
Cells were washed in hanks balanced salt solution (HBSS) and lysed in CelLytic™ M 
solution (125 µl/1 x 10
6
 cells) containing 10 % protease inhibitor cocktail. The cell 
lysate solution was incubated at room temperature for 15 min on an orbital shaker 
Gene Assay ID Assay Sequence (FAM) 
PGC1 Hs01016719_m1 AAGGCAATTGAAGAGCGCCGTGTGA 
Gadd45β Hs00199608_m1 AGTTGATGAATGTGGACCCAGACAG 
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(125 rpm). The resulting solution was transferred to a clean eppendorf and centrifuged 
for 15 min at 13.9 x g to pellet the cell debris. The protein containing supernatant 
fraction was removed and concentration determined using a BCA assay. 
 
3.2.16 Protein Concentration 
The Bicinchoninic Acid (BCA) assay (Kader et al., 1997) was used to determine 
whole cell protein concentration. Whilst protein samples were thawed on ice for 30 
min, bovine serum albumin (BSA) standards were prepared in a flat-bottomed 96-well 
clear plate. BSA (50 mg) was dissolved in 1 mL of CelLytic™ M solution containing 
10 % protease inhibitor cocktail. All standards and samples were completed in 
duplicate. 40 μl of standard/sample was added to each well and 1:2 dilutions 
completed across the plate to achieve a range of concentrations (1-2000 µg/ml). 
Reagent A and reagent B were prepared and combined in a 1:50 dilution respectively 
to produce the standard working stock of which 80 μl was dispensed across the wells. 
The plate was incubated for 30 min at 60 
o
C, cooled and absorbance measured on a 
Tecan Magellan plate reader at 562 nm and analysed using XFluor software. 
Reagent A: 1 g sodium bicinchoniate, 2 g sodium carbonate, 0.16 g sodium tartrate, 
0.4 g sodium hydroxide, 0.95 g sodium bicarbonate, made to 100 ml with deionized 
water and adjusted to pH 11.25 with 10 mM sodium hydroxide. 
Reagent B: 0.4 g cupric sulphate (5X hydrated) made to 10 ml using deionized water. 
 
3.2.17 Protein Quantification 
50 μg of total cell protein was added to 10 μl of sample buffer, 1 μl of NuPage 
reducing agent and made to 21 μl using deionised water. Samples were heated to 70 
o
C for 10 min and centrifuged for 30 sec to gather any condensation. 20 μl of the 
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sample was loaded onto NuPage 4-12% bis-tris gels and electrophoresed for 1.5 hours 
at 180 V. The gel was released from the slide, placed onto iBlot gel stacks and 
transferred onto a nitrocellulose membrane using iBlot gel transfer programme for 6 
min according to manufacturer’s instructions.  
For Gadd45β and PGC1α the membrane was blocked in 5% BSA/0.01% tween-tris 
buffered saline (T-TBS) for 2 hours at room temperature, washed in 0.01% T-TBS for 
5 min (completed 3 times) followed by an overnight incubation at 4 
o
C and 150 rpm 
with the primary antibody (1/1000 in 3% non-fat dried milk (NFDM)/ 0.01% T-TBS). 
For the positive control β-actin, the membrane was blocked in 10% NFDM overnight 
at 4 
o
C and 150 rpm. The following day the membrane with Gadd45β and PGC1α was 
washed in 0.01% T-TBS for 5 min (completed 3 times) and incubated with the 
secondary antibody containing horseradish peroxidase (HRP) (1/3000 in 2% NFDM/ 
0.01% T-TBS) for 2 hours at 4 
o
C and 150 rpm. For β-actin, the membrane was 
washed in 0.01% T-TBS for 5 min (completed 3 times) and incubated with the 
primary antibody (1/5000 in 2% NFDM/ 0.01% T-TBS) at 4 
o
C and 150 rpm. 
Following a 2 hour incubation with the β-actin primary antibody, the membrane was 
washed in 0.01% T-TBS for 5 min (completed 3 times) and incubated with the 
secondary antibody containing HRP (1/2000 in 2% NFDM/ 0.01% T-TBS) for 1 hour 
at 4 
o
C and 150 rpm. After incubation with the secondary antibodies all membranes 
were washed for 5 min in 0.01% T-TBS (completed 3 times) followed by two 20 min 
washes in 0.01% T-TBS.  
Enhanced chemiluminescence (ECL) was used to visualise the bands produced on the 
membrane. Following the final wash, the nitrocellulose membrane was blotted dry 
and ECL solution added for approximately 30 seconds. The membrane was blotted 
dry and in the dark room, X-ray film placed on top of the blot and film exposed for 20 
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sec for β-actin and 20 min for Gadd45β and PGC1α. The X-ray film was placed in 
developing solution until the image was revealed (approximately 30 sec), it was then 
removed and placed in fixing solution for 1 min, and water for 1 min. 
 
3.2.18 Densitometry 
Western blot films were transferred onto the computer using a GS800 densitometer 
scanner and the Quantity One 4.6.1 (Basic) BioRad programme (BioRad, USA). 
Relative protein band density was determined using Total Lab Quant programme. 
Optical band density and relative protein quantification was determined by selecting 
each sample and normalising it against β-Actin (loading control). The background 
signal of the ECL treated nitrocellulose membrane was subtracted from the 
normalised protein band density measurement for each sample.  
 
3.2.19 Measurement of CYP3A4 enzyme activity 
CYP3A4 activity was determined as described in section 2.2.9. 
Activity endpoint assay calculation: 
CYP3A4 Activity (%) = 
          1  –   Relative fluorescence of transfected cells        x  100 
           Relative fluorescence of control cells 
 
 
3.2.20 HPLC analysis of midazolam and its 1’-hydroxy metabolite 
MDZ, 1’-hydroxymidazolam, and RIF were made in a solution of HPLC grade 
methanol to obtain a ﬁnal concentration of 1 mg/ml; all stock solutions were stored at 
-20 ˚C until use, within 1 month. Previous reports suggest MDZ (302, 303), 1’-
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hydroxymidazolam (304, 305) and RIF (306) are stable in solution at -20
o
C for at 
least 30 days. Following 60 min incubation with MDZ at 37 
oC, MDZ and 1’-
hydroxymidazolam were analysed in the media of: control HepG2 cells (non-
transfected control-optiMEM media (NTCO)), Gadd45β, PGC1α and complex 
transfected HepG2 cells and 6 primary human hepatocyte donors. MDZ was chosen 
as a selective CYP3A4 substrate at a concentration of 3.37 μM as described 
previously (89, 236, 307, 308). Additional samples were also incubated with 
rifampicin (RIF) (0.5, 5, 10 μM) for 24 hours to determine the effect of the 
transfections on induction potential. Prior to separation, the compounds were 
extracted from the media to ensure a clean sample passed through the C18 column. 
Briefly, 100 μl of media was removed from the cells to an eppendorf following 
incubation with MDZ. Metabolism was stopped by the addition of 500 μl of diethyl 
ether. The eppendorf was placed on a turntable for 30 min at room temperature 
followed by 5 min centrifugation at 17,000 x g, 4 
o
C. To ensure only the supernatant 
fraction (containing the compound) was removed from the sample, the eppendorf was 
placed at -80 
o
C for 20 min to allow the aqueous media to freeze. The organic phase 
supernatant fraction was transferred to a glass tube and placed in a vacuum centrifuge 
for 20 min at 37 
o
C (to ensure stability of the compounds) and evaporated until dry. 
The resulting pellet was resuspended in 125 μl of solvent (25% ACN/ 75% H2O). 
MDZ and 1’-hydroxymidazolam were chromatographically separated using a Thermo 
Finnigan HPLC (Thermo Scientific, Herts, UK) and a Fortis
®
 column (3 μm, C18, 
100 x 4.6 mm; Fortis
®
 Technologies Ltd, Neston, UK). 
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Conditions were as follows: 
 
Gradient mobile phase run conditions: 
 
 
 
 
 
 
After each sample, the needle was washed twice with 5 ml of wash bottle solution 
followed by 250 μl of the internal wash reservoir to ensure all solute was removed. 
Calibration curves were prepared using 8 calibration points, containing blank media 
and a range of concentrations for MDZ and 1’-hydroxymidazolam (0.138 - 13.81 
μM). A linear through zero calibration curve was used. Absorbance was monitored 
using the PDA surveyor across a total scan. Peaks of interest; MDZ and 1’-
hydroxymidazolam were quantified using XCalibur software and an ICIS peak 
algorithm to determine peak area. A baseline window of 40, area noise factor 5 and 
peak noise factor 10 was set as a standard for each sample.  
 
Mobile phase A 5% ACN, 94.95% H2O, 0.05% formic acid – pH 3.14 
Mobile phase B 
70% ACN, 25% MeOH, 4.95% H2O, 0.05% formic 
acid – pH 4.45 
Wash bottle 50% H2O, 50% MeOH 
Internal wash reservoir 100% H2O 
Flow rate 1 ml/min
-1
 
Injection volume 50 μl 
Detector PDA 
Peak algorithm ICIS 
Plot type Total scan 
Time (min) Mobile Phase A (%) Mobile Phase B (%) 
0.0 90 10 
0.5 90 10 
0.6 70 30 
4.0 40 60 
4.1 0 100 
6.0 0 100 
6.1 90 10 
8.0 90 10 
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Precision and accuracy were determined by analysing 3 sets of quality controls (QCs) 
(low, 0.5 μM; medium, 1.5 μM and high, 11.5 μM) in each run, on 3 consecutive 
days. Precision was determined by calculating the standard deviation at each QC 
concentration. Accuracy was defined as the percent deviation from the nominal 
concentration. Limit of detection (LOD) was expressed as the concentration that 
yielded a signal-to-noise ratio of 3:1 (MDZ, 54 nM and 1’-hydroxymidazolam, 97 
nM). The limit of quantification (LOQ) for accuracy and precision was set to < 20%. 
LOQ analysis complied with the European guidelines (27). Average recovery of MDZ 
and 1’-hydroxymidazolam was determined by comparing the peak area of the drug 
extracted from the 3 QCs against direct injection samples (the same concentration of 
drug in reconstitution solution) (recovery was 93% for MDZ and 92% for 1’-
hydroxymidazolam).  
 
3.2.21 Microfluidic Assay 
To ensure no off-target effects were apparent following transfection and induction 
with 0.5 and 10 μM of RIF after 24 h, key drug disposition genes (see Table 4.2 for 
details of genes analysed) were analysed in control and transfected HepG2 cells and 3 
primary human hepatocyte donors (see Table 2.1 for donor details) using microfluidic 
analysis. mRNA (100 ng per reaction) was added to custom Taqman microfluidic 
cards and centrifuged at 1200 x g for 2 min. Quantification of genes (Table 4.2) was 
recorded in real time using an Applied Biosystems 7900HT PCR system. PCR 
conditions were 30 min at 50 
o
C (to reverse transcribe the mRNA, activate 
polymerase, denature cDNA and initiate PCR) followed by 40 cycles of 15 sec at 94.5 
o
C (denaturation), 30 seconds at 97 
o
C (annealing) and 60 seconds at 59.7 
o
C 
(extension of the product). Fluorescence was collected at the end of each cycle. 
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A geometric mean was calculated for 6 housekeeping genes (18s, UBC, ACTB, B2M, 
GAPDH, HPRT1) and the value used to normalise the expression data. Gene 
expression was then quantified against untreated cells using the comparative threshold 
cycle (C(t)) method (Ct=2^
-∆∆C(t)
). To ensure only gene amplification was measured 
the C(t) was set to ignore any aberrant fluorescence such as that from primer-dimer 
formation. 
 
3.2.22 Data analysis 
Each data point is the average of 3 independent samples completed in triplicate. 6 
primary hepatocyte donors (see Table 5.1 for donor details) were analysed in 
duplicate to determine CYP3A4 activity and metabolism of MDZ on the HPLC. 
Normality was assessed using Shapiro Wilk and data were assessed using Mann 
Whitney for non-normal and unpaired t test for normally distributed data. Results 
were considered significant if; *, p < 0.05; **, p < 0.01; ***, p < 0.001. Statistics 
were calculated using Stats Direct (Version 2.4.6 Stats Direct Ltd). 
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3.3 Results 
3.3.1 BsaAI restriction enzyme digest to confirm the presence of Gadd45β and 
PGC1α 
pEZ-M02 vectors containing Gadd45β and PGC1α were grown in chemically 
competent 5-α E.coli. Following extraction of single colonies, BsaAI restriction 
enzyme was used to determine if the plasmid DNA was present and its correct 
orientation. Figure 3.1a and 3.2a show the restriction sites of pEZ-M02 containing 
Gadd45β and PGC1α, respectively and the BsaAI restriction sites with the vector. 
Figure 3.1b and 3.2b show a virtual digest of band orientation that is produced if the 
insert is present, in addition to this, Figure 3.1c and 3.2c detail the approximate size of 
the bands produced in each digest. 
 
Figure 3.3 shows a representative agarose gel of positive colonies that were identified 
following the transformation of chemically competent 5α E.coli with the pEZ-M02 
plasmids and confirmed the orientation and presence of Gadd45β and PGC1α in each. 
The band patterns for each colony selected matched the virtual digest for each 
plasmid as they contained the required DNA in the correct orientation. 
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Figure 3.3. Representative agarose gel BsaAI restriction enzyme digest of pEZ-
M02 plasmids containing PGC1α and pEZ-M02 plasmids containing Gadd45β (A), a 
virtual digest of PGC1α (B) and Gadd45β (C).  
 
3.3.2 Optimisation of Gadd45β and PGC1α transfection via Lipofectamine2000  
Following initial attempts to use nucleofection (resulted in >95% cell death) and 
calcium chloride (large amounts of DNA required/sample) as techniques of 
transfection it was decided the best method to use was Lipofectamine2000. To 
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determine the optimum plasmid DNA concentration, Lipofectamine2000 volume and 
incubation time, a range of preliminary experiments were conducted. According to 
manufacturer’s instructions (LifeTechnologies Ltd, Paisley, UK) the optimum volume 
of Lipofectamine2000 ranges from 0.4-1.1 μl/96-well and plasmid DNA 
concentrations range from 0.02-1 μg. A matrix of Lipofectamine2000 volumes against 
a constant DNA concentration (0.2 μg/96-well) was set out as described in section 
3.2.11. Figure 3.4a shows the effect of increasing volumes of Lipofectamine2000, 
using 0.2 μg plasmid DNA, on the mRNA expression of Gadd45β and PGC1α and 
Figure 3.4b shows the associated toxicity of increasing volumes of 
Lipofectamine2000.  
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Figure 3.4. Relative mRNA expression of Gadd45β (-) and PGC1α (-) (A) and cell 
viability (B) following the transfection of plasmid DNA into HepG2 cells using 0.4-
1.1 μl of Lipofectamine2000 and 0.2 μg DNA. 
 
A sizeable increase in Gadd45β and PGC1α mRNA expression was achieved with 
larger volumes of Lipofectamine2000 (Figure 3.4a). A positive correlation in 
Lipofectamine2000 volume and cell viability was observed (Figure 3.4b). Using ≥1 μl 
of Lipofectamine2000/96-well resulted in ≥25% cell toxicity. Compared to primary 
human hepatocytes, 100% mRNA expression was achieved for both genes when using 
as little as 0.6 μl of Lipofectamine2000 with no associated cell toxicity.  
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In addition, a matrix of plasmid DNA concentrations against a constant 
Lipofectamine2000 volume (0.8 μl/96-well) was set out as described in section 
3.2.11. Figure 3.5a shows the effect of increasing concentrations of plasmid DNA and 
holding Lipofectamine2000 volume at 0.8 μl, on the mRNA expression of Gadd45β 
and PGC1α and Figure 3.5b shows the associated toxicity with increasing 
concentrations of plasmid DNA.  
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Figure 3.5. Relative mRNA expression of Gadd45β (-) and PGC1α (-) (A) and cell 
viability (B) following the transfection of plasmid DNA into HepG2 cells using 0.02-
0.64 μg of plasmid DNA and 0.8 μl Lipofectamine2000. 
 
An increase in Gadd45β and PGC1α mRNA expression was achieved when higher 
concentrations of plasmid DNA were transfected (Figure 3.5a). A correlation was 
observed between plasmid DNA concentrations and cell viability (Figure 3.5b). Using 
>0.32 μg of plasmid DNA/96-well resulted in ≥20% cell toxicity. Compared to 
primary human hepatocytes, 100% mRNA expression was achieved for both genes 
when using as little as 0.16 μg of plasmid DNA with no associated cell toxicity.  
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For subsequent experiments, 0.6 μl of Lipofectamine2000 and 0.16 μg of plasmid 
DNA were used for transient transfections. 
 
To achieve mRNA expression similar to primary human hepatocytes it was key to 
determine if incubation time had an effect on the level of mRNA expression of 
Gadd45β and PGC1α and/or toxicity. Gadd45β and PGC1α mRNA expression 
decreased as incubation time increased (Figure 3.6). A 24 hour incubation achieved 
115% Gadd45β mRNA expression and 119% PGC1α mRNA expression when 
compared to primary human hepatocytes.  
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Figure 3.6. Relative mRNA expression of Gadd45β (A) and PGC1α (B) following 
the transfection of plasmid DNA into HepG2 cells using Lipofectamine2000 for 24, 
48 and 72 hours. 
 
In addition, it was favourable to determine if optimum mRNA expression could be 
achieved with the plasmid DNA transfected into HepG2 cells as a complex. Figure 
3.7 shows mRNA expression of Gadd45β and PGC1α when transfected as a complex 
into HepG2 cells with varying concentrations of plasmid DNA. 24 hour incubations 
achieved the highest levels of mRNA expression, consistent with the data from single 
transfections. All plasmid DNA ratios were made to a final concentration of 0.16 
μg/96-well, as determined in earlier optimisation assays, except for the complex (1:1) 
where the total plasmid DNA concentration was 0.32 μg. The complex (1:1) 
transfection achieved 105% and 109% mRNA expression of Gadd45β and PGC1α, 
respectively when compared to primary human hepatocytes. 
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Figure 3.7. Relative mRNA expression of Gadd45β (A) and PGC1α (B) following 
the transfection of plasmid DNA into HepG2 cells using Lipofectamine2000 for 24, 
48 and 72 hours.  
 
It was crucial to determine the effect of incubation times and transfection complexes 
on cell viability. Figure 3.8 shows the cell viability of transfected HepG2 cells after 
24, 48 and 72 hours with a range of plasmid DNA concentrations. All plasmid DNA 
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concentrations were made to a final quantity of 0.16 μg/96-well, as determined in 
earlier optimisation assays, except for the complex (1:1) transfection where the total 
plasmid DNA concentration was 0.32 μg. For all time points and plasmid DNA ratios 
no associated toxicity was observed (Figure 3.8). 
 
Figure 3.8. Cell viability of HepG2 cells following the transfection of plasmid 
DNA using Lipofectamine2000 for 24 (A), 48 (B) and 72 (C) hours. 
 
Although the complex transfection used a double amount of plasmid DNA compared 
to single transfections, it was encouraging to find the complex did not interfere with 
gene expression or associate with any toxicity. Therefore, to assess whether the genes 
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had an additive effect on expression and activity of CYP3A4, subsequent experiments 
compared single transfections (0.6 μl of Lipofectamine2000 and 0.16 μg of single 
plasmid DNA) to complex transfections (0.6 μl of Lipofectamine2000 and 0.16 μg of 
each plasmid DNA). 
 
3.3.3 Determination of Gadd45β and PGC1α protein expression using Western blot 
analysis 
HepG2 cells were transfected with plasmid DNA containing Gadd45β, PGC1α and a 
complex of Gadd45β and PGC1α under optimal conditions as described in section 
3.3.2. As shown in Figure 3.6 and 3.7, transfection of Gadd45β and PGC1α increased 
the mRNA expression similar to that of primary human hepatocytes. However, to 
determine if protein expression was also increased to levels observed in the primary 
human hepatocyte a western blot analysis was set up as described in section 3.2.13.  
 
To ensure equal transfer of protein, ponceau red was used to stain the nitrocellulose 
membrane. In addition, β-actin was used as a loading control. As shown in Figure 3.9, 
β-actin levels were consistent across all samples.  
 
From the results shown in Figure 3.9, Gadd45β and PGC1α protein was present at 
much lower levels in the control HepG2 cells (NTCO) compared to primary human 
hepatocytes (10 - 35%) (Figure 3.9, Table 3.2). Transfection of Gadd45β and PGC1α 
into HepG2 cells resulted in higher levels of protein compared to NTCO. In 
agreement with mRNA results, the highest levels of protein were achieved following 
24 h incubations, with very little protein present for 48 or 72 h incubations. Single 
transfection of Gadd45β and PGC1α positively increased the respective protein levels 
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after 24 hours. An increase in Gadd45β protein was observed in HepG2 cells 
transfected with PGC1α, with the same effect observed for PGC1α protein levels in 
HepG2 cells transfected with Gadd45β (this effect was not observed at the mRNA 
level). However, only a slight additive effect was observed following the complex 
(1:1) transfection (Figure 3.9, Table 3.2). Levels of protein were consistent across all 
24 h incubations. 24 hours was confirmed as the optimum incubation time for single 
and complex transfections (Figure 3.9). 
 
 
Figure 3.9. Representative immunoblot following the transfection of HepG2 cells 
with Gadd45β and PGC1α for 24, 48 and 72 hours.  
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Table 3.2. Relative protein expression of transfected HepG2 cells with Gadd45β 
and PGC1α as a percent of primary human hepatocyte protein levels 
 
 
3.3.4 Fluorescent analysis of CYP3A4 rate of activity  
Following the confirmation of successful transient transfection, a preliminary analysis 
of CYP3A4 activity rate was determined in complex (1:1) transfected HepG2 cells, 
primary human hepatocytes and control HepG2 cells (NTCO) using a Vivid
®
 
fluorescent assay (Figure 3.10). 
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Figure 3.10. Effect of HepG2 cell complex transfection on the activity of CYP3A4 
after 24 h incubation. Values are expressed as the mean relative fluorescent unit ± S.D 
of 3 independent experiments completed in triplicate. Primary human hepatocyte data 
are the mean relative fluorescent unit of 3 donors completed in duplicate 
 
The rate of CYP3A4 activity was greatest in primary human hepatocytes (2106 
RFU/min) compared to complex transfected (1309 RFU/min) and control cells (132 
RFU/min) (Figure 3.10). Complex transfected HepG2 cells enhanced the activity of 
CYP3A4 by 54% compared to control cells (Table 3.3).  
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Table 3.3. CYP3A4 activity rate 
 
3.3.5 Validation of HPLC-PDA method for quantification of MDZ and 1’-
hydroxymidazolam in mammalian cell medium 
To confirm the activity of CYP3A4 in the transfected HepG2 cells and their 
inducibility upon RIF treatment, MDZ was used as a probe substrate and the 
formation of its main metabolite (1’-hydroxymidazolam) was quantified using high 
performance liquid chromatography (HPLC). 
 
The retention time was 4.38 ± 0.1 min for MDZ and 4.79 ± 0.1 min for 1’-
hydroxymidazolam. The retention time for RIF was 5.69 ± 0.1 min, therefore it did 
not interfere with either peak of interest. A chromatogram representing the top 
standard concentration (13.81 μM) and the maximum concentration of RIF used (10 
μM) is shown in Figure 3.11. 
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Figure 3.11. Representative chromatogram of 4X the top standard concentration (50 
μM) of MDZ and 1’-hydroxymidazolam and the maximum concentration of RIF (10 
μM). Y axis is absorbance and X axis is time. 
 
The regression coefficient (r
2
) of all calibration curves was ≥0.994. A linear through 
zero regression was selected as MDZ and 1’-hydroxymidazolam showed an excellent 
linear response up to 13.81 μM (Figure 3.12). All data, including precision and 
accuracy varied <15%, in accordance with European guidelines (27). 
 
 143 
 
Figure 3.12. Representative calibration curve of MDZ and 1’-hydroxymidazolam 
peak area 
 
3.3.6 Quantification of MDZ and 1’-hydroxymidazolam in mammalian cell medium 
Basal activity of CYP3A4 was greatest in primary human hepatocytes with 1.38 μM 
of 1’-hydroxymidazolam produced (Figure 3.13). Compared to primary human 
hepatocytes, basal activity of CYP3A4 was 23% in control cells (in comparison to 6% 
observed in the fluorescent analysis (Figure 3.10)). However, similar to the 
fluorescent assay, basal activity of CYP3A4 in complex transfected HepG2 cells was 
65% compared to primary human hepatocytes (Figure 3.13). Single transfection of 
HepG2 cells with Gadd45β or PGC1α produced 1.11 and 1.35 μM of 1’-
hydroxymidazolam, respectively.  
 
To determine inducibility, cells were treated with 0.5, 5 and 10 μM of RIF (Figure 
3.13). Primary human hepatocytes produced significantly more 1’-hydroxymidazolam 
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when treated with 5 and 10 μM of RIF compared to control cells. Significant 
induction was observed when cells were treated with >0.5 μM RIF in NTCO and 
complex transfected HepG2 cells. Complex transfected cells produced 2 μM of 1’-
hydroxymidazolam (p<0.0001) when treated with 10 μM RIF compared to 1.71 μM 
(p<0.0001) by primary human hepatocytes. HepG2 cells transfected with PGC1α 
DNA required at least 5 μM of RIF for statistically significant production of 1’-
hydroxymidazolam whilst Gadd45β transfected HepG2 cells required 10 μM of RIF 
for statistically significant production (Figure 3.13).  
 
Figure 3.13. Conversion of MDZ to 1’-hydroxymidazolam in primary human 
hepatocytes, transfected HepG2 cells and induced cells with 0.5, 5 and 10 μM of RIF. 
Data are expressed as the mean of 3 independent experiments completed in triplicate 
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± S.D. for HepG2 cells and the mean of 6 donors completed in triplicate ± S.D. for the 
primary human hepatocytes. 
 
3.3.7 Assessment of potential off-target effects following transfection 
To determine if transfection of HepG2 cells using Lipofectamine2000 and plasmid 
DNA (Gadd45β and PGC1α) had any off-target effects in control or RIF induced 
cells, the mRNA expression of 40 genes involved in the regulation, metabolism and 
disposition of drugs was investigated (see Table 4.2). 10 of the 40 genes were not 
detected in the analysis (CAR, CYP1A2, CYP2C19, UGT1A4, OATP1B1, 
OATP1B3, OATP2B1, OATP10A1, ABCB11 and HDAC2). The lack of gene 
detection was in agreement with previous analysis (89, 261, 273, 309, 310). Figure 
3.14 shows that treatment with Lipofecatmine2000/plasmid DNA for 24 h altered the 
expression of 6 genes analysed (PXR, HNF4α, CYP3A4, HDAC1, Gadd45β and 
PGC1α). 
 
No notable changes in the mRNA expression of either UDP-glucuronosyltransferases 
(Figure 3.14e and 3.14f) or transporters (Figure 3.14g and 3.14h) were observed.  
 
Compared to NTCO a small increase in VDR mRNA expression was observed in 
complex transfected HepG2 cells (Figure 3.14a). However, this effect was not 
observed when expression was compared to primary human hepatocytes (Figure 
3.14b). No notable changes were apparent in FXR mRNA expression (Figure 3.14a 
and 3.14b). PXR and HNF4α mRNA expression were increased in all transfected cell 
types when compared to NTCO and primary human hepatocytes (Figure 3.14a and 
3.14b). 
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Of the 4 cytochrome P450 enzymes detected in the assay, the greatest effect was 
observed in CYP3A4 mRNA expression. Compared to control cells, CYP3A4 
expression was increased by ~150% in all transfected cell types (Figure 3.14c). In 
comparison to primary human hepatocytes, CYP3A4 mRNA expression was 
increased to similar levels in all transfected cell types (Figure 3.14d). 
 
In agreement with single gene analysis (Figure 3.6), an increase in Gadd45β and 
PGC1α mRNA expression was observed in single Gadd45β and PGC1α transfected 
cells, repsectively, with both genes increased in complex transfected HepG2 cells 
(Figure 3.14i and 3.14j). In contrast, HDAC1 mRNA expression was decreased in all 
transfected cell types when compared to NTCO (Figure 3.14i) or primary human 
hepatocytes (Figure 3.14j). No notable changes in any other co-regulator were 
observed.  
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A concentration dependent increase in PXR (Figure 3.15a), HNF4α (Figure 3.15b), 
CYP3A4 (Figure 3.15c) and HDAC1 (Figure 3.15d) mRNA expression was observed 
in transfected cells treated with 0, 0.5 and 10 μM of RIF. HNF4α, HDAC1 and 
PGC1α mRNA expression was not altered in control cells (NTCO) treated with 
increasing concentrations of RIF. No notable changes in Gadd45β mRNA expression 
were observed in any cell type (Figure 3.15e). An increase in PGC1α mRNA 
expression was observed following treatment with 10 μM of RIF (Figure 3.15f). 
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3.4 Discussion 
As described in Chapter 2, the loss of hepatic phenotype in HepG2 and Huh7 cells is 
partly due to the altered expression of transcriptional regulators including; 
chaperones, co-chaperones, co-activators and co-repressors. Importantly, the down 
regulation of one co-activator can alter the activity of numerous transcription factors, 
resulting in distinct biological events (311). Indeed, we have shown lower levels of 
the Gadd45β and PGC1α genes in HepG2 cells correspond to a deficient expression 
and activity of CYP3A4, with the levels reducing further as cell passage increases, in 
comparison to primary human hepatocytes. However, restoration of the regulatory 
proteins may not be sufficient to restore CYP expression to primary human 
hepatocyte levels. 
 
Whilst previous studies have demonstrated the role of PGC1α alone or in combination 
with other NR co-activators for CYP expression (95, 207, 288), this work defines a 
novel role of the co-activators Gadd45β and PGC1α in the constitutive expression and 
activity of CYP3A4. The prominent effect of PGC1α on CYP3A4 is further 
demonstrated here. Although expression in the liver is relatively low, PGC1α 
stimulates genes that regulate adaptive thermogenesis in the liver as well as activating 
mitochondrial processes and Phase I metabolism (312, 313). Temperature, physical 
exercise, food and insulin alter PGC1α levels (312). Whilst fasting induces PGC1α 
and CYPs (314), insulin suppresses basal PGC1α and CYP expression (96, 315). 
Previous studies have reported PGC1α activates CYP genes via interaction with NRs, 
PXR and HNF4α and the co-activator nuclear receptor co-activator 1 (NCOA1) (92, 
95). Our results have demonstrated PGC1α transfection and complex (Gadd45β and 
PGC1α) transfection increases PXR mRNA expression (Figure 3.14). However, upon 
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induction with rifampicin (RIF), HNF4α mRNA expression was induced in both 
transfections compared to control cells (Figure 3.15). Further investigation is 
warranted to determine if media supplements could be utilised to further enhance 
CYP3A4 activity and expression by PGC1α. 
 
Gadd45β positively regulates apoptosis, preventing the proliferation of damaged cells 
following exposure to xenobiotics (316). Ligands of the NRs, CAR and PXR, directly 
induce Gadd45β independent of two alternative pathways: transforming growth factor 
beta (TGF-β) activation initiated by Smad3 and Smad4 (317) or nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-κB) activation via upstream regulatory 
regions (12). Previous reports have found Gadd45β-/- mice compensate for the lack of 
co-activator by over expressing other co-activators, for example, NCOA1 and 
mediator complex subunit 1 (Med1) (202). However, this mechanism was not 
observed here or in Chapter 2. Transfection of Gadd45β in HepG2 cells positively 
upregulated the mRNA expression of PXR and CYP3A4 but no effect was observed 
for CAR, suggesting the primary target of Gadd45β is PXR. Gadd45β transfected 
cells displayed a similar induction profile upon RIF treatment for PXR and HNF4, 
whereas Gadd45β mRNA expression was not affected (Figure 3.15). 
 
Two critical objectives required for successful transfection of Gadd45β and PGC1α in 
HepG2 cells were to increase Gadd45β and PGC1α mRNA and protein expression 
significantly, and to ensure specificity to Gadd45β and PGC1α to ultimately produce 
a cell line with a CYP3A4 phenotype similar to primary human hepatocytes. Figure 
3.6 shows Gadd45β and PGC1α mRNA were increased to ~110% of the primary 
human hepatocytes following treatment with individual plasmid DNA for 24 h. When 
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transfected as a complex for 24 h, mRNA expression was ~100% of the primary 
human hepatocytes (Figure 3.7). In the current study, Gadd45β, PGC1α and complex 
transfections were screened against 40 genes to determine off-target effects (Figure 
3.14). Similar to previous work, 10 genes were not detected in the analysis (89, 261, 
273, 309, 310) and no major differences in mRNA were observed for genes that were 
not directly linked (according to the literature) to Gadd45β and PGC1α. The 
transfections were selective to CYP3A4 in comparison to previous studies that 
upregulated numerous isoforms (95, 96, 288, 309). In accordance with the findings of 
other groups (96, 288, 318), PXR, HNF4α, Gadd45β, PGC1α and CYP3A4 mRNA 
expression was, as expected, greatly increased in transfected HepG2 cells. In contrast, 
the co-repressor HDAC1 was reduced to mRNA levels similar to primary human 
hepatocytes, suggesting a negative feedback loop was in effect. In contrast to prior 
studies, similar to the primary human hepatocytes, all 6 genes listed above, were 
induced following treatment with the potent CYP3A4 inducer RIF (Figure 3.15) 
(288). These data demonstrate clearly that the current complex and single 
transfections can specifically increase Gadd45β and PGC1α mRNA, and protein with 
no overt off-target effects. Therefore, the transfections used in this study appear to be 
more specific than those previously applied.  
 
Expression of hepatocyte nuclear factor 1 (HNF1) is regulated by HNF4α (319). 
HNF1 mediates the expression of hepatospecific features such as fibrinogen and 
albumin (320, 321). Thus, to determine the restoration extent of hepatospecific 
function and phenotype, future work should analyse the secretion of these proteins in 
the transfected cells. 
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Figure 3.9 and Table 3.2 show Gadd45β and PGC1α protein was increased to ~89% 
of the primary human hepatocytes following treatment with plasmid DNA for 24 h. 
Specific to protein expression, transfection of HepG2 cells with Gadd45β resulted in 
an increase of PGC1α protein, and vice versa. However, when transfected as a 
complex, an additive effect was observed. The exact mechanism of this process 
requires further investigation, but post-translational effects may play a role that result 
in stabilisation of the protein with no change in mRNA.  
 
Preliminary investigation of CYP3A4 activity was assessed using a CYP3A4 Vivid 
probe assay (Figure 3.10). In comparison to control HepG2 cells (NTCO), CYP3A4 
activity was increased by 54% in complex transfected HepG2 cells but 38% less 
activity compared to primary human hepatocytes (Table 3.3). In contrast, Novotna et 
al., (271) and Martinez-Jimenez et al., (96) could not increase CYP3A4 activity or 
mRNA expression in their stably transfected HepG2 cells with PGC1α. Whilst both 
groups achieved restoration of PGC1α mRNA expression it should be noted the 
transfections optimised were for the generation of a stable cell line, in contrast to 
transient transfections herein. Furthermore, the aim of this work was to achieve 
mRNA expression similar to the primary human hepatocytes rather than over-
expressing the gene (in contrast to Martinez-Jimenez et al., (96)). It should also be 
noted the data generated by Novotna et al., (271) compared transfections to control 
HepG2 cells rather than primary human hepatocytes. Further work utilised the 
specific CYP3A4 substrate, MDZ to determine CYP3A4 activity by the production of 
1-hydroxymidazolam in single and complex transfected cells (Figure 3.12). CYP3A4 
responded significantly to Gadd45β and PGC1α transfections with production of 1-
hydroxymidazolam similar to the levels observed by primary human hepatocytes. 
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Comparable to the mRNA expression but in contrast to the protein expression, 
complex transfected cells displayed no additive effect. However, the complex cells 
responded significantly to the CYP3A4 inducer, RIF, with a dose dependent response. 
The single transfections did not portray the same pattern with induction observed at 
10 μM for Gadd45β and 5 μM for PGC1α. It is interesting to note that although the 
single transfections resulted in higher mRNA expression and activity, the complex 
transfection maintained and enhanced the cell induction potential similar to the 
primary human hepatocytes. 
 
The lack of exact correlations between Gadd45β and PGC1α mRNA levels and the 
target gene, CYP3A4, may be a consequence of: 1) the initially low expression of 
CYP3A4 in HepG2 cells that may not be restored sufficiently by over expressing just 
two co-activators; other key co-regulators may still be absent or over expressed; 2) the 
adenoviral vector expression of Gadd45β and PGC1α are different from the 
endogenously expressed mRNA. The distinct 3’ and 5’ untranslated regions (introns) 
that govern translation efficiency may differ, leading to discrepancies between the 
protein and mRNA levels in the transfected and control cells. 
 
CYP3A4 is the main CYP isoform in the liver, responsible for metabolising over 50% 
of therapeutically administered drugs (41). Individual variability in the metabolism of 
CYP3A4 substrates can result in toxicity, therapeutic failure or tolerance and may be 
a consequence of single nucleotide polymorphisms (SNPs). Hence, SNPs altering the 
expression of co-activators Gadd45β and PGC1α could influence CYP3A4 expression 
and activity. Further analysis is warranted to identify any co-regulator SNPs that may 
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contribute significantly to CYP3A4 expression and this could be preliminarily 
investigated using the approach presented here. 
 
In conclusion, this chapter highlights the importance of rigorous optimisation of assay 
conditions to utilise key technologies to their full potential. In this case, a transfection 
method was developed to specifically increase Gadd45β and PGC1α expression in 
HepG2 cells to produce a cell line with a CYP3A4 phenotype, similar to primary 
human hepatocytes without significant off-target effects. The significant roles of NR 
co-activators in sustaining NR and hence CYP3A4 expression, are reinforced herein 
along with the emphasis that NR co-regulators work in concert to regulate gene 
expression. The overall strategy can be employed for other proteins of interest such as 
ABCB1 or OATP1B1, which clearly utilise different mechanisms. It is particularly 
interesting for OATP1B1, which was undetectable here but is an essential pre-
requisite for uptake and subsequent CYP3A metabolism. In addition, knock-out of 
NR co-repressors may be of benefit to further enhance CYP3A4 activity or induction 
response. Further work to produce a stable cell line expressing Gadd45β and PGC1α 
could allow future application of this strategy in determining CYP3A4 mediated DDIs 
in early drug discovery. 
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CHAPTER 4 
 
The use of siRNA to dissect the 
relative contribution of OATP1B1 to 
the hepatic uptake of xenobiotics 
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4.1 Introduction 
Perhaps the two most critical tasks for drug metabolism departments are to predict 
human pharmacokinetics and dose accurately (307) and to provide a realistic 
assessment of the potential for new chemical entities (NCE) to cause drug-drug 
interactions (DDIs)(322). Historically, many of these evaluations have focused on 
cytochrome P450’s (CYPs) but it has become evident over the last decade that 
transporters can play a significant role in the disposition of many drugs (278).  
 
The organic anion transporting polypeptides (OATPs) have received considerable 
attention since they have been shown to mediate the sodium-independent uptake of a 
broad array of organic amphiphilic compounds including bile acids, thyroid 
hormones, antibiotics and anti-hypertensives (41). In addition, the inhibition of 
OATPs has been implicated in a number of DDIs where drugs such as cyclosporine 
have been shown to significantly increase (up to 20-fold) the plasma exposure of a 
number of drugs including atorvastatin (323), lovastatin (324), pravastatin (325, 326), 
rosuvastatin (327) and pitavastatin (328). While CYP3A4 may contribute to the 
increase in plasma exposure observed for atorvastatin and lovastatin, the lack of 
involvement of this isoform in the metabolism of rosuvastatin, pitavastatin or 
pravastatin suggests that the inhibition of OATPs is a more likely cause for these 
DDIs (329).  
 
Human embryonic kidney cell lines heterologously expressing relevant OATP 
isoforms have been commonly used to detect OATP inhibitors (13, 330, 331). 
However, a robust characterisation of the cell line and selection of an appropriate 
control substrate has been shown to be critical in obtaining clinically relevant data 
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(13, 332). Furthermore, several groups have now started to utilise the emerging 
OATP1B1 inhibition data available to create in silico models (13, 331).   
 
In addition to their use in determining inhibitors of OATPs, recombinant cell lines 
expressing OATP1B1, OATP1B3 and OATP2B1 have been invaluable in elucidating 
the major role they play in the hepatic uptake of anionic drugs (333). Mutation studies 
have identified both the transmembrane domain (334) and even the key amino acid 
residues that confer OATP activity (335). However, the broad substrate overlap 
between OATP1B1 and OATP1B3 in particular has hampered the identification of 
specific substrates for individual isoforms (331).  
 
Many groups have utilised hepatocytes to obtain an overall assessment of hepatic 
uptake (336). Soars et al., (262) developed a high-throughput “media loss” assay in 
suspended hepatocytes to predict the clearance of 36 drugs where hepatic uptake was 
suspected to be involved in drug disposition. Subsequent studies have used the more 
traditional “oil spin” technique to confirm the utility of this approach by expanding 
datasets (337, 338) and providing a more detailed analysis of the individual kinetic 
processes involved (339). Several groups have shown that uptake data can be used to 
predict the profile of drugs such as atorvastatin, (340) and valsartan (341) as well as 
clearance. Most recently, Jones et al., (2012) used sandwich-cultured hepatocytes in 
conjunction with physiologically based pharmacokinetic modelling to incorporate 
efflux processes into these predictions. 
 
Attempts to attribute hepatic uptake to individual transporters have primarily focused 
on the relative activity factor (RAF) approach, which has been used successfully in 
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the CYP field (342). Hirano et al., (2004) used estrone-3-sulfate (E3S) and 
cholecystokinin 8 (CCK-8) as probes for OATP1B1 and OATP1B3, respectively. 
However, the data obtained using this technique has yet to be confirmed using an 
alternative methodology. In addition, the RAF approach requires a specific substrate 
to elucidate the role of a particular transporter, which is often not available. Therefore, 
an investigation into other potential tools such as siRNA may facilitate our 
understanding in this area. 
 
The promise of siRNA as a gene knockdown technique was highlighted by the 
seminal study of Fire et al., (1998).  In subsequent years, siRNA has been used as a 
powerful tool to confirm target validation and more recently in the explosion of RNA 
interference therapeutics, which are currently under development for respiratory, 
cardiovascular, and oncological diseases (343, 344).  However, the use of this 
technique in the drug disposition area has primarily focused on the inhibition of key 
efflux transporters such as P-glycoprotein and breast cancer resistance protein 
expressed either in recombinant cell lines (345) or in sandwich cultured hepatocytes 
(346). To date, the number of studies investigating the use of siRNA to knockdown 
drug transporters in human hepatocytes has been limited and often the level of 
functional knockdown obtained in such studies has precluded their use in assigning 
the individual transporter responsible for hepatic uptake (347). Previous studies with 
AtuFect01-based siRNA lipoplexes have demonstrated effective and specific mRNA 
and protein knockdown (348-350). Of importance, the small quantities of AtuFect01 
required to complex the siRNA are important since the three positive charges of 
siRNA are able to bind one molecule of AtuFect01 correlating to reduced toxicity 
(350).  
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The aims of this chapter were two-fold: to develop and characterise a robust in vitro 
assay to selectively inhibit OATP1B1 in human hepatocytes using a siRNA approach; 
and to determine the relative role of OATP1B1 in the hepatic uptake of a range of 
drugs. 
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4.2 Methods and Materials 
4.2.1 Materials 
All chemicals and reagents were of the highest available grade. Olmesartan, valsartan, 
rosuvastatin, atorvastatin and pitavastatin were sourced from Sequoia Research 
Products Ltd. (Oxford, UK). Lopinavir was supplied by Moravec Chemicals (Brea, 
CA). [
3
H]-estrone-3-sulfate (specific activity 2120 GBq/mmol) was purchased from 
PerkinElmer Life Sciences (Boston, MA, USA). AtuFECT01 was kindly supplied by 
Silence Therapeutics (Berlin, Germany). Cryopreserved hepatocyte recovery medium 
(CHRM
®
 media), Williams E Media, plating and supplement media, OATP siRNA 
duplex oligoribonucleotides, Quant-iT Ribogreen Assay kit, cryopreserved human 
hepatocytes (same donors used in chapter 2; Table 2.1), plating cocktail, maintenance 
cocktail, RNase free DNase kit, Vivid® CYP450 screening assay and 96-well 
collagen coated plates were purchased from Invitrogen Ltd (Paisley, Scotland, UK). 
WST-1 reagent was purchased from Roche Applied Science (Hertfordshire, UK). 
RNeasy 96 kit and QuantiTect Probe one step RT-PCR Master Mix Kit was obtained 
from Qiagen Ltd (Crawley, UK). 96-well plates pre-coated with collagen IV were 
purchased from BD Biosciences (Oxford, UK). All other chemicals were purchased 
from Sigma-Aldrich (Poole, Dorset, UK) unless otherwise indicated. 
 
Donor Viability Gender 
Donor Demographics 
Age/Race Characteristics 
Hu8089 91 % Male 36year old, Caucasian Alcohol abuse, smoking 
Hu8085 97 % Female 1 year old, Caucasian No alcohol abuse, no smoking 
Hu4244 89 % Male 3 year old, Caucasian No alcohol abuse, no smoking 
 
Table 4.1 Human donor demographics of the cryopreserved hepatocytes used in 
the study 
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4.2.2 Thawing and plating of cryopreserved primary human hepatocytes 
Cryopreserved human hepatocytes were thawed as previously described in section 
2.2.3. Donor demographics are detailed in Table 4.1. 
 
4.2.3 Cell viability 
Cell viability and density of primary human hepatocytes were calculated using trypan 
blue exclusion as described in section 2.2.4. 
 
4.2.4 Plating and maintaining primary human hepatocytes 
Cells were seeded in 96-well plates pre-coated with collagen at a density of 4.5 x 10
4
 
cells/well and incubated for 24 h at 37 ºC with 5% CO2 and 95% humidity as 
described in section 2.2.5. Media was replaced with 100 μl William’s E media 
supplemented with optiMEM media and a maintenance cocktail of 0.1 μM 
dexamethasone, a 0.5% solution of penicillin-streptomycin, 2 mM GlutaMAX™, 15 
mM HEPES, 6.25 μg/ml human recombinant insulin, 6 μg/ml human transferrin, 6 
μg/ml selenous acid, 1.25 μg/ml bovine serum albumin and 5.35 μg/ml linoleic acid 
(CHRM
® 
supplement B) (Invitrogen), 1 h prior to siRNA treatment. The same volume 
of optiMEM media was added to the non-transfected control cells (NTCO).  
 
4.2.5 Determining cell density 
To ensure the cells were plated at an optimum density varying numbers of cells 
(15,000, 30,000, 45,000, 75,000 and 100,000) were plated in a 96-well collagen 
coated plate and incubated at 37 
o
C, 5% CO2 humidified incubator for four hours. 
Density was assessed using a light microscope to determine confluence and 
comparison of [
3
H] E3S uptake. 
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4.2.6 OATP1B1 siRNA in plated primary human hepatocytes 
For siRNA treatment, AtuFect01 and OATP1B1 siRNA were vortexed for 1 min in a 
polystyrene bijou and incubated for 30 min at 37 ºC prior to addition to the cells (final 
concentration of AtuFect01 was 1 µg/ml and siRNA was 40 nM). The OATP1B1 
siRNA oligomer was purchased as a kit from Sigma Aldrich. The kit contained 3 
siRNA sequences for OATP1B1 and the first sequence quoted below achieved the 
greatest inhibition of OATP1B1. 
 
OATP1B1 siRNA sequences:  
A.   5’- 
CACUAUCAGGAUAACUCCUACUGAUAUCAGUAGGAGUUAUCCUGAUAG
UG-3’ 
 
B.   5’- 
    CCUCACAUGUCAUGCUGAUUGUUAAUUAACAAUCAGCAUGACAUGUGAGG 
-3’ 
 
C.   5’- 
    GGCAGAUAGUGAAACACAUUGUUAAUUAACAAUGUGUUUCACUAUCUGCC 
-3’ 
 
Cells were incubated with AtuFect01:siRNA complex at 37 ºC with 5% CO2 and 95% 
humidity from 4 to 192 h. For the 192 h timepoint, cells were treated with 
lipid/siRNA complex for 144 h and media was replaced with control media for the 
subsequent 48 h to ensure cell viability. All experiments were conducted in triplicate.  
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Four control conditions were also included: maintenance media (Non-transfected 
control (NTC)), optiMEM control (Non-transfected optiMEM control (NTCO)), 
phosphatase and tensin homolog (PTEN) (siRNA positive control) and luciferase 
(negative control). 25 μl of each condition was added to the maintenance media, 
which provided the required nutrients to maintain cell viability and incubated at 37 
o
C, 5% CO2 humidified incubator for the required time. 
 
Phosphatase and tensin homolog (PTEN) and luciferase (sequences below) were used 
as positive and negative controls, respectively, throughout the experiment.  
PTEN sequence: 5’ - AGUUGUUGGGUUACACCGUGAUA - 3’ 
Luciferase product number: AM4629 (LifeTechnologies/Ambion) 
 
4.2.7 Assessment of cell viability   
Primary hepatocytes were seeded in a 96-well plate and cell viability was measured 
using a fluorometric assay. Mitochondrial activity was assessed by the cleavage of the 
tetrazolinium salt, 4-[3-(-4-Iodophenyl)-2-(4-nitrophenyl0-2H-5-tetrazolio]-1,3-
benzene disulphonate (WST-1) by dehydrogenase (according to the manufacturer’s 
protocol). Maintenance media was aspirated to waste and cells were incubated with 
100 µl of WST-1 (1 mL WST-1 reagent/10 mL maintenance media) at 37 ºC, 5% 
CO2, 95% humidity, for 1 h. Each plate contained samples, blanks and controls with 
three replicates each and absorbance was measured at 450 nm using a SPECTRAmax 
v2.1.28 absorbance reader. Cells were assessed for toxicity using WST-1 reagent at 
all time points. 
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4.2.8 Isolation of mRNA 
β-mercaptoethanol (100 μl) was added to the cells following the removal of the WST-
1 reagent. A further 100 μl of RNase free 70% ethanol was added to each well, mixed 
using a pipette and transferred to a 96-well RNeasy plate. The plate was centrifuged at 
5600 x g for 4 min at room temperature and the subsequent flow-through was 
discarded. The DNase I pellet was dissolved in 550 μl of RNase free water, inverted 
to allow mixing and 3850 μl of RDD buffer was added. DNase I enzyme (80 μl) was 
pipetted into each well and left to incubate at room temperature for 15 min. RW1 
buffer (800 μl) was then added to each well, the plate was again incubated at room 
temperature for 5 min and centrifuged at 5600 x g for 4 min. The flow-through was 
discarded, 800 μl of RPE buffer/80% ethanol was added to each well, centrifuged at 
5600 x g at room temperature for 5 min. This step was completed twice with a 
centrifugation of 10 min on the second wash. The RNA was then eluted into an 
elution microtube rack. RNase free water (50 μl) was added to the membrane of each 
well, incubated at room temperature for one minute and centrifuged at 5600 x g at 
room temperature for 4 min. This step was completed twice. The flow-through was 
labeled and stored at -80
o
C for future use. 
 
4.2.9 RNA Quantification 
Total RNA was quantified fluorometrically using a Quant-iT Ribogreen RNA assay 
kit. The 20X TE buffer (10 mM Tris-HCl, 1mM EDTA, pH 7.5) was diluted with 
RNase free H20 and 95 μl added to a ribogreen assay plate. The mRNA was aliquot to 
each well (5 μl). The provided standard solution (20 μl) was added to wells for a 
standard curve of which sample mRNA was serial diluted and aliquot (5 μl). A 1 in 
150 dilution of the ribogreen dye was completed with diluted TE buffer. The 
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ribogreen dye (100 μl) was added to each well, the plate was wrapped in foil away 
from light and incubated at room temperature for 5 min. The Soft Max Pro Plate 
Reader was used to read the fluorescence produced with excitation at 485nm and 
emission at 530nm. 
  
4.2.10 Quantitative real-time polymerase chain reaction analysis  
Purified mRNA samples (2 µl) were analysed by one-step quantitative real time RT-
PCR performed on an Mx3005P real-time thermo cycler with MxPro software 
(Stratagene, La Jolla, CA). The mRNA samples were thawed on ice and 2 μl added to 
a 96-well Abgene semi-skirted PCR plate. Qiagen’s One Step Quantitect Probe RT-
PCR kit was used to reverse transcribe the mRNA to cDNA and amplify the gene. 
qPCR solutions were prepared for each well as follows; 10 μM probe, 10 μM forward 
and reverse primer  (purchased from Eurogentec, sequences below), 12.5 μl 2X 
master mix, 10.075 μl RNase free H20 and 0.25 μl reverse transcriptase to make a 
final volume of 23 μl. Primers and probe sequences were as follows: 
 
OATP1B1 primer and probe sequences: 
Forward primer -  5’-CTGGGTTTCCACTCAATGGT–3’ 
Reverse primer - 5’-TCAATCAGAGCCCCAAAATA–3’ 
Probe (FAM)   -  5’-CGAGCACTAGGAGGAATTCTAGCTCCAA–3’ 
 
No template controls, no reverse transcriptase controls and a standard curve were 
generated in duplicate to ensure no contamination, specific amplification and 
maximum amplification, respectively. Quantification was recorded in real time using 
a Stratgene MXP3005P Real Time Thermocycler. PCR conditions were 15 min at 95 
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o
C (to activate polymerase, denature cDNA and initiate PCR) followed by 50 cycles 
of 15 sec at 94 
o
C (denaturation) and 60 seconds at 60 
o
C (annealing/extension of the 
product). Fluorescence was collected at the end of each cycle. Relative quantification 
of gene expression was determined by comparing cycle threshold values to that 
obtained from a standard curve prepared from untreated controls. Data were 
normalised to total RNA determined by Ribogreen assay. 
 
4.2.11 Microfluidic Assay 
mRNA (100 ng per reaction) was added to custom Taqman microfluidic plates and 
gene expression normalised and quantified as described in section 3.2.21.  
 
 171 
Table 4.2 
     
Gene Description Alias 
Chromosomal 
location 
Reference 
sequence 
Regulatory 
function 
Reference 
NR1I2 
Nuclear receptor 
subfamily 1, group I, 
member 2 
PXR 3q12-q13.3 NM_033013.2 
Nuclear 
receptor 
Meyer zu 
Schwabedissen 
et al., 2009 
NR1H4 
Nuclear receptor 
subfamily 1, group H, 
member 4 
RIP14 12q23.1 NM_005123.3 
Nuclear 
receptor 
Meyer zu 
Schwabedissen 
et al., 2010 
NR1I3 
Nuclear receptor 
subfamily 1, group I, 
member 3 
CAR 1q23.3 NM_005122.4 
Nuclear 
receptor 
Meyer zu 
Schwabedissen 
et al., 2009 
NR1I1 
Nuclear receptor 
subfamily 1, group I, 
member 1 
VDR 12q13.11 NM_000376.2 
Nuclear 
receptor 
Lindh et al., 
2011 
NR2A1 
Nuclear receptor 
subfamily 2, group A, 
member 1 
HNF4A 20q13.12 AY680696.1 
Nuclear 
receptor 
Kamiyama et al., 
2007 
PPARGC1A 
Peroxisome proliferator 
activated receptor 
gamma coactivator 1 
alpha 
PGC1α 4p15.1 NM_013261.3 
Nuclear 
receptor co-
regulator 
Itoh et al., 2006 
NCoA1 
Nuclear receptor 
coactivator 1 
SRC1 2p23 NM_147233.2 
Nuclear 
receptor co-
regulator 
Muangmoonchai 
et al., 2001 
NCoA2 
Nuclear receptor 
coactivator 2 
GRIP-1 8q13.3 NM_006540.2 
Nuclear 
receptor co-
regulator 
di Masi et al., 
2009 
NCoA6 
Nuclear receptor 
coactivator 6 
PRIP 20q11 NM_014071.3 
Nuclear 
receptor co-
regulator 
Surapureddi et 
al., 2008 
NCOR1 
Nuclear receptor co-
repressor 1 
TRAC1 17p11.2 NM_006311.3 
Nuclear 
receptor co-
regulator 
Moore et al., 
2002 
HDAC1 Histone deacetylase 1 HD1 1p34 NM_004964.2 
Nuclear 
receptor co-
regulator 
Bae et al., 2004 
HDAC2 Histone deacetylase 2 RPD3 6q21 NM_001527.3 
Nuclear 
receptor co-
regulator 
Ponugoti et al., 
2007 
HSP90AA1 
Heat shock protein 
90kDa alpha (cytosolic), 
class A member 1 
Hsp90 14q32.33 NM_005348.3 
Nuclear 
receptor co-
regulator 
Squires et al., 
2004 
TMTC3 
Transmembrane and 
tetratricopeptide repeat 
containing 3 
SMILE 12q21.33 NM_181783.3 
Nuclear 
receptor co-
regulator 
Xie et al., 2009 
CYP3A4 
Cytochrome P450, family 
3, subfamily A, 
polypeptide 4 
CYP3A3 7q21.1 NM_017460.5 
Metabolism 
enzyme 
Martinez-
Jimenez et al., 
2007 
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Gene Description Alias 
Chromosomal 
location 
Reference 
sequence 
Regulatory 
function 
Reference 
CYP3A5 
Cytochrome P450, family 3, 
subfamily A, polypeptide 5 
CP35 7q21.1 NM_000777.3 
Metabolism 
enzyme 
Niemi et al., 
2005] 
CYP2B6 
Cytochrome P450, family 2, 
subfamily B, polypeptide 6 
CPB6 19q13.2 NM_000767.4 
Metabolism 
enzyme 
Wang et al., 
2003 
CYP2D6 
Cytochrome P450, family 2, 
subfamily D, polypeptide 6 
CPD6 22q13.1 NM_001025161.1 
Metabolism 
enzyme 
Westerink 
et al., 2007 
CYP1A2 
Cytochrome P450, family 1, 
subfamily A, polypeptide 2 
CP12 15q24.1 NM_000761.3 
Metabolism 
enzyme 
Landi et al., 
1999 
CYP2C9 
Cytochrome P450, family 2, 
subfamily C, polypeptide 9 
CYP2C10 10q24.1 NM_000771.3 
Metabolism 
enzyme 
Holstein et 
al., 2012 
CYP2C19 
Cytochrome P450, family 2, 
subfamily C, polypeptide 
19 
CYP2C 10q24 NM_000769.1 
Metabolism 
enzyme 
Goldstein et 
al., 1994 
CYP2E1 
Cytochrome P450, family 2, 
subfamily E, polypeptide 1 
CYP2E 10q24.3 NM_000773.3 
Metabolism 
enzyme 
Nelson et 
al., 2004 
UGT2B4 
UDP 
glucuronosyltransferase 2 
family, polypeptide B4 
UGT2B11 4q13 NM_021139.2 
Metabolism 
enzyme 
Congiu et 
al., 2009 
UGT2B7 
UDP 
glucuronosyltransferase 2 
family, polypeptide B7 
UGT2B9 4q13 NM_001074.2 
Metabolism 
enzyme 
Ohtsuki et 
al., 2012 
UGT2B15 
UDP 
glucuronosyltransferase 2 
family, polypeptide B15 
UGT2B8 4q13 NM_001076.3 
Metabolism 
enzyme 
Ohtsuki et 
al., 2012 
UGT1A1 
UDP 
glucuronosyltransferase 1 
family, polypeptide A1 
UGT1A 2q37 NM_000463.2 
Metabolism 
enzyme 
Fisher et al., 
2001 
UGT1A4 
UDP 
glucuronosyltransferase 1 
family, polypeptide A4 
UGT1D 2q37 NM_007120.2 
Metabolism 
enzyme 
Ji et al., 
2012 
UGT1A9 
UDP 
glucuronosyltransferase 1 
family, polypeptide A9 
UGT1AI 2q37 NM_021027.2 
Metabolism 
enzyme 
Zhou et al., 
2013 
SLCO1B1 
Solute carrier organic 
anion transporter family, 
member 1B1 
OATP1B1 12p NM_006446.4 
Influx 
transporter 
Shitara et 
al., 2011 
SLCO1B3 
Solute carrier organic 
anion transporter family, 
member 1B3 
OATP1B3 12p12 NM_019844.3 
Influx 
transporter 
Shitara et 
al., 2011 
SLCO2B1 
Solute carrier organic 
anion transporter family, 
member 2B1 
OATP2B1 11q13 NM_007256.4 
Influx 
transporter 
Fahymayr et 
al., 2010 
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Gene Description Alias 
Chromosomal 
location 
Reference 
sequence 
Regulatory 
function 
Reference 
SLC10A1 
Solute carrier family 10 
(sodium/bile acid 
cotransporter family), 
member 1 
NTCP 14q24.1 NM_003049.3 
Influx 
transporter 
Funk et al., 
2008 
SLC22A7 
Solute carrier family 22 
(organic anion 
transporter), member 7 
OAT2 6p21.1 NM_153320.2 
Influx 
transporter 
Funk et al., 
2008 
SLC22A1 
Solute carrier family 22 
(organic cation 
transporter), member 1 
OCT1. 6q25.3 NM_153187.1 
Influx 
transporter 
Fahrmayr et 
al., 2010 
ABCG2 
ATP-binding cassette, sub-
family G (WHITE), member 
2 
BCRP 4q22 NM_004827.2 
Efflux 
transporter 
Muller et al., 
2011 
ABCB11 
ATP-binding cassette, sub-
family B (MDR/TAP), 
member 11 
BSEP 2q24 NM_003742.2 
Efflux 
transporter 
Stieger et al., 
2011 
ABCB1 
ATP-binding cassette, sub-
family B (MDR/TAP), 
member 1 
P-gp 7q21.12 NM-000927.4 
Efflux 
transporter 
Muller et al., 
2011 
ABCC2 
ATP-binding cassette, sub-
family C (CFTR/MRP), 
member 2 
MRP2 10q24 NM_000392.3 
Efflux 
transporter 
Ieri et al., 
2009 
ABCC3 
ATP-binding cassette, sub-
family C (CFTR/MRP), 
member 3 
MRP3 17q22 NM_003786.3 
Efflux 
transporter 
Le Vee et al., 
2009 
ABCC6 
ATP-binding cassette, sub-
family C (CFTR/MRP), 
member 6 
MRP6 16p13.1 NM_001171.5 
Efflux 
transporter 
Keppler 2011 
 
Table 4.2 List of genes including description, function, chromosomal location 
and reference sequence analysed in the microfluidic assay 
 
4.2.12 Uptake assays using primary human hepatocytes 
Prior to the assay, cells were washed 3 times with hepatocyte buffer (Dulbecco’s 
modified Eagle’s medium; 1 litre powder supplemented with 2.34 g/l HEPES and 0.4 
g/l D-fructose, pH 7.4) pre-warmed to 37ºC.  After the third wash, cells were pre-
incubated at 37ºC for 60 min in 200 µl of pre-warmed Krebs Henseleit solution; 
uptake assays were initiated with the addition of substrate prepared in hepatocyte 
buffer. [
3
H]-E3S final substrate concentration was 5 nM and test substrates were made 
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to a final concentration of 1 µM. To estimate passive uptake atorvastatin (ATV) was 
added to the selected wells (at the same time as the probe and test substrates) varying 
in concentration (0.1-500 μM) to determine complete OATP1B1 inhibition (ATV IC50 
in hepatocytes was 5.9 µM). In all cases the final concentration of dimethyl sulfoxide 
(DMSO) did not exceed 1% (v/v). Optimum substrate incubation time was also 
determined. Optimisation time-points were completed from 15–240 sec. Initial studies 
showed that the uptake of all substrates investigated was linear under the conditions 
used. Uptake assays containing [
3
H]-E3S were terminated after 1 min (2 min for 
assays containing test substrates) via the addition of ice-cold hepatocyte buffer to 
ensure the reaction had terminated. Cells were washed a further two times with ice-
cold hepatocyte buffer before all buffer was aspirated.  
 
For uptake studies using [
3
H]-E3S, cells were lysed by incubating with 500 µl of 
0.1% (v/v) Triton X-100 for 30 min at room temperature. Following the addition of 5 
mL scintillation cocktail, the amount of radioactivity in the cells was determined 
using a Packard 2200CA Tri-Carb liquid scintillation counter (Packard Instrument Co, 
Pangbourne, UK). For all other uptake studies cells were lysed by incubating with 500 
µl of methanol:acetonitrile (50:50) for 1 min. The samples were placed at -20 ºC for 1 
h and then centrifuged at 2000 g for 15 min. 100 µl of the supernatant fraction plus 
100 µl of water were transferred to Agilent 96-well microtitre plates for LC-MS/MS 
analysis (see below). 
 
To calculate the contribution by OATP1B1 the following equation was applied: 
OATP1B1 Inhibition (%) =     1   –   (OATP1B1 – ATV)      x 100 
               (NTCO – ATV) 
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4.2.13 LC-MS/MS analysis of hepatocyte uptake samples 
Mass spectrometric analysis for rosuvastatin, pitavastatin, olmesartan, valsartan, and 
lopinavir was conducted on a ThermoScientific TSQ Quantum Ultra Mass 
spectrometer (ThermoScientific, Hemel, UK) using an Accela High pressure 
Quaternary Pump for separation. Analysis was by multiple reaction monitoring using 
a heated electrospray ionisation source, in either positive or negative ion mode. Tube 
lens and collision energy were optimised for each compound. 
 
Assay optimisation and validation for all 5 compounds had already been conducted in 
house within AstraZeneca, Charnwood, UK. In these analyses, chromatographic 
separation was achieved using a Waters Acquity UPLC BEH C18 (2.1 x 100 mm, 1.7 
μm) column. The mobile phase consisted of water with 0.1% (v/v) formic acid with 
the organic phase being methanol containing 0.1% (v/v) formic acid. All 
chromatography was performed using a generic gradient (t = 0 min 5% organic, t = 
0.25 min 5% organic, t = 2 min 100% organic, t = 3 min 100% organic, t = 3.1 min 
5% organic, t = 4 min 5% organic). The flow rate was set at 0.6 ml/min, with the 
column temperature set at 60 ºC. 
 
4.2.14 Measurement of CYP3A4 enzyme activity 
Primary hepatocytes (4.5 x 10
4
/well) were seeded in a black 96-well plate and 
CYP3A4 activity assessed using a Vivid® CYP450 screening assay as described in 
Section 2.2.9.  
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Activity endpoint assay calculation: 
CYP3A4 Activity (%)  
=   1 –   Relative fluorescence of OATP1B1 siRNA treated cells  x 100 
   Relative fluorescence of control cells 
 
4.2.15 Data analysis 
Within the study each assay was conducted in triplicate. To estimate passive transport 
into human hepatocytes, the OATP1B1 inhibitor atorvastatin was added to 
incubations at a final concentration of 500 µM. The following equation was used to 
estimate % inhibition of OATP1B1: 
 
Where OATP1B1 siRNA was defined as uptake of the test compound conducted with 
cells treated with OATP1B1 siRNA for 144 h, ATV was uptake of test compound 
with the addition of 500 µM atorvastatin conducted with cells treated with OATP1B1 
siRNA for 144 h and NTCO was uptake of test compound conducted with 
hepatocytes treated with control media. 
 
All optimisation experiments were completed in triplicate using human hepatocyte 
donor Hu8089. Upon method application and off target assessment experiments were 
completed in triplicate for all 3 human hepatocyte donors (Table 2.1/4.1). 
 
Normality was assessed using Shapiro Wilk and data were assessed using Mann 
Whitney for non-normal and unpaired t test for normally distributed data. Results 
were considered significant if; *, p < 0.05; **, p < 0.01; ***, p < 0.001. The IC50 of 
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atorvastatin was calculated using a non-compartmental model (WinNonLin, version 
4.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Schematic of the siRNA process 
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4.3 Results 
4.3.1 Initial optimisation of siRNA delivery to human hepatocytes using AtuFect01 
Initial work focused on assessing the utility of AtuFect01 to deliver siRNA specific to 
phosphatase and tensin homolog (PTEN) gene. Previous work in the laboratory 
showed this siRNA could knockdown PTEN in other cell types (data not shown). 
Therefore, this experiment aimed to validate AtuFect01 delivery of siRNA to primary 
human hepatocytes. Luciferase was used as a negative control to ensure specific 
inhibition. Figure 4.3A shows the effect of PTEN siRNA treatment on PTEN mRNA 
expression after human hepatocytes were exposed to the AtuFect01/siRNA complex 
for 4, 24, 48 and 72 hours. PTEN mRNA expression decreased with exposure time to 
the AtuFect01/siRNA complex resulting in a 98% reduction by 72 h, compared to 
cells which had been incubated with control optimum media (NTCO). Figure 4.3B 
shows that the decrease in PTEN mRNA over time was not associated with 
cytotoxicity as assessed by mitochondrial dehydrogenase activity. In subsequent 
experiments, PTEN was included as a positive control for AtuFect01 and luciferase 
was used as a negative control.    
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Figure 4.3 The effect of PTEN siRNA treatment on PTEN mRNA (A) and cell 
viability (B) after treatment for 4, 24, 48 and 72 h relative to non-transfected control-
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optiMEM (NTCO). Each bar shows the mean ± S.D. of 3 wells. The conditions were 
statistically compared using an unpaired T test or Mann Whitney; * = p < 0.05, ** = p 
< 0.01,*** = p < 0.001.  
 
4.3.2 Initial optimisation of estrone 3 sulfate uptake into human hepatocytes 
The significant overlap in substrate selectivity for individual OATP isoforms has 
hampered the selection of specific OATP1B1 substrates (331, 351). However, it has 
been suggested that the uptake of E3S at low substrate concentrations may be 
selective for OATP1B1 (352, 353). Therefore, the uptake of E3S at a final substrate 
concentration of 5 nM was selected as a probe of OATP1B1 activity. Initial studies 
investigated the linearity of E3S uptake into hepatocytes with respect to both time and 
cell density. Uptake was linear over 3 min (Figure 4.4B) and also across the cell 
densities investigated (15,000 to 45,000 cells per well) (Figure 4.4A). An incubation 
time of 1 min and a cell density of 45,000 cells/well were chosen for siRNA studies 
due to a 75% increase in E3S uptake compared to 30,000 cells/well and well 
confluence was 95% (Figure 4.4). 
 
 
 181 
 
 
Figure 4.4 Effect of hepatocyte cell and number (A) and incubation time (B) on 
E3S uptake 
 
Since E3S uptake into human hepatocytes has active and passive components and 
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siRNA will only knockdown active transport, it was crucial to obtain an estimate of 
passive uptake. Historically, uptake studies conducted at 4 
o
C have been used to give 
an estimation of passive uptake but recent data have shown this to be inaccurate since 
membrane permeability varies with temperature (354). Therefore, the use of ATV as a 
competative OATP1B1 inhibitor to estimate passive permeability was investigated. 
Initial studies with a range of ATV concentrations (0.1–500 μM) showed that ATV 
inhibited uptake of E3S into human hepatocytes with an IC50 of 5.9 µM (Figure 4.5). 
The addition of 500 µM ATV in uptake studies completely inhibited the active 
component of estrone-3-sulfate uptake and these assay conditions were used to 
estimate the passive permeability component. 
 
Figure 4.5 Inhibition of E3S uptake in human hepatocytes  
 
 
4.3.3 Delivery of OATP1B1 siRNA to human hepatocytes 
The effect of the lipid/OATP1B1 siRNA complex on human hepatocyte cytotoxicity 
(Figure 4.6A), OATP1B1 mRNA expression (Figure 4.6B) and uptake of E3S (Figure 
4.6C) was assessed over 192 h. Figure 4.6A shows that although cell viability 
decreased over the time course investigated, even after 192 h, cell viability was 
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deemed to be within acceptable limits (>80% of controls). OATP1B1 mRNA 
decreased between 24 and 144 h of exposure to lipid/siRNA complex with a maximal 
knockdown of 98% observed compared to controls after 144 h (see Figure 4.6B). The 
uptake of E3S also decreased over 144 h with a 93% decrease in uptake observed at 
144 h (see Figure 4.6C). It should be noted that the uptake of E3S into human 
hepatocytes treated with control media did not decrease over the time course 
investigated (24-192 h, Figure 4.7C) which agrees with previous studies that showed 
OATP activity was retained in long-term cultures of human hepatocytes (355). 
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Figure 4.6 The effect of OATP1B1 siRNA on cell viability (A), OATP1B1 
mRNA (B), E3S uptake (C) and OATP1B1 mRNA and E3S combined (D) after 
treatment with siRNA for 24, 48, 72, 144 and 192 h. Each bar shows the mean ± S.D. 
of 3 wells. The conditions were statistically compared using a Shapiro Wilks and 
Unpaired T test; * = p < 0.05, ** = p < 0.01,*** = p < 0.001. 
 
144 h was selected as the optimum time for siRNA treatment; achieving the greatest 
inhibition of OATP1B1 mRNA, E3S uptake without any associated toxicity. 
 
To examine the inter-donor variability in knockdown of OATP1B1 mRNA and 
inhibition of E3S uptake, two further human hepatocyte donors were treated with 
lipid/siRNA complex for 144 h. Figure 4.7A shows that the knockdown in OATP1B1 
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mRNA in donors Hu4244 and Hu8085 was consistent with results observed for donor 
Hu8089 (94% decrease for both Hu4244 and Hu8085). In addition, the reduction in 
E3S activity was also consistent between donors (82, 90 and 93% for Hu4244, 
Hu8085 and Hu8089, respectively, see Figure 4.7B). 
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Figure 4.7 The effect of OATP1B1 siRNA on OATP1B1 mRNA (A) and E3S (B) 
in three different donor of human hepatocytes following treatment with siRNA for 
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144 h and the uptake of E3S over time in control and siRNA treated cells for one 
donor (C). Values are expressed as a percentage relative to NTCO. Each bar shows 
the mean±S.D. of 3 replicates. The results were statistically compared using an 
unpaired T test or Mann Whitney; ***, p<0.001. 
 
4.3.4 Assessment of potential off-target effects using OATP1B1 siRNA delivery 
To determine if OATP1B1 siRNA had any off-target effects, the mRNA expression of 
40 genes involved in the regulation, metabolism and disposition of drugs was 
investigated (see Table 4.1 and Figure 4.8). Figure 4.8 shows that treatment with 
OATP1B1 siRNA for 144 h had no significant effect on the investigated nuclear 
receptors or nuclear receptor co-regulators. 
 
No notable changes in the mRNA expression of either UDP-glucuronosyltransferases 
(see Figure 4.8D), influx transporters (Figure 4.8E) or efflux transporters (see Figure 
4.8F) were observed. Overall, no significant (classified as either 50% increase or 
decrease in gene expression) off target effects were observed for the 40 genes 
investigated following treatment with OATP1B1 siRNA. 
 
Figure 4.8C shows that of the 8 CYP genes investigated the greatest effect was a 27% 
decrease in CYP3A4 mRNA expression. While this decrease in expression was not 
considered significant, the high importance of CYP3A4 in drug metabolism prompted 
further studies.  Therefore, CYP3A4 activity was assessed in human hepatocytes 
which had been treated with OATP1B1 siRNA for 144 h and compared with those 
incubated with control medium. For the three donors investigated CYP3A4 actvity 
only decreased 3% following OATP1B1 siRNA treatment (Figure 4.9).  
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Figure 4.8 The effect of OATP1B1 siRNA on the hepatic mRNA expression of 
common nuclear hormone receptors (A), co regulators (B), cytochrome P450’s (C), 
uridine diphospho glucuronosyltransferases (D), uptake transporters (E) and efflux 
4.8E	
4.8D	4.8C	
4.8B	4.8A	
4.8F	
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transporters (F) after 144 h of siRNA treatment. Each bar shows the mean ± S.D. of 3 
donors completed in triplicate. The conditions were statistically compared using a 
Shapiro Wilks and Unpaired T test; ***, p < 0.001. 
 
 
Figure 4.9 Effect of OATP1B1 siRNA oligo complex on the activity of CYP3A4 
in plated human hepatocytes after 144 h. Values are expressed as the mean±S.D of 3 
donors completed in triplicate. Calculated from the rate in relative fluorescent units 
(RFU) per minute in siRNA treated cells, expressed as a percent (%) of the rate in 
control cells (NTCO). 
 
 
4.3.5 Determination of relative contribution of OATP1B1 to the hepatic uptake of 
five drugs 
Initial work determined that the uptake of two angiotensin II inhibitors (valsartan and 
olmesartan), two HMG-co-enzyme A reductase inhibitors (rosuvastatin and 
pitavastatin) and a HIV protease inhibitor (lopinavir) into human hepatocytes was 
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linear with respect to time (up to 120 sec) (Figure 4.10). The uptake of each drug into 
hepatocytes with or without siRNA treatment was then assessed and the relative 
contribution of OATP1B1 was calculated accounting for passive uptake (see Methods 
section for details). A schematic of the siRNA process is shown in Figure 4.2. Table 
4.2 shows that lopinavir, pitavastatin, olmesartan and rosuvastatin were 
predominantly taken up into human hepatocytes by OATP1B1 (64–89%, 84–98%, 
42–62% and 64–72%, respectively). For these drugs, the percentage contribution of 
OATP1B1 was consistent across the three donors investigated (low inter-donor 
variability). By contrast, the inter-donor variability in OATP1B1 contribution for 
valsartan was much greater (28-71%), suggesting this may not be the main uptake 
transporter of the compound. Interestingly, the data obtained using this siRNA 
approach was in good agreement with that determined previously using the relative 
activity factor method (RAF) approach (Table 4.2).  
 
 
Figure 4.10 Effect of incubation time on the uptake of selected compounds in 
primary human hepatocytes 
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In contrast to the siRNA method, the RAF approach simultaneously defines the 
uptake of the influx transporters OATP1B1 and OATP1B3 hence it requires a 
selective substrate for both transporters and a HEK293 transfected cell for each gene. 
It uses E3S and cholecystokinin (CCK-8) as substrate probes for OATP1B1 and 
OATP1B3, respectively. It estimates the OATP1B1 and OATP1B3 mediated portion 
of uptake of selected compounds by: 
 
Ract, OATP1B1    =      CLHep,E3S    Ract,OATP1B3   =       CLHep,CCK8 
  CLOATP1B1,E3S                           CLOATP1B3,CCK8 
 
CLhep,test,OATP1B1  =  CLOATP1B1,test . RactOATP1B1               CLhep,test,OATP1B3  =  CLOATP1B3,test . RactOATP1B3 
                              
CLhep,test   =   CLhep,test,OATP1B1  +   CLhep,test,OATP1B3       (356) 
 
  OATP1B1 uptake contribution (%)   
Compound 
SiRNA 
RAF Reference 
Hu4244 Hu8085 Hu8089 
Olmesartan 62 42 54 44-62 Yamada et al., 2007 
Rosuvastatin 72 66 64 66-84 Kitamura et al., 2008 
Pitavastatin 84 98 90 88-95 Hirano et al., 2004 
Valsartan 43 28 81 22-71 Yamashiro et al., 2006 
Lopinavir 64 69 89 
Data not 
available 
  
 
Table 4.2 Percentage contribution by OATP1B1 for the hepatic uptake of 
selected compounds.  
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The passive component of uptake for the five drugs investigated ranged from 28-62% 
for low logD7.4 drugs such as valsartan and olmesartan (logD7.4 -1.1 and -1.6 
respectively) to 37% for pitavastatin, which has a logD7.4 of 1.2. These findings are 
consistent with those observed by Yabe et al., (2011) using rat hepatocytes. 
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4.4 Discussion 
OATPs play a pivotal role in the disposition of anionic drugs across a number of 
therapeutic areas (333). However, the lack of selective substrates/inhibitors for the 
individual OATP isoforms has hampered progress in identifying the relative 
importance of OATP1B1, OATP1B3 and OATP2B1 to the hepatic uptake of drugs. 
Obtaining this added level of detail when characterising the disposition of drugs in 
development could be critical in determining the potential impact of known 
polymorphisms of OATP1B1 (357) or the fraction of drug transported by a particular 
isoform to produce more accurate DDI predictions. Indeed, this has been the case for 
CYPs when utilising fraction metabolised data (358). To address this issue, the 
current study has focused on the development of a method for determining the role of 
OATP1B1-mediated uptake of compounds into human hepatocytes using a siRNA 
approach. This method was then applied to quantify OATP1B1-mediated uptake for 
five commonly prescribed drugs (Table 4.2).   
 
Two critical objectives required for successful utilisation of siRNA to knockdown of 
OATP1B1 in human hepatocytes were to inhibit OATP1B1 mRNA and activity 
significantly and to ensure specificity to OATP1B1. Figure 4.6B shows that 
OATP1B1 mRNA was reduced by 98% following treatment with siRNA for 144 h 
which is consistent with the results of Liao et al., (2010) who also observed a ~98% 
knockdown of OATP1B1 mRNA after 96 hours. However, minimal effects on 
OATP1B3 and OATP2B1 mRNA were observed in the current study (inhibition of 
12% and increase of 10% respectively), while up to 50% inhibition of OATP1B3 and 
a 70% increase in OATP2B1 mRNA were observed in the previous study by Liao et 
al., (2010). In addition, Liao et al., (2010) screened a mixture of OATP1B1, 1B3 and 
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2B1 siRNA and showed a >50% change in mRNA for 5 non-target genes including 
CYP2B6 (70% increase). In the current study OATP1B1 siRNA was screened against 
40 genes (Figure 4.8) and no significant differences in mRNA were observed 
(including CYP2B6 where only a 10% increase was observed). These data 
demonstrate clearly that the current siRNA/lipid complex can specifically inhibit 
OATP1B1 mRNA with no overt off target effects. Therefore, the siRNA oligos used 
in this study appears to be more specific to OATP1B1 than that used previously.  
 
Although the transport of estrone-3-sulfate has been shown previously by some 
investigators to be mediated by OATP1B1, OATP1B3 and OATP2B1 (351), it has 
been reported to be selective for OATP1B1 at low substrate concentrations (352, 
353). The active uptake of estrone-3-sulfate at a final substrate concentration of 5 nM 
was decreased by ~50% following treatment with siRNA for 72 h (Figure 4.6C) 
which was similar to the 65% knockdown of activity observed by Liao et al., (2010) 
after 96 h of OATP1B1 siRNA treatment. However, an 82-93% decrease in the active 
uptake of estrone-3-sulfate was observed in the three different human hepatocyte 
donors studied after 144 h of OATP1B1 siRNA treatment (Figure 4.6C). The high 
level of inhibition and the consistency of estrone-3-sulfate uptake across multiple 
hepatocyte donors suggest that these assay conditions are suitable to assess OATP1B1 
mediated uptake in human hepatocytes. By contrast, Liao et al., (2010) required a 
mixture of OATP1B1, 1B3 and 2B1 siRNA to inhibit estrone-3-sulfate uptake by 70-
80% suggesting that the method was not isoform-specific. It is interesting to note that 
maximal inhibition of estrone-3-sulfate uptake required 144 h of exposure to 
OATP1B1 siRNA (Figure 4.6C) whereas maximal inhibition of OATP1B1 mRNA 
was achieved after 72 h (Figure 4.6B). These differences provide information on 
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protein turnover for OATP1B1 in human hepatocytes and offer a guide to the 
timescales required to obtain meaningful knockdown of this transporter. A potential 
limitation of the current study is that OATP1B1 protein expression was not assessed. 
Commercial antibody’s against OATP1B1 are currently available but suffer from a 
lack of specificity. Therefore, the high level of knockdown observed in the current 
study indicates that these data would be of limited value. Because of this and the 
availability of functional activity data, protein expression was not assessed.      
 
The application of a siRNA approach to dissect the role of OATP1B1 in the hepatic 
uptake of 5 drugs is shown in Table 4.2. The remarkable similarity in the results 
obtained using either the siRNA or RAF approach agrees with the hypothesis that the 
uptake of estrone-3-sulfate (5nM) by OATP1B1 is concentration dependent. 
Therefore, these data provide additional evidence that the RAF approach proposed by 
Hirano et al., 2004, is a suitable method to determine the relative contribution of 
OATP1B1 to the hepatic uptake of drugs. However, the RAF method relies on prior 
availability of specific transporter substrates and although CCK-8 is specific for 
OATP1B3 the availability of specific substrates for other transporters (including those 
of determined and as yet undetermined importance), limits broad applicability of the 
RAF approach. Since the siRNA approach does not require selective substrates, the 
methodology has clear advantages in determining the relative contribution of other 
transporters to drug disposition. Along with ready to use reagents and easy 
transfection methods, the process can readily be applied for high throughput 
application with minimal off target effects. However, there are disadvantages of using 
siRNA including cost and specific knockdown times. The use of specific inhibitors to 
determine drug transport has been discussed previously (Soars et al., 2012). Key 
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disadvantages include the requirement of additional substrates and in silico modeling 
to generate robust data. Soars et al. (2012), in particular noted a 10-fold under 
prediction of inhibition when using various substrates. 
 
Further evidence to support the role of OATP1B1 in the disposition of the 5 drugs 
investigated in Table 4.2 can be found in pharmacokinetic studies conducted with 
patients who have genetic polymorphisms in SLCO1B1 (coding for OATP1B1). In 
particular, studies comparing the pharmacokinetics of substrates in patients with the 
common allele compared with those who have the SLCO1B1*15 haplotype 
(associated with reduced function) have been informative (357). Ieiri et al., (2007) 
showed a 3.1-fold higher pitavastatin AUC in patients homozygous for SLCO1B1*15. 
This is consistent with findings of this study, which suggest that OATP1B1 has a 
major role in pitavastatin disposition (Table 4.2). A significantly higher exposure of 
both rosuvastatin (359) and lopinavir (49) have also been reported for SLCO1B1*15, 
although the magnitude of difference was less than that observed for pitavastatin. This 
indicates that the involvement of OATP1B1 in the disposition of these drugs is more 
moderate (Table 4.2), and that other uptake/clearance pathways also contribute. 
Olmesartan pharmacokinetics have also been investigated according to SLCO1B1*15 
haplotype but differences in AUC were not statistically significant (360). Finally, 
Maeda et al., (2006) saw no significant difference in valsartan AUC in SLCO1B1*15 
heterozygotes. This suggests that the role of OATP1B1 in hepatic uptake of valsartan 
might be at the lower range of the 28-81% contribution observed in this study and/or 
other mechanisms of clearance predominate for this drug.   
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In conclusion, this chapter highlights the importance of rigorous optimisation of assay 
conditions to utilise key technologies to their full potential. In this case a siRNA 
method was developed to specifically inhibit OATP1B1-mediated uptake into human 
hepatocytes without significant off-target effects. The application of this technique to 
elucidate the role of OATP1B1 in the hepatic uptake of 5 drugs was then 
demonstrated. Future application of this strategy is likely to have broad importance in 
determining relative contribution that individual transporters play in drug disposition. 
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CHAPTER 5 
 
Induction of influx and efflux 
transporters and CYP3A4 in 
primary human hepatocytes by 
rifampicin, rifabutin and rifapentine 
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5.1 Introduction 
To prevent accumulation and toxicity of xenobiotics, biotransformation and transport 
of foreign compounds occurs, whereby the lipophilic structures are converted into 
water soluble metabolites that are easily excreted. Whilst these mechanisms serve to 
protect the body, they reduce the bioavailability of orally administered compounds. 
Induction is the process in which a compound, such as, rifampicin (RIF), 
initiates/enhances the expression of a gene, for example cytochrome P450 3A4 
(CYP3A4) or drug transporters, thereby altering the pharmacokinetics (PK) of the 
perpetrator (RIF) or victim drug (e.g. midazolam (MDZ)), contributing to numerous 
clinically significant drug-drug interactions (DDIs). 
 
Tuberculosis (TB) is a major global health problem caused by the bacteria 
mycobacterium tuberculosis (361-364). In 2011 there were over 8.7 million new cases 
of TB and 1.4 million deaths (365). As a single infection it is the worlds second 
biggest killer worldwide (to human immunodeficiency virus (HIV)) with over 95% of 
the mortalities occurring in low- and middle-income countries. Although the 
prevalence of TB has dropped by 41% since 1990 it is responsible for over 25% of 
deaths in HIV infected patients (366). However, the efforts to achieve the Millennium 
Development Goal to suppress TB infection by 2015 is on target (367). 
 
Current treatment is effective, with combined therapy of isoniazid, RIF, pyrazinamide 
and ethambutol (368). However, to avoid relapse and occurrence of multi-drug 
resistant TB, treatment is prescribed for 6 months (369). Rifamycins, bactericidal 
antibiotics, inhibit bacteria DNA-dependent RNA synthesis. The drug binds adjacent 
to the RNA polymerase active centre thereby blocking RNA synthesis through steric 
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occlusion, which prevents extension of RNA products beyond 2-3 nucleotides in 
length (370). Rifamycins represent a key drug class used in first line TB regimens 
(371). First identification of the compounds was in 1972 due to their treatment 
shortening potential (372). However, the optimal and maximum dose for RIF or RPT 
was never established in mouse models or in humans (373). The renewed interest in 
this class of drugs is driven by the potential of further treatment shortening times and 
related drug-drug interactions (DDIs). Drug resistance commonly occurs through 
mutations in the rpoB portion of the β subunit in RNA polymerase (374). Although 
the drugs are well tolerated, hepatotoxicity and flu-like syndrome are common.  
 
RIF is a potent antibactericidal and inducer of cytochrome P450 (CYP) and phase 2 
metabolising enzymes (89, 95, 375). Clinically significant DDIs are common due to 
induction of CYP3A4 and key drug transporters due to a lower maximum 
concentration (Cmax) and area under the curve (AUC) of co-administered drugs (375) 
(examples and more detail are included in Chapter 1).  
 
Rifabutin (RBT), a semi-synthetic derivative of rifamycin B is considered a less 
potent inducer and is often used in place of RIF for patients receiving antiretroviral 
drugs for HIV to reduce risk of drug interactions (85, 376, 377). Although 
bioavailability of RBT is 85% (compared to 95% for RIF) it has a much longer half-
life (t1/2) (28-62 h compared to 2.3-5.1 h for RIF) and is therefore effective in patients 
with a lower CD4+ T cell count as these individuals are more susceptible to 
developing drug resistance (85, 376, 378). 
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Rifapentine (RPT) a lipophilic, cyclopentyl RIF antibiotic derivative has a lower 
mean inhibitory concentration against mycobacterium TB in comparison to RIF and a 
longer half-life (~17 h), suggesting it is a possible alternative for the current RIF 
regimen (379). Substitution of RPT for RIF may reduce treatment duration required 
for cure, but its induction potential is comparatively understudied (375, 380). RPT 
sterilising activity is dose-dependent in an established mouse model of TB, with 
eradication possible in three months or less when high-dose RPT is substituted for 
RIF in a multidrug treatment regimen (375, 381). However, dose increases resulted in 
less than dose-proportional increases in RPT exposures in the clinic (368, 381, 382). 
In addition, the mean AUC of oral MDZ, a CYP3A4 probe, decreased by 75% when 
co-administered with RIF, compared to 92% when co-administered with RPT, each 
given at 10 mg/kg daily (383).  
 
The aim of this chapter was to evaluate the impact of the prototypical inducer RIF as 
well as RBT and RPT in vitro on the mRNA expression of CYP3A4, ABCB1, 
ABCC1, ABCC2, OATP1B1 and OATP1B3 in six primary human hepatocyte donors. 
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5.2 Methods and Materials 
5.2.1 Materials 
Primary human hepatocytes, Williams E media, optiMEM media, cryopreserved 
hepatocyte recovery medium (CHRM
®
), CHRM
®
 supplements and Hanks balanced 
salt solution were purchased from LifeTechnologies, Ltd (Paisley, Scotland). Taqman 
reagents and assays, reverse transcription products and real time-qPCR master mix 
were obtained from Applied Biosystems (Warrington, UK). 24-well plates pre-coated 
with collagen IV were purchased from BD Biosceinces (Oxford, UK). Rifampicin 
(R3501), rifabutin (R3530), rifapentine (R0533) and all products were of analytical 
grade and purchased from Sigma-Aldrich (Poole, UK). 
 
5.2.2 Primary human hepatocytes  
Cryopreserved human hepatocytes were thawed as previously described in section 
2.2.3. Donor demographics are detailed in Table 5.1. 
Table 5.1 Human donor demographics of the cryopreserved hepatocytes used in the 
study 
 
 
 
Donor Viability Gender Age Race 
Hu1389  96 % Female 36 year old Caucasian 
Hu1414 95 % Male 68 year old  Caucasian 
Hu4228 94 % Female 47 year old Indian 
Hu4248 95 % Female 12 year old Caucasian 
Hu1413 95 % Female 72 year old African American 
Hu4197 91 % Male 31 year old Caucasian 
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5.2.3 Cell viability 
Cell viability and density of primary human hepatocytes were calculated using trypan 
blue exclusion as described in section 2.2.4. 
 
5.2.4 Plating and maintaining primary human hepatocytes 
Cells were seeded in 24-well plates pre-coated with collagen at a density of 2 x 10
5
 
cells/well and incubated for 24 h at 37 ºC with 5% CO2 and 95% humidity as 
described in section 2.2.5.  
 
5.2.5 Primary human hepatocyte treatment 
24 hours post plating, plating media was replaced with maintenance media (as 
described in section 2.2.5) containing rifampicin (RIF), rifabutin (RBT) or rifapentine 
(RPT) at concentrations spanning the therapeutic range (0.5, 5 and 10 μM) for 24 
hours. 
 
5.2.6 mRNA and cDNA Quantification 
mRNA was extracted using Trizol reagent and reverse transcribed using standard 
methodology as described in section 2.2.6 and 2.2.7.  
 
5.2.7 Quantitative real time-PCR  
A Chromo4™ real-time PCR (LifeTechnologies, UK) was used to determine the gene 
expression of selected genes (Table 5.2) as described in section 2.2.8.  
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Table 5.2. Information on genes analysed using real-time PCR. Assay ID is the 
Applied Biosystems reference number and gene ID is the NCBI reference number.  
Dye - FAM: 6-carboxyfluorescein 
 
 
5.2.8 Data Analysis.  
All primary human hepatocyte data herein was mean of six donors completed in 
triplicate. Normality of all data was assessed using a Shapiro-Wilk test and statistical 
analysis conducted using paired t-test or Wilcoxon signed-rank test for normally or 
non-normally distributed data, respectively. Statistics were calculated using Stats 
Direct (Version 2.4.6 Stats Direct Ltd). Results were considered significant if; *, p < 
0.05; **, p < 0.01; ***, p < 0.001. 
 
Gene Description Alias
Chromosomal 
location
Reference 
sequence
Assay ID Gene ID
CYP3A4
Cytochrome P450, family 3, 
subfamily A, polypeptide 4
CP33, CYP3A 7q21.1 NM_017460.5 Hs00604506_m1 1576
ABCB1
ATP-binding cassette, subfamily 
B (MDR/TAP), member 1
ABC20, P-GP 7q21.12 NM_000927.4 Hs00184500_m1 5243
ABCC1
ATP-binding cassette, subfamily 
C (CFTR/MRP), member 1
MRP, ABCC 16p13.1 NM_004996.3 Hs01561502_m1 4363
ABCC2
ATP-binding cassette, subfamily 
C (CFTR/MRP), member 2
ABC30, MRP2 10q24 NM_000392.3 Hs00166123_m1 1244
SLCO1B1
Solute carrier organic anion 
transporter family, member 1B1
OATP1B1, OATP2 12p NM_006446.4 Hs00272374_m1 10599
SLCO1B3
Solute carrier organic anion 
transporter family, member 1B3
OATP1B3, OATP8 12p12 NM_019844.3 Hs00251986_m1 28234
 206 
5.3 Results 
5.3.1 OATP1B1 and OATP1B3 gene expression 
RIF significantly upregulated the expression of OATP1B1, with maximal induction 
observed at 10 μM (2-fold increase, p=0.03) (Figure 5.1a).  Treatment with RBT or 
RPT had no significant impact on the expression of OATP1B1. 
 
No significant induction of OATP1B3 was observed upon treatment with RIF or RPT 
at any concentration (Figure 5.1b). However, the expression was significantly induced 
when incubated with 5 μM RBT (4-fold increase, p=0.04). Whilst the mean 
expression of OATP1B3 was greater with 10 μM RBT, the increase was not 
significant; large donor variability was observed at 10 μM RBT, with the top whisker 
regarded as an outlier (outlier = ≥1.5 times the interquartile range (IQR)). 
Interestingly, the data observed for OATP1B1 and OATP1B3 were much more 
variable between donors treated with RIF and RBT in comparison to RPT. 
 
5.3.2 ABCC1 and ABCC2 gene expression 
RIF, RBT and RPT had no significant impact at any concentration on the mRNA 
expression of ABCC1 (Figure 5.2a). A dose-dependent increase in expression was 
observed when cells were treated with RBT however, the same trend did not occur for 
RIF and RPT. Large variability in ABCC1 expression was observed for all drugs. 
 
Expression of ABCC2 was consistent across all donors when treated with RIF, RBT 
or RPT (Figure 5.2b). Whilst a dose-dependent increase in ABCC2 expression was 
observed for all drugs, only RIF significantly upregulated ABCC2, with maximal 
induction at 10 μM (3-fold increase, p=0.03). 
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5.3.3 CYP3A4 and ABCB1 gene expression 
A significant induction of CYP3A4 was observed at the lowest concentration of RIF 
(0.5 μM, 11-fold, p=0.04). A concentration-dependent profile was observed for 
CYP3A4 when treated with RIF with maximal induction observed at 10 μM (5 μM, 
35-fold increase, p=0.03; 10 μM, 80-fold increase, p=0.02) (Figure 5.3a). RBT also 
significantly upregulated the expression of CYP3A4 at 5 μM (10-fold increase, 
p=0.05), with greatest induction observed at 10 μM (20-fold increase, p=0.05). 
Treatment with RPT displayed large donor variability and although a dose-dependent 
increase in CYP3A4 expression was observed, the difference when compared to the 
control was not significant. When analysed as an average of the 6 donors RPT did not 
significantly induce the expression of CYP3A4 but significant induction was observed 
in 3 of 6 donors when analysed individually.  
 
In contrast to CYP3A4, when treated with the 3 rifamycins, the expression of ABCB1 
was comparable between donors (Figure 5.3b). RIF elicited a significant upregulation 
of ABCB1 from 5 μM (5-fold increase, p=0.03). A concentration-dependent 
upregulation was observed with greatest induction observed at 10 μM (10-fold 
increase, p=0.03). Treatment with RBT had no significant impact on ABCB1 
expression. However, ABCB1 was the only gene significantly induced by RPT (4-
fold increase; p=0.04) at 10 μM.  
 
In comparison to previous studies (4), the results herein suggest the rifamycins’ 
potency as CYP3A4 inducers as rifampicin > rifabutin > rifapentine. 
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Figure 5.1. Relative gene expression of OATP1B1 (A) and OATP1B3 (B) in 
primary hepatocytes when incubated with RIF, RBT or RPT at 0, 0.5, 5 and 10 μM. 
Data was normalised to GAPDH housekeeping gene and to control primary 
hepatocytes (0 μM) using the comparative C(t) method (C(t)=2^-ddC(t)). Tukey box 
plot represents the mean of 6 donors completed in triplicate with box showing inter-
quartile range (IQR) and whiskers representing <1.5 x IQR. Data outside 1.5 x IQR 
are labelled as outliers (). 
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Figure 5.2. Relative gene expression of ABCC1 (A) and ABCC2 (B) in primary 
hepatocytes when incubated with RIF, RBT or RPT at 0, 0.5, 5 and 10 μM. Data was 
normalised to GAPDH housekeeping gene and to control primary hepatocytes (0 μM) 
using the comparative C(t) method (C(t)=2^
-ddC(t)
). Tukey box plot represents the 
mean of 6 donors completed in triplicate with box showing inter-quartile range (IQR) 
and whiskers representing <1.5 x IQR. Data outside 1.5 x IQR are labelled as outliers 
().
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Figure 5.3. Relative gene expression of CYP3A4 (A) and ABCB1 (B) in primary 
hepatocytes when incubated with RIF, RBT or RPT at 0, 0.5, 5 and 10 μM. Data was 
normalised to GAPDH housekeeping gene and to control primary hepatocytes (0 μM) 
using the comparative C(t) method (C(t)=2^
-ddC(t)
). Tukey box plot represents the 
mean of 6 donors completed in triplicate with box showing inter-quartile range (IQR) 
and whiskers representing <1.5 x IQR. Data outside 1.5 x IQR are labelled as outliers 
().
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5.4 Discussion 
This work highlights the extent to which RIF induces CYP3A4-mediated metabolism 
and the transport of compounds compared to RBT, and RPT as potential alternatives. 
Consistent with all primary hepatocyte studies, large inter-donor variability was 
observed (244). However, concentration-dependent responses were seen for most 
genes (including CYP3A4).  
 
Conversely to RIF and RPT, RBT is metabolised by CYP3A4 and has been shown to 
induce its own metabolism (369), although as described previously and here, the 
induction effects are much less profound compared to RIF and RPT (Figure 5.3) 
(376). In vitro analysis has shown RPT is more potent after a 600mg dose once a 
week compared to a 600mg dose once a day for RIF (380, 381). In comparison, 
clinical data does not demonstrate the same trend with relapse rates greater for RPT 
compared to RIF (380). At the same micromolar concentration, larger increases in 
CYP3A4 mRNA expression were observed when hepatocytes were treated with RIF 
compared to RBT or RPT. In contrast to data herein, a study with healthy volunteers 
found the AUC of MDZ was decreased 17% more when coadministered with RPT 
compared to RIF (380). However, at standard daily doses (10mg/kg), RIF, RBT and 
RPT average concentrations are approximately 2.3 μM, 0.3 μM and 15.7 μM, 
respectively (376, 377, 384). Of particular note, plasma concentrations of rifabutin in 
patients are comparatively low, and this may help rationalise the limited induction 
seen clinically by rifabutin. Thus, the spectrum of induction by RIF, RBT and RPT 
are different but the data should be interpreted in the context of differences in plasma 
concentrations seen clinically. The data should also be interpreted in the context that 
concentrations in hepatocytes and/or gut may exceed those found in the plasma of 
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patients. The unbound plasma concentration is often used to estimate clinical drug 
interactions. However, protein binding can be dependent on health status. For 
example, rifampicin is 87-91% bound in healthy individuals but 84-88% bound in 
tuberculosis-infected individuals (372). Nonetheless, it should be noted that previous 
investigations have shown effects at mRNA level are not always translated to activity 
(85, 271, 385).  
 
ATP binding cassette transporter (ABC), ABCB1, is a transmembrane efflux protein 
responsible for the removal of a broad range of bile acids, lipids and xenobiotics out 
of hepatocytes (see Chapter 1 for more detail) (30). RIF and RPT significantly 
induced ABCB1; hence an enhanced clearance of co-administered substrates may be 
predicted. Also, RIF, RPT, ethambutol and isoniazid are all substrates of ABCB1 (85, 
386, 387) suggesting a potential role in autoinduction and potential effects between 
drugs within a TB regimen. Polymorphisms within the ABCB1 gene may also affect 
RIF and RPT pharmacokinetics (30) although association studies with ABCB1 SNPs 
for other drugs have always been contradictory.  
 
The main hepatic influx protein, organic anion transporting polypeptide (OATP) 1B1 
mediates the sodium-independent uptake of a broad array of organic amphiphilic 
compounds (58) (see Chapter 4 for more detail). A significant upregulation of 
OATP1B1 mRNA was observed with 10 μM RIF. Given that RIF is itself a substrate 
for OATP1B1 (388) and that polymorphisms within the SLCO1B1 gene affect RIF 
pharmacokinetics (389), these data indicate an involvement of OATP1B1 in the 
reported RIF autoinduction (390). 
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Many RIF drug interactions arise during HIV treatment (375). Contraindications 
occur with the concomitant use of RIF with antiretrovirals due to marked PK 
interactions. For example, the AUC of amprenavir, efavirenz, indinavir, ritonavir and 
saquinavir is decreased by 82%, 26%, 92%, 35% and 70%, respectively (68, 369, 375, 
388, 391, 392). The majority of CYP3A4 substrates overlap with ABCB1 and 
OATP1B1 resulting in an enhanced pharmacokinetic (PK) shift. Significant induction 
by RPT was only evident for ABCB1 suggesting contraindications with antiretrovirals 
may be avoided/reduced with this RIF substitution. 
 
Current clinical trials are investigating high-dose daily RPT (Tuberculosis Trials 
Consortium Study 29X) and high-dose RIF (PanACEA Consortium) (393) as 
potential TB treatment shortening regimens. In vitro results suggest increasing the 
concentration of RPT may lead to clinically relevant DDIs mediated through ABCB1. 
Boeree et al., 2013, found 35mg/kg of RIF daily was safe and well tolerated over 14 
days and early bactericidal activity increased with increasing dose, with no apparent 
plateau (394). Trials are now being planned to assess the activity of high-dose RIF 
over 8 weeks.  
 
Parallel to optimising the use of rifamycins detailed above, novel innovative 
approaches utilising immunomodulating compounds to work in concert with 
bactericidal antibiotics are under investigation (395-397). Understanding and 
clarification of the human immunological response to mycobacterium tuberculosis 
proves an obstacle for the development of these compounds (373). Nevertheless, 11 
candidates for TB vaccination are undergoing trials (398-400). 
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Data herein suggest that concentration-dependent induction should be considered 
when interpreting results of ongoing trials of higher-dose RIF and RPT since it cannot 
be assumed that maximum autoinduction is achieved at standard doses. With the 
absence of an apparent ceiling as drug exposure increases (394), RIF doses above 
those used in the clinic today may lead to significant and highly variable DDIs, which 
is of considerable clinical concern.  
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CHAPTER 6 
 
Regulation of CYP3A4, ABCB1 and 
OATP1B1 gene expression by VDR 
and the effects of VDR SNPs 
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6.1 Introduction 
Vitamin D was identified over 90 years ago as an antirachitic substance (103). 
Humans are exposed to 2 primary sources of vitamin D: diet (mainly cod liver oil and 
oily fish) and via ultraviolet light (UV-B, 290-315nm) absorption (401). Upon UV-B 
exposure, 7-dehydrocholesterol is converted into cutaneous previtamin D3, which is 
spontaneously thermal isomerised into vitamin D3. As vitamin D3 enters the systemic 
circulation it is hydroxylated into 25-hydroxyvitamin D3 by cytochrome P450, family 
27, subfamily A, polypeptide 1 (CYP27A1) and further converted into 1α,25-
dihydroxyvitamin D3 (1α,25-(OH)2D3) (active vitamin D) by CYP27B1. 
 
Parathyroid hormone modulation of the CYP27B1 gene tightly regulates the levels of 
1α,25-(OH)2D3. However, other factors contribute to the circulating levels. For 
example, individuals located close to the equator maintain high levels of 1α,25-
(OH)2D3 all year round, skin pigmentation determines the amount of UV-B required 
to produce 1α,25-(OH)2D3, body surface area, duration spent outside and VDR single 
nucleotide polymorphisms (SNPs) (Table 6.1) can all alter the levels of 1α,25-
(OH)2D3 (218, 402, 403). In contrast, efforts to prevent the incidence of skin cancer 
through UV-B absorption (e.g. clothing, sun cream) may unintentionally result in 
vitamin D deficiency (404). 
 
Vitamin D receptor (VDR; NR1I1) is a class II steroid nuclear receptor (NR) 
responsible for mediating 1α,25-(OH)2D3 effects (405). High affinity binding of 
1α,25-(OH)2D3 to the VDR hydrophobic pocket, induces VDR heterodimerisation 
binding with retinoid x receptor (RXR) (406). The regulatory region of the target gene 
possess vitamin D receptor responsive elements (consisting of a direct repeat NR half-
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site, separated by 3 nucleotides (DR3)) which the heterodimer binds and 
transactivates (407), regulating bone mineralisation and resorption, calcium and 
phosphate homeostasis, parathyroid hormone synthesis and cell growth (408), within 
vitamin D responsive organs (intestine, parathyroid gland, kidney, bone) (88). To a 
lesser extent, the liver, pancreas, brain and muscle also express the VDR gene, which 
regulates many biological processes (403, 409, 410).  
 
Recent studies have identified several functioning cis-acting response elements for 
constitutive androstane receptor (CAR), pregnane x receptor (PXR) and VDR on the 
CYP3A4 gene promoter (an everted repeat, separated by 6 nucleotides in the CYP3A4 
proximal promoter and a xenobiotic responsive enhancer module with a functional 
direct repeat, separated by 3 nucleotides upstream of the CYP3A4 transcription 
activation site) (411-414). PXR and VDR have been found to synergistically increase 
CYP3A4 expression and activity in intestinal cell lines (103, 402). This effect has been 
observed in vivo with seasonal variations (fluctuations in 1α,25-(OH)2D3 
concentrations by UV-B intensity) apparent for CYP3A4 substrate concentrations. 
Plasma concentrations for tacrolimus and sirolimus differ between summer and winter 
by 7% and 17%, respectively (415).  
 
Many NRs and transcription factors regulate ATP-binding cassette, subfamily B, 
member 1 transporter (ABCB1) expression (416). VDR exhibits a similar homology to 
CAR and PXR (417) but only recently has been identified as a regulator of ABCB1 
expression in colon carcinoma cell lines (418-420), which contains vitamin D receptor 
response elements (421). Treatment with 1α,25-(OH)2D3 has been shown to double 
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the expression of ABCB1 in LS174T cells with the effect further enhanced upon 
ketoconazole treatment, mediated through VDR activation (422). 
 
Under normal physiological conditions, the solute carrier organic anion transporter 
family member 1B1 (OATP1B1) expression is restricted mainly to the liver but upon 
inflammation or cancer, expression of the influx transporter is not as firmly restricted 
(4, 423). For example, OATP1B1 is expressed in colon, pancreatic, ovarian and lung 
cancer (423). The significant role of OATPs in drug disposition and the occurrence of 
cancer through altered VDR expression, make this transporter and its potential for 
induction by VDR, of significant pharmacological relevance.  
 
Over 245 polymorphisms have been identified in the VDR gene of British Caucasians 
(424). Many VDR single nucleotide polymorphisms (SNPs) (Table 6.1) are associated 
with the occurrence and prognosis of disease through altered VDR structure and 
activity, but studies show very contrasting and controversial results (425-428). Hence, 
the work presented in this chapter focused on VDR SNPs that have been found to alter 
the function or activity of the protein. Transcriptional activity of VDR is influenced by 
a SNP in the 5’-regulatory region (-29649A>G, Cdx2, rs11568820), while the stability 
of VDR is affected by SNPs in the 3’-untranslated region (UTR) (IVS8-283G>A, 
Bsm1, rs1544410; 1056C>T, Taq1, rs731236; IVS8-49C>A, Apa1, rs7975232) and 
protein function is hindered by the addition of 3 amino acids in the VDR translation 
initiation codon (2T>C, Fok1, rs2228570) (429-431). 
 
Studies suggest the conventional and highly researched xenobiotic sensors PXR and 
CAR are not solely responsible for altered drug pharmacokinetics; fluctuations in 
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VDR activation by 1α,25-(OH)2D3 or VDR SNPs may also contribute to CYP3A4 
and/or ABCB1 substrate concentrations. Although 1α,25-(OH)2D3 has been shown to 
benefit human health (403), an upregulation of intestinal CYP3A4 and ABCB1 
through VDR activation may have a significant impact on drug-drug interactions, 
altered drug disposition, efficacy and toxicity. Within the intestine CYP3A4 is a 
dominant enzyme responsible for 1α,25-(OH)2D3 catabolism; hence gene induction 
could also contribute to altered cell homeostasis, calcium absorption and CYP3A4 
substrates including ketoconazole (402, 432). A further understanding and 
clarification of VDR expression, VDR SNPs and its targets in vivo is essential.  
 
The aims of this chapter were two-fold: to confirm the association between PXR and 
CYP3A4 expression and, PXR and ABCB1 expression in 84 human intestinal donors; 
and to further characterise any relationship between VDR expression and PXR, 
CYP3A4 and ABCB1 expression, and determine if VDR SNPs (rs2228570, 
rs11568820, rs731236, rs7975232, rs1544410) have an impact on the expression 
observed. 
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Table 6.1   
SNP
Alleles 
(ancestral) 
Chromosome
Chromosome 
Position
Strand
Location and 
characteristics
Effect of SNP
MAF/Minor Allele 
Count
Population Frequency Disease Association
PubMed 
Reference 
Number
rs7929 A>C/G 12  46522890 - UTR3 G=0.485/610 European A/A 0.372  A/C 0.398  C/C 0.23
17130574, 
19682379, 
S.S.Africa (Nigerian) A/A 0.372  A/C 0.469  C/C 0.159 18593774
S.S.Africa (Kenyan) A/A 0.35  A/C 0.538  C/C 0.112
Asian (Han Chinese) A/A 0.14  A/C 0.326  C/C 0.535
Asian (Japanese) A/A 0.118  A/C 0.459  C/C 0.424
rs17878969 12 48236407 - UTR3 Short tadem repeat -
>18 A-repeats = protection against 
HIV infection (L)
18205531, 
19450131, 
Altered mRNA stability
<18A repeats = association with 
VDDR type1
19052755
rs2228570 T>A/C/G 12 47070443 + Non-synonymous Low/medium risk A=0.266/334 European A/A 0.195  A/G 0.434  G/G 0.372
G allele = protection against HIV 
infection
21693626, 
21613960,  
Fokl Exon 2
Decreased VDR = decreased 
1α,25-(OH)2D3 levels
Asian (Han Cinese) A/A 0.186  A/G 0.512  G/G 0.302
19105801, 
18205735, 
Altered protein structure and 
capacity
Asian (Japanese) A/A 0.163 A/G 0.326  G/G 0.512
19760020, 
19584489, 
S.S.Africa (Nigerian) A/A0.036  A/G 0.312  G/G 0.655
10707958, 
20473893,  
S.S.Africa (Kenyan) A/A 0.028  A/G 0.352  G/G 0.62
19124512, 
19450131
rs3847987 C>A 12 47035619 + UTR3 A=0.149/187 European A/A 0.27  A/C 0.195  C/C 0.779
17130574, 
19105801, 
S.S.Africa (Nigerian)  A/C 0.124  C/C 0.876
21610492, 
15282199
S.S.Africa (Kenyan) A/A 0.007  A/C 0.105  C/C 0.888 C allele = T1D protection
Asian (Han Chinese) A/A 0.116  A/C 0.302  C/C 0.581
Asian (Japanese) A/A 0.047  A/C 0.349  C/C 0.605
(A)13/16/1
8/19/23/24
Base change eliminates the 
translation start site in exon 2, 
encoded protein is shortened by 3 
amino acids. The smaller protein 
exhibits less transcription activity
≥18 A-repeats = 
long (L, major 
allele),  <18 A-
repeats = short (S, 
minor allele) 
Increased VDR = increased 1α,25-
(OH)2D3 levels
C allele = protective against type 1 
diabetes (T1D)
Increased VDR = increased 1α,25-
(OH)2D3 levels
A allele = increased risk of COPD 
onset in men, protective marker 
against HIV infection
A allele = higher asthma morbidity, 
low spirometric measures, positive 
aeroallergen skin test, increased 
immunoglobulin E levels in 
A.American,  increased breast, 
ovarian and pancreatic cancer risk, 
increased risk of type 2 diabetes 
(T2D)
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Table 6.1  
SNP
Alleles 
(ancestral) 
Chromosome
Chromosome 
Position
Strand
Location and 
characteristics
Effect of SNP
MAF/Minor Allele 
Count
Population Frequency Disease Association
PubMed 
Reference 
Number
rs1544410 G>A 12 47037386 - Intron 8 Intronic enhancer A=0.280/352 European A/A 0.211  A/G 0.434  G/G 0.345
17135034, 
21365644, 
Bsml Low risk Asian (Han Chinese) A/G 0.047  G/G 0.953
19734102, 
18279374,  
Decreased VDR = decreased 
1α,25-(OH)2D3 levels
Asian (Japanese) A/G 0.244  G/G 0.756
20642435, 
20361340,   
S.S.Africa (Nigerian) A/A0.071  A/G 0.416  G/G 0.513
18161000, 
18086759
S.S.Africa (Kenyan) A/A 0.149  A/G 0.44  G/G 0.411
21198767, 
18205531
rs7975232 C>A 12 46525104 + Intron 8 Intronic enhancer C=0.482/606 European A/A 0.372  A/C 0.398  C/C 0.23
21548019, 
21198767, 
Apal Low risk S.S.Africa (Nigerian)  A/A 0.398  A/C 0.478  C/C 0.133
19622139, 
19499989, 
Variation in mRNA stability and 
protein structure 
S.S.Africa (Kenyan) A/A 0.448  A/C 0.455  C/C 0.0.98
19734102, 
18849534
Decreased VDR = decreased 
1α,25-(OH)2D3 levels
Asian (Han Chinese) A/A 0.14  A/C 0.326  C/C 0.535
Asian (Japanese) A/A 0.116  A/C 0.453  C/C 0.43
rs731236 C>T 12 47036308 - Cds-synonymous Medium risk G=0.280/352 European C/C 0.221  C/T 0.434  T/T 0.345
21816760, 
21664963, 
Taql Alters modulation of VDR S.S.Africa (Kenyan) C/C 0.1  C/T 0.344  T/T 0.556
19734102, 
19644412, 
Decreased VDR = decreased 
1α,25-(OH)2D3 levels
S.S.Africa (Nigerian) C/C 0.147  C/T 0.573  T/T 0.28
21168462, 
21076051, 
Exon 9 Asian (Han Chinese) C/T 0.024  T/T 0.976
17135034, 
17130574, 
 Asian (Japanese) C/T 0.235  T/T 0.765
21198767, 
19584489
rs11568820 A>G 12  46588812 - 5' UTR T=0.461/580 European A/A 0.035  A/G 0.336  G/G 0.628
12968672, 
19309297, 
Cdx2 Asian (Han Chinese) A/A 0.326  A/G 0.442  G/G 0.233
14991752, 
11450701, 
Asian (Japanese) A/A 0.247  A/G 0.435  G/G 0.318
18205531, 
18086759
S.S.Africa (Nigerian) A/A 0.995  A/G 0.045
A allele =protection against 
fracture, ovarian and prostate 
cancer
18936471, 
18086783
S.S.Africa (Kenyan) A/A 0.601  A/G 0.35  G/G 0.049
Functional effect, 
transcriptional 
activity
Sense/synonymo
us; Splicing 
regulation  
Anonymous 
polymorphism 
Decreased VDR = decreased 
1α,25-(OH)2D3 levels
A to G base substitution (referring 
to the minus strand) eliminates 
the Cdx binding site and reduces 
transcriptional activity of VDR to 
70% of the A allele
A/A = 2 fold increase in surgical 
menopause, association with 
melanogenesis, T1D, association 
with rapid progression to AIDS, 
increase VDR linked to HIV 
resistance 
bbaATT and BBAAtt haplotypes 
associated with increased ovarian 
cancer risk in Caucasian women
C allele = association with multiple 
sclerosis (MS), increase in surgical 
menopaus, associated with 
T1D/T2D
T allele = protection against MS 
but an increases chronic 
periodontitis, risk of pancreatic 
cancer 
G allele = decreased survival in 
NSCLC, protective against HIV, 
VDDR type 2A, homozygous 
require increased calcium for 
optimal vertebral mass accrual 
during adolescence
Chronic periodontitis higher freq of 
AA in Asians
A allele = associated with T1D, 
increased risk of asthma, 
protection from follicular 
carcinoma, development of 
sporadic pancreatic cancer
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Table 6.1 
 
SNP
Alleles 
(ancestral) 
Chromosome
Chromosome 
Position
Strand
Location and 
characteristics
Effect of SNP
MAF/Minor Allele 
Count
Population Frequency Disease Association
PubMed 
Reference 
Number
rs4516035 C>T 12 47097576 + Near gene 5 C=0.202/254 European C/C 0.203  C/T 0.508  T/T 0.288
21365644, 
20398755, 
(-)1012 locus of 
the promoter
S.S.Africa (Kenyan) C/C 0.007  C/T 0.21  T/T 0.783
19679055, 
19615888, 
S.S.Africa (Nigerian)  C/T 0.009  T/T 0.991
18205531, 
20046590, 
Asian (Han Chinese) C/T 0.044  T/T 0.956 19309297
Asian (Japanese) C/T 0.012  T/T 0.988
rs11574010 G>A 12 48298902 - Near gene 5 - A=0.006 Global  A/G 0.011  G/G 0.989
G allele = increased risk of MS in 
low sun exposure
19383647
Promoter region
rs11168287 A>G 12 46571681 + Intron - G=0.452/569 European A/A 0.333  A/G 0.5  G/G 0.167 21365644
Asian (Han Chinese) A/A 0.186  A/G 0.465  G/G 0.349
Asian (Japanese) A/A 0.111  A/G 0.533  G/G 0.356
S.S.Africa (Nigerian) A/A 0.55  A/G 0.383  G/G 0.067
rs739837 T>G 12 48238221 + 3 UTR - G=0.492/619 European A/A 0.23  A/G 0.398  G/G 0.372 G allele = associated with fair skin 19105801
Asian (Han Chinese) A/A 0.535  A/G 0.326  G/G 0.14
Asian (Japanese) A/A 0.43  A/G 0.453  G/G 0.116
S.S.Africa (Nigerian) A/A 0.168  A/G 0.531  G/G 0.306
S.S.Africa (Kenyan) A/A 0.14  A/G 0.448  G/G 0.413
A allele = association with 
increased breast cancer risk
A allele = association with non 
small cell lung carcinoma
A allele = risk of cutaneous 
melanoma
Decreased VDR = decreased 
1α,25-(OH)2D3 levels
A allele = significant role in 
melaloma disease progression, 
risk of cutaneous melanoma, 
linked with height in europeans
G allele = girls require more milk 
for for optimal vertebral mass 
accrual, protective against HIV
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Table 6.1 Selected VDR polymorphisms that result in altered levels of 1α,25-(OH)2D3 and are associated with disease (including gene 
characteristics and PubMed reference number). 
SNP
Alleles 
(ancestral) 
Chromosome
Chromosome 
Position
Strand
Location and 
characteristics
Effect of SNP
MAF/Minor Allele 
Count
Population Frequency Disease Association
PubMed 
Reference 
Number
rs2238135 G>C 12 48278190 - Intron 4 - G=0.243/306 -
19753122, 
19255064, 
17932346, 
17130574
rs3782905 C>G 12 48266167 - Intron 2 - C=0.241/303 European C/C 0.509  C/G 0.386  G/G 0.105
15282199, 
15282200,  
Asian (Han Chinese) C/C 0.644  C/G 0.311  G/G 0.044
20687218, 
19956101
Asian (Japanese) C/C 0.795  C/G 0.205
G allele = recurrence/progression 
of pancreatic cancer
S.S.Africa (Nigerian) C/C 0.633 C/G 0.3  G/G 0.067
rs2239179 A>G 12 47055317 + Intron 3 - C=0.335/421 European A/A 0.363  A/G 0.345  G/G 0.298
15282200, 
15651992, 
Asian (Han Chinese) A/A 0.512  A/G 0.419  G/G 0.007 19753122
Asian (Japanese) A/A 0.625  A/G 0.302  G/G 0.07
S.S.Africa (Nigerian) A/A 0.331  A/G 0.458  G/G 0.211
S.S.Africa (Kenyan) A/A 0.496  A/G 0.425  G/G 0.08
rs2239185 C>T 12 47042110 - Intron 6 G=0.494/621 S.S.Africa (Nigerian)  C/C 0.217  C/T 0.483  T/T 0.3
15282199, 
15282200,   
Asian (Han Chinese) C/C 0.533  C/T 0.333  T/T 0.133
15282200, 
20006704, 
Asian (Japanese) C/C 0.326  C/T 0.558  T/T 0.116
19745160, 
19622139, 
15282199, 
19753122
G allele = associated with lower 
bronchodilator responsiveness, 
increased risk of pancreatic cancer
C allele = associated with asthma 
susceptibility in childhood and 
adult asthma
C allele = associated with asthma 
susceptibility in childhood 
C allele = 2 fold increase in 
pancreatic cancer risk, enhanced 
BMD of the femoral neck
T allele = fluctuations in serum 
homocysteine and blood lead 
concentrations, increased risk of 
renal cancer
Decreased VDR = 
decreased 1α,25-
(OH)2D3 levels
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6.2 Materials and Methods 
6.2.1 Materials.  
Absolute™ QPCR Master Mix (2X), DNA polymerase, MgCl2, dNTPs and buffer 
were obtained from Thermo Fisher, (Loughborough, UK). Custom assays for VDR 
(rs11568820A>G, rs2228570A>G, rs1544410G>A, rs7975232C>A, rs731236C>T) 
allelic discrimination analysis were purchased from Applied Biosystems (Warrington, 
UK). Isopropyl alcohol and ethanol were obtained from Fisher Scientific 
(Loughborough, UK). White 96-well PCR plates (Hard-Shell
®
) and real-time PCR 
machines (Chromo4™) were obtained from Bio-Rad Laboratories Ltd (Hertfordshire, 
UK). Absolute™ QPCR clear adhesive plate covers were purchased from ABgene 
House (Surrey, UK). Genomic DNA extraction kit (QIAmp
®
) and enzymes were 
purchased from Qiagen Ltd (West Sussex, UK). All other materials were of highest 
analytical grade and purchased Sigma-Aldrich Ltd (Dorset, UK). 
 
6.2.2 Donor information  
Healthy human volunteers were recruited from the Royal Liverpool University 
Hospital. Each participant gave informed, written consent for extraction of whole 
blood and D2 intestinal biopsies and the study was approved by the local research 
Ethics committee. Gene expression and genotype analysis were completed in all 84 
donors. Ethnic origins were as follows; 4 Caucasian European, 75 Caucasian British, 
4 African and 1 Cantonese Chinese. Due to the small size of the different ethnic 
groups, it was not possible to assess the effect of ethnicity on vitamin D gene 
expression or SNPs. Donor age range was 19 years old to 88 years old with an 
average age of 60 years old. The cohort included 43 males and 41 females. 
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6.2.3 mRNA and cDNA Quantification 
mRNA was extracted from D2 biopsies using Trizol reagent and reverse transcribed 
using standard methodology as described in section 2.2.6 and 2.2.7.  
 
6.6.4 Quantitative real time-PCR 
A Chromo4™ real time-PCR (LifeTechnologies, UK) was used to determine the gene 
expression of selected genes (Table 2.2) and conditions were completed as described 
in section 2.2.8. 
 
6.2.5 Extraction of genomic DNA 
Whole blood donor samples were inverted, warmed to room temperature and 200 μl 
of sample added to 20 μl of Qiagen protease buffer in a sterile eppendorf. Following 
the addition of 200 μl lysis buffer AL, the samples were pulse-vortexed for 15 sec. 
Samples were incubated for 10 min at 56 
oC, 200 μl of 100% ethanol added to each 
sample and again pulse-vortexed for 15 sec. Without touching the rim, the sample 
solution was transferred to a spin column and centrifuged for 1 min at 6000 x g. The 
filter was removed to a clean collection tube and filtrate discarded. The sample was 
washed in 500 μl of wash buffer AW1 and centrifuged for 1 min at 6000 x g. The 
filter was again removed to a clean collection tube and washed further in 500 μl of 
wash buffer AW2 and centrifuged at 17000 x g for 3 min to dry the membrane 
completely. All filtrate was discarded. The filter was transferred to a new sterile 
eppendorf and 50 μl of elution buffer AE added to the membrane. The membrane was 
incubated for 3 min at room temperature and centrifuged for 1 min at 6000 x g to 
elute the genomic DNA (gDNA). The filter was discarded and gDNA 
spectrophotometrically analysed using a Nanodrop1000 (as per the method described 
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in section 2.2.6) to determine the concentration and purity. The sample was stored at -
20 
o
C for future use. 
 
6.2.6 Genotyping of VDR polymorphisms by real time-PCR based allelic 
discrimination 
Real time-PCR reactions were made to a total volume of 25 μl in a 96-well plate, 
comprising of the following ingredients: 2X Absolute™ QPCR Mix (12.5 μl) 
containing buffer, MgCl2, dNTPs and DNA polymerase (Thermo-Start™), 9.5 μl 
protease and nuclease free water, 40X primer/probe custom assay (0.625 μl) and 
genomic DNA (40 ng/μl) was added (each sample was completed in duplicate). To 
ensure specific amplification a negative control was included where water was 
substituted for the gDNA (6 wells). In addition, a positive control was included for all 
alleles (heterozygote, homozygous common allele and homozygous variant allele) (2 
wells/allele). The 96-well plate was covered with an Absolute™ QPCR optically clear 
adhesive film and centrifuged at 500 x g for 2 min, allowing the components to mix, 
remove air bubbles and ensure the ingredients had collected at the bottom of the well 
and to prevent evaporation during the heat cycling. 
The real time-QPCR thermal cycling was completed using a Chromo4™ PCR 
machine to genotype the five VDR polymorphisms rs11568820A>G, rs2228570A>G, 
rs731236C>T, rs1544410G>A, rs7975232C>A (Table 6.2). Thermal cycling 
conditions consisted of: 15 min at 95 
o
C to activate the enzyme, followed by 50 cycles 
of 15 sec at 95 
o
C for enzyme denaturation and 60 sec at 60 
o
C for annealing and 
extension. The Chromo4™ was set to excite FAM and VIC at a wavelength of 488nm 
and absorbance was read at 518 nm and 552 nm, respectively. The intensity of the 
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fluorescence for each dye/allele was recorded using Opticon Monitor™ software. 
Genotypes were determined from fluorescence intensity at endpoint. 
Table 6.2 Applied Biosystems Assay ID and sequence of the VDR polymorphism 
for SNP analysis by realtime-PCR. 
6-FAM: 6-carboxyfluorescein; VIC: vasoactive intestinal contractor 
The bold underlined style represents the site of the variant allele. 
 
6.6.7 Data analysis 
Results for categorical data were completed in duplicate for each donor and expressed 
as the median with interquartile range (IQR) unless stated otherwise. Distribution of 
the data was determined via Shapiro-Wilk test. Categorical data was compared using 
the Kruskal Walis or Mann-Whitney test. Univariate and multivariate linear 
regression analysis was completed (SPSS Statistics Software, Version 21, IBM) and 
to avoid false positives Bonferroni correction was applied. Pearson’s rank or 
Spearman correlation coefficient was used to assess the correlation of continuous 
data. Bonferroni correction: 
 
 
 
Gene SNP ID 
SNP 
Alleles 
Assay ID Assay Sequence ([VIC/FAM]) 
VDR rs2228570 A/G C__12060045_20 
GGAAGTGCTGGCCGCCATTGCCTCC[A/G]TCCCTGTA
AGAACAGCAAGCAGGCC 
VDR rs7975232 A/C C__28977635_10 
AAGGCACAGGAGCTCTCAGCTGGGC[A/C]CCTCACT
GCTCAATCCCACCACCCC 
VDR rs731236 A/G C___2404008_10 
TGGACAGGCGGTCCTGGATGGCCTC[A/G]ATCAGCG
CGGCGTCCTGCACCCCAG 
VDR rs11568820 C/T C___2880808_10 
ACCCATAATAAGAAATAAGTTTTTA[C/T]TGTGACCT
AGTTTACTCAGGAATAT 
VDR rs1544410 C/T C___8716062_10  
GAGCAGAGCCTGAGTATTGGGAATG[C/T]GCAGGCC
TGTCTGTGGCCCCAGGAA 
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6.3 Results 
6.3.1 Summary of gene expression analysis in D2 biopsies 
ABCB1, CAR and OATP1B1 expression were detectable in all samples; VDR 
expression was detectable in 76 out of 84 samples, PXR in 80 out of 84 samples and 
CYP3A4 in 81 out of 84 samples.  
 
6.3.2 Summary of genotype frequencies in D2 biopsies 
Genotype was characterised and achieved for 5 VDR SNPs in the D2 biopsies (Table 
6.3). Population frequencies were in agreement with published data (see Table 6.1). 
 
Table 6.3 VDR genotype frequencies in the donor D2 biopsies 
 
6.3.3 Univariate and multivariate analysis for associations with VDR expression 
Univariate linear regression analysis showed no associations with VDR expression 
and donor demographics/physical characteristics such as gender or age. VDR 
expression was correlated with PXR and CAR expression (p<0.0000001 and 
p=0.000001, respectively). Bonferroni corrected multivariate stepwise linear 
regression analysis confirmed PXR expression (p=0.002) was independently 
associated with VDR expression. However, CAR did not withstand Bonferroni 
correction (Table 6.4). 
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Table 6.4 Bonferroni corrected, multivariate analysis of VDR expression with 
donor demographics/physical characteristics, gene expression or genotype 
 
6.3.4 Univariate and multivariate analysis for associations of VDR expression with 
VDR SNPs 
The 5 VDR SNPs (rs11568820, rs731236, rs1544410, rs2228570, rs7975232) were 
compared to VDR mRNA expression. rs2228570 and rs7975232 were significantly 
correlated to lower expression in VDR (p=0.03 and p=0.04, respectively). All other 
SNPs had no significant effect on VDR expression (Table 6.5). 
 
 
Table 6.5 Effect of VDR SNPs on VDR gene expression (significance determined 
using Kruskal Walis test) 
 
VDR	Polymorphism	 Effect	on	VDR	expression	(p	value)	
rs11568820	 0.39	
rs731236	 0.26	
rs1544410	 0.25	
rs2228570	 0.03	
rs7975232	 0.04	
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Univariate linear regression analysis showed no associations with VDR expression 
and donor demographics/physical characteristics including gender or age. Bonferroni 
corrected univariate stepwise linear regression analysis confirmed VDR expression 
was correlated to the genotype rs2228570 (p=0.002) (Table 6.6).  
 
 
Table 6.6 Multivariate analysis of VDR expression with donor 
demographics/physical characteristics or genotype 
 
Due to the presence of 2 clear VDR expresser groups, for each VDR SNP, the donors 
were grouped into 2 classes (high and low VDR expressers) and association with 
VDR expression determined (Table 6.7). A statistically significant association was 
observed between rs2228570 (T allele) and VDR expression (p=0.024). No 
association was observed with VDR expression and any other SNP. 
 
VDR	 Univariate	
Covariate	
β	(95%	Confid
e
nce	
Interval)	
P		
Bonferroni	
Corrected	P	
Age	 0.013	(-0.016	–	0.041)	 0.39	 -	
Gender	 -0.145	(-1.109	–	0.818)	 0.76	 -	
rs11568820	 0.061	(-0.441	–	0.564)	 0.81	 -	
rs731236	 0.32	(-0.182	–	0.822)	 0.21	 -	
rs1544410	 0.342	(-0.159	–	0.844)	 0.18	 -	
rs2228570	 1.185	(0.571	-	-1.798)	 0.0002	 0.002	
rs7975232	 -0.461	(-1.496	-	0.575)	 0.38	 -	
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Table 6.7 Effect of VDR SNPs (when grouped as 2 classes; high and low VDR 
expressers) on VDR gene expression (significance determined using Mann-Whitney U 
test) 
 
The association of rs2228570 and VDR expression as 3 separate alleles or 2 groups 
(homozygous T allele and homo-/heterozygous C allele) are illustrated in Figure 6.1a 
and b). There was no significant difference in VDR expression between the C/C or 
C/T alleles. However, when compared to T/T allele, both C/C and C/T alleles 
expressed significantly less VDR mRNA (p<0.0001) (Figure 6.1a). The T allele 
impacts on the amino acid sequence, reducing the protein capacity and transcriptional 
activation (alters the initial AUG) hence the lower CYP3A4 and ABCB1 mRNA 
expression is to be expected. However, the C allele was associated with significantly 
lower VDR mRNA expression but more CYP3A4 and ABCB1 mRNA expression 
when compared to individuals homozygous for the T allele (p<0.001) (Figure 6.8, 
6.10). The results suggest the longer amino acid sequence has more efficient 
transcriptional activity (in comparison to the shorter sequence) but hinders the 
posttranslational activity. 
 
 
VDR	Polymorphism	 Effect	on	VDR	expression	(p	value)	
rs11568820	 0.84	
rs731236	 0.10	
rs1544410	 0.10	
rs2228570	 0.02	
rs7975232	 0.08	
 232 
 
 
Figure 6.1 Box plots illustrating the association between VDR rs2228570 (2T>C) 
(A) and VDR rs2228570 (2T>C) as 2 groups (high and low VDR expressers) (B) and 
VDR expression. Statistical analysis was conducted using a Mann–Whitney U test, 
*p, 0.05; **p, 0.01; ***p, 0.001. Data is expressed as median values (horizontal line) 
and IQR (bars) with outliers (donors) numbered 
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6.3.5 Univariate and multivariate analysis for associations with PXR expression 
Univariate linear regression analysis showed no associations with PXR expression and 
donor demographics/physical characteristics including gender or age. PXR expression 
was correlated with VDR and CAR expression (p<0.0000001 and p<0.0000001, 
respectively). Bonferroni corrected multivariate stepwise linear regression analysis 
confirmed VDR expression (p=0.001) and CAR expression (p=0.005) were 
independently associated with PXR expression (Table 6.8). 
 
 
Table 6.8 Bonferroni corrected multivariate analysis of PXR expression with 
donor demographics/physical characteristics or gene expression 
 
 
6.3.6 Univariate and multivariate analysis for associations of PXR with VDR SNPs 
The 5 VDR SNPs (rs11568820, rs731236, rs1544410, rs2228570, rs7975232) were 
compared to PXR mRNA expression. rs2228570 was significantly correlated to lower 
expression of PXR (p=0.03). All other SNPs had no significant effect on PXR 
expression (Table 6.9). 
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Table 6.9 Effect of VDR SNPs on PXR gene expression (significance determined 
using Kruskal Walis test) 
 
Univariate linear regression analysis showed no associations with PXR expression and 
donor gender or age. PXR expression was correlated with the genotype rs2228570 
(p=0.002). Bonferroni corrected multivariate stepwise linear regression analysis 
confirmed the VDR genotype rs2228570 (p=0.01) was independently associated with 
PXR expression (Table 6.10). 
 
 
Table 6.10 Multivariate analysis of PXR expression with donor 
demographics/physical characteristics or VDR genotype 
 
VDR	Polymorphism	 Effect	on	PXR	expression	(p	value)	
rs11568820	 0.53	
rs731236	 0.61	
rs1544410	 0.58	
rs2228570	 0.03	
rs7975232	 0.79	
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6.3.7 Univariate and multivariate analysis for associations with CAR expression 
Univariate linear regression analysis showed no associations with CAR expression and 
donor demographics/physical characteristics including gender or age. CAR expression 
was correlated with VDR and PXR expression (p=0.00001 and p<0.0000001, 
respectively). Bonferroni corrected multivariate stepwise linear regression analysis 
confirmed PXR expression (p=0.001) was independently associated with CAR 
expression. However, VDR did not withstand Bonferroni correction (Table 6.11). 
 
 
Table 6.11 Bonferroni corrected, multivariate analysis of CAR expression with 
donor demographics/physical characteristics or gene expression 
 
 
6.3.8 Univariate and multivariate analysis for associations of CAR expression with 
VDR SNPs 
The 5 VDR SNPs (rs11568820, rs731236, rs1544410, rs2228570, rs7975232) were 
compared to CAR mRNA expression. rs2228570 was significantly correlated with a 
lower expression in CAR (p=0.008). All other SNPs had no significant effect on CAR 
expression (Table 6.12). 
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Table 6.12 Effect of VDR SNPs on CAR gene expression (significance determined 
using Kruskal Walis test) 
 
Univariate linear regression analysis showed no associations with CAR expression and 
donor demographics/physical characteristics including gender or age. CAR expression 
was correlated with the genotype rs2228570 (p=0.02). However, the genotype 
rs2228570 did not withstand Bonferroni correction (Table 6.13). 
 
 
Table 6.13 Multivariate analysis of CAR expression with donor 
demographics/physical characteristics or VDR genotype 
 
 
VDR	Polymorphism	 Effect	on	CAR	expression	(p	value)	
rs11568820	 0.82	
rs731236	 0.90	
rs1544410	 0.93	
rs2228570	 0.008	
rs7975232	 0.58	
CAR	 Univariate	
Covariate	
β	(95%	Confid
e
nce	
Interval)	
P		
Bonferroni	
Corrected	P	
Age	 0.008	(-0.006	–	0.023)	 0.26	 -	
Gender	 0.223	(-0.219	–	0.736)	 0.39	 -	
rs11568820	 -0.125	(-0.407	–	0.156)	 0.38	 -	
rs731236	 0.013	(-0.254	–	0.317)	 0.83	 -	
rs1544410	 0.021	(-0.267	–	0.308)	 0.89	 -	
rs2228570	 -0.441	(-0.809	-	-0.073)	 0.02	 -	
rs7975232	 0.160	(-0.426	–	0.745)	 0.59	 -	
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6.3.9 Univariate and multivariate analysis for associations with CYP3A4 expression 
CYP3A4 mRNA expression was positively correlated with PXR and CAR mRNA 
expression but negatively correlated with VDR mRNA expression. Correlation 
coefficients, R
2
, ranged from 0.68 (p<0.0000001), 0.31 (p<0.0000001) and 0.38 
(p<0.0000001), respectively (Figure 6.2a, b, c). 
 
 
Figure 6.2 Scatter plot representing the correlation between CYP3A4 and PXR 
(A), CAR (B) and VDR (C) expression in 76 donors. 
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Univariate linear regression analysis showed no associations with CYP3A4 expression 
and donor demographics/physical characteristics including gender or age. CYP3A4 
expression was correlated with VDR, PXR, CAR, ABCB1 and OATP1B1 expression 
(p<0.0000001, p<0.0000001, p<0.0000001, p=0.000001 and p=0.001, respectively). 
Bonferroni corrected multivariate stepwise linear regression analysis confirmed PXR 
expression (p<0.0000005) was independently associated with CYP3A4 expression. 
However, VDR, CAR, ABCB1 and OATP1B1 expression were not statistically 
significant in the multivariate analysis (Table 6.14). 
 
 
Table 6.14 Bonferroni corrected, multivariate analysis of CYP3A4 expression with 
donor demographics/physical characteristics or gene expression 
 
 
6.3.10 Univariate and multivariate analysis for associations of CYP3A4 expression 
with VDR SNPs 
The 5 VDR SNPs (rs11568820, rs731236, rs1544410, rs2228570, rs7975232) were 
compared with CYP3A4 mRNA expression. rs2228570 was significantly correlated to 
lower expression of CYP3A4 (p=0.04). All other SNPs had no significant effect on 
CYP3A4 expression (Table 6.15). 
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Table 6.15 Effect of VDR SNPs on CYP3A4 gene expression (significance 
determined using Kruskal Walis test) 
 
Univariate linear regression analysis showed no associations with CYP3A4 expression 
and donor demographics/physical characteristics including gender or age. CYP3A4 
expression was correlated with the genotype rs2228570 (p=0.02). Multivariate 
analysis was therefore not conducted; the genotype rs2228570 did not withstand 
Bonferroni correction (Table 6.16). 
 
 
Table 6.16 Bonferroni corrected univariate analysis of CYP3A4 expression with 
donor demographics/physical characteristics or VDR genotype 
 
VDR	Polymorphism	
Effect	on	CYP3A4	expression		
(p	value)	
rs11568820	 0.35	
rs731236	 0.64	
rs1544410	 0.65	
rs2228570	 0.04	
rs7975232	 0.78	
CYP3A4	 Univariate	
Covariate	
β	(95%	Confid
e
nce	
Interval)	
P		
Bonferroni	
Corrected	P	
Age	 0.005	(-0.021	–	0.031)	 0.69	 -	
Gender	 0.327	(-0.561	–	1.215)	 0.47	 -	
rs11568820	 -0.307	(-0.777	–	0.163)	 0.20	 -	
rs731236	 -0.121	(-0.595	–	0.353)	 0.61	 -	
rs1544410	 -0.141	(-0.618	–	0.336)	 0.56	 -	
rs2228570	 -0.705	(-1.309	-	-0.102)	 0.02	 -	
rs7975232	 -0.015	(-0.996	–	0.996)	 0.98	 -	
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6.3.11 Univariate and multivariate analysis for associations with ABCB1 expression 
ABCB1 mRNA expression was positively correlated with PXR and CAR mRNA 
expression but negatively correlated with VDR mRNA expression. Correlation 
coefficients, R
2
, ranged from 0.78 (p<0.0000001), 0.31 (p=0.000001) and 0.29 
(p=0.000001), respectively (Figure 6.3a, b and c).  
 
 
Figure 6.3 Scatter plot representing the correlation between ABCB1 and PXR 
(A), CAR (B) and VDR (C) expression in 76 donors. 
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Univariate linear regression analysis showed no associations with ABCB1 expression 
and donor demographics/physical characteristics including gender or age. ABCB1 
expression was correlated with VDR, PXR, CAR, CYP3A4 and OATP1B1 expression 
(p<0.0000001, p<0.0000001, p=0.000001, p=0.00001 and p=0.0003, respectively). 
Bonferroni corrected multivariate stepwise linear regression analysis confirmed VDR 
and PXR expression (p=0.02, p<0.0000005, respectively) were independently 
associated with ABCB1 expression. However, CAR, CYP3A4 and OATP1B1 
expression were not statistically significant in the multivariate analysis (Table 6.17). 
 
 
Table 6.17 Bonferroni correct multivariate analysis of ABCB1 expression with 
donor demographics/physical characteristics or gene expression 
 
 
6.3.12 Univariate and multivariate analysis for associations of ABCB1 expression 
with VDR SNPs 
The 5 VDR SNPs (rs11568820, rs731236, rs1544410, rs2228570, rs7975232) were 
compared with ABCB1 mRNA expression. No significant effect on ABCB1 
expression was observed with any VDR SNP (Table 6.18). 
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Table 6.18 Effect of VDR SNPs on ABCB1 gene expression (significance 
determined using Kruskal Walis test) 
 
Univariate linear regression analysis showed no associations with ABCB1 expression 
and donor demographics/physical characteristics including gender, age or ethnicity or 
VDR genotype (Table 6.19). Therefore, multivariate analysis was not conducted. 
 
 
Table 6.19 Multivariate analysis of ABCB1 expression with donor 
demographics/physical characteristics or VDR genotype 
 
 
VDR	Polymorphism	
Effect	on	ABCB1	expression		
(p	value)	
rs11568820	 0.51	
rs731236	 0.52	
rs1544410	 0.55	
rs2228570	 0.19	
rs7975232	 0.56	
ABCB1	 Univariate	
Covariate	
β	(95%	Confid
e
nce	
Interval)	
P		
Age	 0.008	(-0.002	–	0.036)	 0.56	
Gender	 0.446	(-0.498	–	1.390)	 0.35	
rs11568820	 0.220	(-0.274	–	0.714)	 0.38	
rs731236	 -0.041	(-0.542	–	0.460)	 0.87	
rs1544410	 -0.020	(-0.525	–	0.484)	 0.94	
rs2228570	 -0.447	(-1.110	–	0.215)	 0.18	
rs7975232	 -0.093	(-1.122	–	0.936)	 0.86	
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6.3.13 Univariate and multivariate analysis for associations with OATP1B1 
expression 
In contrast to current literature a negative correlation was observed between 
OATP1B1 mRNA expression and PXR and CAR mRNA expression, with correlation 
coefficient coefficients ranging from 0.14 (p=0.001) and 0.29 (p=0.0000001), 
respectively (Figure 6.4a and b). A positive correlation was observed between 
OATP1B1 mRNA expression and VDR mRNA expression with a correlation 
coefficient of 0.14 (p=0.001) (Figure 6.4c). 
 
 
Figure 6.4 Scatter plot representing the correlation between OATP1B1 and PXR 
(A), CAR (B) and VDR (C) expression in 76 donors. 
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Univariate linear regression analysis showed no associations with OATP1B1 
expression and donor demographics/physical characteristics including gender. 
OATP1B1 expression was correlated with age, VDR, PXR, CAR, CYP3A4 and ABCB1 
expression (p=0.003, p=0.001, p=0.001, p=0.000001 and p=0.000035, respectively). 
Bonferroni corrected multivariate stepwise linear regression analysis confirmed age 
and CAR expression (p=0.04 and p=0.0003, respectively) were independently 
associated with OATP1B1 expression. However, VDR, PXR, CYP3A4 and ABCB1 
expression were not statistically significant in the multivariate analysis (Table 6.20). 
 
 
Table 6.20 Bonferroni corrected multivariate analysis of OATP1B1 expression 
with donor demographics/physical characteristics or gene expression 
 
 
6.3.14 Univariate and multivariate analysis for associations of OATP1B1 expression 
with VDR SNPs 
The 5 VDR SNPs (rs11568820, rs731236, rs1544410, rs2228570, rs7975232) were 
compared with OATP1B1 mRNA expression. No significant effect on OATP1B1 
expression was observed with any VDR SNP (Table 6.21). 
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Table 6.21 Effect of VDR SNPs on OATP1B1 gene expression (significance 
determined using Kruskal Walis test) 
 
Univariate linear regression analysis showed no associations with OATP1B1 
expression and donor demographics/physical characteristics including gender or VDR 
genotype. OATP1B1 expression was correlated with donor age (p=0.003). 
Multivariate analysis was therefore not conducted. Bonferroni corrected univariate 
stepwise linear regression analysis confirmed OATP1B1 expression (p=0.02) was 
independently associated with age (p=0.02) (Table 6.22).  
 
 
Table 6.22 Multivariate analysis of OATP1B1 expression with donor 
demographics/physical characteristics or VDR genotype 
VDR	Polymorphism	
Effect	on	OATP1B1	expression		
(p	value)	
rs11568820	 0.95	
rs731236	 0.64	
rs1544410	 0.56	
rs2228570	 0.37	
rs7975232	 0.53	
OATP1B1	 Univariate	
Covariate	
β	(95%	Confid
e
nce	
Interval)	
P		
Bonferroni	
Corrected	P	
Age	 -0.027	(-0.044	-	-0.010)	 0.003	 0.02	
Gender	 0.304	(-0.319	–	0.926)	 0.33	 -	
rs11568820	 -0.027	(-0.353	–	0.298)	 0.87	 -	
rs731236	 -0.129	(-0.456	–	0.198)	 0.43	 -	
rs1544410	 -0.111	(-0.441	–	0.219)	 0.50	 -	
rs2228570	 0.376	(-0.054	–	0.806)	 0.09	 -	
rs7975232	 -0.106	(-0.781	–	0.569)	 0.76	 -	
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6.3.15 Exploratory analysis of PXR between high and low VDR expressers 
When analysed as a whole group, the expression of VDR was negatively correlated 
with PXR mRNA expression (Figure 6.5a). However, due to the observation of 2 
distinct groups an arbitrary division for VDR expression was applied in subsequent 
exploratory analysis (VDR high expressers >-1.71). There was a significant difference 
in PXR mRNA expression between the 2 VDR groups (p<0.0000001) (Figure 6.5b). 
The correlation of PXR mRNA expression with low VDR expressers (Figure 6.5c) 
and high expressers (Figure 6.5d) was determined. Low and high VDR mRNA levels 
were positively correlated with mRNA expression of PXR when analysed separately, 
with correlation coefficients, R
2
, ranging from 0.11 (p=0.008) and 0.49 (p=0.03), 
respectively (Figure 6.5c and d). 
 
 
Figure 6.5 Correlations between VDR and PXR expression as a whole group (A), 
box plot of high and low VDR expressers (median values (horizontal line), IQR 
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(bars)) (B), scatter plot representing the correlation between low VDR expressers and 
PXR expression (C) and high VDR expressers and PXR expression (D) (high VDR 
expression >-1.71). 
 
6.3.16 Exploratory analysis of CAR between high and low VDR expressers 
A similar analysis was completed for CAR. There was a significant difference in CAR 
mRNA expression between the 2 VDR groups (p<0.00001) (Figure 6.6b). The 
correlation of CAR mRNA expression with low VDR expressers (Figure 6.6c) and 
high expressers (Figure 6.6d) was determined. Low and high VDR mRNA levels were 
positively correlated with mRNA expression of CAR when analysed separately, with 
correlation coefficients, R
2
, of 0.03 (Figure 6.6c and 6.6d). However, the correlation 
for each VDR group was not statistically significant. 
 
Figure 6.6 Correlations between VDR and CAR expression as a whole group (A),  
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box plot of high and low VDR expressers (median values (horizontal line), IQR 
(bars)) (B), scatter plot representing the correlation between low VDR expressers and 
CAR expression (C) and high VDR expressers and CAR expression (D) (high VDR 
expression >-1.71). 
 
 
6.3.17 Exploratory analysis of CYP3A4 between high and low VDR expressers 
A similar analysis was completed for CYP3A4. There was a significant difference in 
CYP3A4 mRNA expression between the 2 VDR groups (p<0.00001) (Figure 6.7b). 
The correlation of CYP3A4 mRNA expression with low VDR expressers (Figure 
6.7c) and high expressers (Figure 6.7d) was determined. Low and high VDR mRNA 
levels were positively correlated with mRNA expression of CYP3A4 when analysed 
separately, with correlation coefficients, R
2
, ranging from 0.09 (p=0.02) and 0.4 
(p=0.05), respectively (Figure 6.7c and d). 
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Figure 6.7 Correlations between VDR and CYP3A4 expression as a whole group 
(A), box plot of high and low VDR expressers (median values (horizontal line), IQR 
(bars)) (B), scatter plot representing the correlation between low VDR expressers and 
CYP3A4 expression (C) and high VDR expressers and CYP3A4 expression (D) (high 
VDR expression >-1.71). 
 
6.3.18 Combined analysis of genotype and gene expression 
To determine if the VDR SNP rs2228570 contributed to the observation of 2 distinct 
VDR expressing groups when compared with CYP3A4 expression, bivariate 
correlation was completed. As observed in Figure 6.8, the C allele was associated 
with less VDR expression and more CYP3A4 expression.  
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Figure 6.8 Scatter plot representing the correlation between VDR and CYP3A4 
expression. Each donor labelled according to their allelic expression of rs2228570 
(C/C = 0, C/T = 1, T/T = 2) 
 
 
6.3.19 Exploratory analysis of ABCB1 between high and low VDR expressers 
A similar analysis was completed for ABCB1. There was a significant difference in 
ABCB1 mRNA expression between the 2 VDR groups (p<0.00001) (Figure 6.9b). 
The correlation of ABCB1 mRNA expression with low VDR expressers (Figure 6.9c) 
and high expressers (Figure 6.9d) was determined. Low and high VDR mRNA levels 
were positively correlated with mRNA expression of ABCB1 when analysed 
separately, with correlation coefficients, R
2
, ranging from 0.1 (p=0.01) and 0.5 
(p=0.01), respectively (Figure 6.9c and d). 
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Figure 6.9 Correlations between VDR and ABCB1 expression as a whole group 
(A), box plot of high and low VDR expressers (median values (horizontal line), IQR 
(bars)) (B), scatter plot representing the correlation between low VDR expressers and 
ABCB1 expression (C) and high VDR expressers and ABCB1 expression (D) (high 
VDR expression >-1.71). 
 
 
6.3.20 Combined analysis of genotype and gene expression 
To determine if the VDR SNP rs2228570 contributed to the observation of 2 distinct 
VDR expressing groups when compared with ABCB1 expression, bivariate 
correlation was completed. As observed in Figure 6.10, the C allele was associated 
with less VDR expression and more ABCB1 expression.  
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Figure 6.10 Scatter plot representing the correlation between VDR and ABCB1 
expression. Each donor labelled according to their allelic expression of rs2228570 
(C/C = 0, C/T = 1, T/T = 2) 
 
6.3.21 Exploratory analysis of OATP1B1 between high and low VDR expressers 
A similar analysis was completed for OATP1B1. There was a significant difference in 
OATP1B1 mRNA expression between the 2 VDR groups (p<0.00001) (Figure 6.11b). 
The correlation of OATP1B1 mRNA expression with low VDR expressers (Figure 
6.11c) and high expressers (Figure 6.11d) was determined. Low and high VDR 
mRNA levels were positively correlated with mRNA expression of OATP1B1, with 
correlation coefficients, R
2
, ranging from 0.03 and 0.5 (p=0.009), respectively (Figure 
6.11c and d). However, the correlation for low VDR expressers was not statistically 
significant. 
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Figure 6.11 Correlations between VDR and OATP1B1 expression as a whole 
group (A), box plot of high and low VDR expressers (median values (horizontal line), 
IQR (bars)) (B), scatter plot representing the correlation between low VDR expressers 
and OATP1B1 expression (C) and high VDR expressers and OATP1B1 expression 
(D) (high VDR expression >-1.71). 
 
6.3.22 Combined analysis of genotype and gene expression 
To determine if the VDR SNP rs2228570 contributed to the observation of 2 distinct 
VDR expressing groups when compared with OATP1B1 expression, bivariate 
correlation was completed. As observed in Figure 6.12, the C allele was associated 
with less VDR expression and less OATP1B1 expression.  
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Figure 6.12 Scatter plot representing the correlation between VDR and OATP1B1 
expression. Each donor labelled according to their allelic expression of rs2228570 
(C/C = 0, C/T = 1, T/T = 2) 
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6.4 Discussion 
Complete functioning of the body’s defense mechanisms requires adequate levels of 
1α,25-(OH)2D3 to ensure production of antimicrobicidal proteins (e.g. cathelicidins), 
chemotaxis of immune cells and regulation of the adaptive and innate immune 
responses (433, 434). Whilst supplementation with vitamin D improves treatment 
outcome against conditions such as tuberculosis, psoriasis and vitamin D-dependent 
rickets (402, 403), alterations of drug pharmacokinetics (PK) may counter-balance the 
benefits and warrants further studies. 
 
This chapter focused on characterising associations in the human intestine between 
VDR expression and key drug disposition genes including, PXR, CAR, CYP3A4, 
ABCB1 and OATP1B1 in 84 healthy volunteers. In addition, the effects of 5 VDR 
SNPs known to regulate VDR expression were analysed. 
 
Known correlations involving PXR and CAR were analysed to provide confidence in 
subsequent analysis. In agreement with previous work, PXR was positively correlated 
to CYP3A4 expression (R
2
=0.68, p<0.0000001) (Figure 6.2a) (57, 402) and ABCB1 
expression (R
2
=0.78, p<0.0000001) (Figure 6.3a) (54, 435). Whilst OATP1B1 is a 
liver specific transporter regulated by the nuclear receptor PXR (436), recent studies 
have established alterations in environment (e.g. inflammation) and cell cycle (e.g. 
cancer) relax gene expression restrictions (433, 437). Currently there is no described 
association between PXR and OATP1B1 expression in the human intestine. The 
correlation between PXR and OATP1B1 reported here suggests that PXR may 
negatively regulate transcription of this transporter in the intestine (R
2
=0.14, p=0.001) 
(Figure 6.4a). PXR negative regulation of OATP1B1 in the intestine could represent a 
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novel pharmacological mechanism. Whilst CYP3A4 is induced by PXR the 
expression of OATP1B1 is reduced, and may thereby enable ‘control’ of 
OATP1B1/CYP3A4 substrate transport and metabolism, improving PK parameters. 
For example, inhibition of OATP1B1 in the hepatic uptake of drugs has lead to 
positive increases in plasma concentrations (4, 55, 375).  
 
CAR was also positively correlated to CYP3A4 expression (R
2
=0.31, p<0.0000001) 
(Figure 6.2b) (106) and ABCB1 expression (R
2
=0.31, p=0.00001) (Figure 6.3b) (438) 
whereas, a negative correlation was also observed between CAR and OATP1B1 
expression (R
2
=0.29, p=0.001) (Figure 6.4b). This negative association is in contrast 
to work by Svoboda et al., 2011. However, their work was completed in cell lines and 
animal models in comparison to the human donors studied here (Figures 6.2-6.4). 
Further analysis is warranted given OATP1B1 is a major determinant of drug PK (as 
described in Chapter 4). 
 
No significant associations with donor demographics/physical characteristics, gene 
expression and genotype were observed for VDR, CAR, CYP3A4 or ABCB1 (Table 
6.4, 6.6, 6.11, 6.13, 6.14, 6.16, 6.17 and 6.19). OATP1B1 mRNA expression was 
significantly associated with donor age (p=0.04) (Table 6.20 and 6.22). A significant 
independent association with PXR expression was observed however it did not 
withstand Bonferroni correction (Table 6.8). Substantial effects on drug disposition 
genes are associated with many PXR SNPs, which vary between populations (233, 
439, 440). However, due to the small cohort and lack of PXR SNPs analysed, this 
association requires further investigation. 
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Bonferroni corrected multivariate analysis identified VDR to be independently 
associated with PXR and ABCB1 expression (p=0.001 and p=0.02, respectively) 
(Table 6.8 and 6.17). However, VDR association with CYP3A4 and CAR expression 
did not withstand Bonferroni correction (Table 6.11 and 6.14). When the correlation 
coefficient of each gene with VDR expression was determined a negative correlation 
was observed (Figure 6.2-6.4). However, due to the presence of 2 significantly 
different VDR expressing groups (p<0.001) (each with their own positive correlation), 
further analysis compared high VDR expressers (>-1.71) and low VDR expressers (≤-
1.71) with each gene of interest. A positive correlation was observed with high and 
low VDR expressers and PXR expression (R
2
=0.11, p=0.008 and R
2
=0.49, p=0.03, 
respectively), CYP3A4 expression (R
2
=0.87, p=0.02 and R
2
=0.38, p=0.05, 
respectively) and ABCB1 expression (R
2
=0.1, p=0.01 and R
2
=0.49, p=0.01, 
respectively) (Figure 6.2-6.4). The associations observed are in agreement with 
previous in vitro work utilising intestinal cell lines (416, 418-420). Whilst a positive 
correlation was observed between high or low VDR expressers and CAR expression, 
the association was not statistically significant (Figure 6.6). The converse was found 
with high or low VDR expressers and OATP1B1 expression. However, this negative 
correlation was only statistically significant for high VDR expressers (R
2
=0.51, 
p=0.008) (Figure 6.11).  
 
Potential drug-drug interactions could be mediated by VDR and this requires further 
investigation. Recently, ketoconazole and 1α,25-(OH)2D3 were shown to enhance 
ABCB1 expression in the intestine via VDR activation (422). Furthermore, positive 
correlations have been found with VDR expression and CYP3A4 or ABCB1 in rat 
kidney, which resulted in a decreased 1α,25-(OH)2D3 plasma concentration and half-
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life (416).  Results herein suggest similar PK alterations and the occurrence of drug 
resistance could apply or be enhanced within the intestine. In addition, 1α,25-(OH)2D3 
is also metabolised by CYP3A4 (402).   
 
In vitro, 1α,25-(OH)2D3 induces CYP3A4 from 100 nM – 5 M (441). In the summer 
months in vivo 1α,25-(OH)2D3 blood concentrations range from 65 – 100 nM (442-
445) suggesting CYP3A4 may not be induced. However, blood concentrations may 
not be equivalent to levels where induction is observed (e.g. liver or intestine), thus 
seasonal therapeutic drug monitoring (TDM) may be beneficial, especially for 
conditions were TDM is rarely completed. 1α,25-(OH)2D3 has been shown to reduce 
the plasma concentrations of nifedipine (446). Moreover, the bioavailability of orally 
administered immunosuppressants and CYP3A4 mRNA expression levels in the 
intestine have been found to be significantly reduced in the summer months compared 
to the winter (415, 447). In agreement with previous studies, the strong correlations 
between VDR expression and key drug disposition genes (targets of CAR and PXR) 
suggest the NR competes with CAR/PXR for the transcription of target genes and 
VDR regulated genes may also be targets of the CAR/PXR pathways (88). 
 
Five SNPs (Table 6.1) with an impact on VDR expression were selected for analysis 
based on their previous characterisation in vitro and in vivo (rs11568820, rs2228570, 
rs731236, rs1544410, rs7975232) (Table 6.1). The VDR SNP rs2228570 was the only 
polymorphism that significantly altered VDR gene expression in this cohort (Table 6.5 
and Figure 6.1). The 2T>C substitution results in the formation of a variable length 
VDR that differs in its amino acid chain. If the substitution occurs in the first 
initiation site, the longer (427 amino acid) inactive VDR is produced (T allele). 
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However, if the variant translation begins at the second initiation site a short (424 
amino acid) VDR is formed (C allele) (448). In contrast to data herein, recent studies 
have linked rs11568820 and rs1544410 VDR SNPs with significantly decreased 
expression of CYP3A4 in intestinal biopsies (218, 421, 447). Possible reasons for this 
discrepancy may be due to the small sample size and/or lack of representative ethnic 
groups. In particular, the A/A genotype of rs1544410 has not been recorded in the 
Asian (Japanese or Han Chinese) population (Table 6.1). Whilst there is evidence of 
VDR regulating the drug transporters ABCB1 and OATP1B1 (420) there is no current 
data describing the effect of VDR SNPs on drug transport. The T allele was associated 
with decreased VDR transactivation capacity but higher mRNA expression (Figure 
6.8, 6.10 and 6.12) (448-452). To determine if the high/low VDR expressing groups 
observed throughout were a result of the rs2228570 SNP, the genotype of each donor 
was labeled in the correlation between VDR and CYP3A4, VDR and ABCB1, and VDR 
and OATP1B1 expression (Figure 6.8, 6.10 and 6.12). 48%, 41% and 52% of the 
donors in the low VDR expressing groups were found to possess the rs2228570 CC 
genotype in the correlation with CYP3A4, ABCB1 and OATP1B1, respectively. A 
further 39%, 34% and 41% possessed the rs2228570 CT genotype. These results 
further confirm the association of the T allele with decreased VDR protein expression 
as well as a novel reason for the observation of 2 distinct VDR expressing groups. 
This SNP may be of significant importance for ABCB1 and CYP3A4 mediated 
metabolism, therefore, further investigation is required. Multivariate analysis also 
confirmed VDR expression is dependent upon the SNP rs2228570 (Table 6.6). 
However, it should be noted the effect observed may also be due to the region of the 
intestine from where the biopsies were taken (data unavailable). Previous 
investigations have noted varying levels of gene expression throughout the intestine. 
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For example, as you move along the intestine the expression of intestinal genes 
reduces which is correlated to a decrease in glucose exposure (glucose acts as a 
carbon source and polarises the apical membrane) (453). 
 
In conclusion, we have identified associations between VDR expression with 
CYP3A4, PXR and ABCB1 as well as VDR rs2228570 polymorphism and CYP3A4 
expression. The results provide an insight into potential reasons for inter- and intra-
individual variability in drug disposition and additional complexity in induction 
mechanisms to those already established. To summarise, this work suggests VDR 
may be capable of controlling the basal and inducible expression of CYP3A4 and 
ABCB1. Further studies to investigate the role of VDR and its genetic variants on 
plasma drug concentrations and drug-drug interactions in the intestine are now 
warranted. 
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CHAPTER 7 
 
General Discussion 
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7.0 Discussion 
The efficacy and success of drug regimens results from several interlinking factors 
between the disease, an individual and their environment. Patient and disease 
characteristics can vary considerably between individuals hence, treatment can be 
very unique. One of the most demanding tasks in drug discovery is the accurate 
prediction of human in vivo pharmacokinetics (PK) and drug metabolism. It is of 
paramount importance that clearance, volume of distribution and half-life are 
calculated. To achieve this goal suitable in vitro models are essential. With the major 
route of clearance occurring via metabolism in the liver the increased use of primary 
human hepatocytes, recombinant enzymes or sub-cellular fractions with co-factors 
over the past 20 years have improved the success of in vitro analysis. However, as 
described in this thesis, the current model systems do not always provide a 
physiologically-relevant phenotype, and factors such as genotype and inter-individual 
variability play a substantial role. The findings herein detail important considerations 
for future study. 
 
The regulatory requirements of scientists to accurately perform in vitro analysis is a 
significant challenge. Production of an organotypic liver model tool will only be 
achieved through the concerted effort of numerous scientific departments. Though the 
obstacle is great, the aim to retain the phenotype and configuration of liver specific 
cell types in perfused conditions is clear. As described in Chapter 1 and 2, increased 
knowledge of factors influencing hepatic function and structure has been 
advantageous to allow application of improved culture methods. Understanding the 
relationships between cell-cells interactions and media/matrix effects on gene 
expression and cell function has been invaluable, yet duplicating the exact in vivo 
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environment still eludes us. Whilst our knowledge has improved, the increased 
complexity of new culture systems poses limitations. Incubation of multiple cell types 
in co-cultures can complicate the definition of drug metabolism and elimination 
hence, further analysis is required to determine the proportion of activity of the co-
incubated cells (237). Maintaining cells within an extracellular matrix sandwich 
prolongs incubation times however; the cells are not susceptible to transfection, 
limiting the range of studies that can be completed (240).  
 
The liver as a whole is divided into three zones. Major metabolic differences are 
evident between zone one (periportal region) and zone three (pericentral region) due 
to altered levels of enzymes, cell morphology and environment (240). It is key to 
note, DDIs and hepatotoxicity can be zone specific hence a major disadvantage of 
using primary human hepatocytes for in vitro analysis is their inability to represent the 
three microenvironments at any one time. Hence, technology is required to engineer a 
three zone organotypic model that will replicate not only decreasing oxygen levels but 
also mimic gene expression profiles, liver specific substrates and perfusion rate. 
Another caveat of using isolated primary human hepatocytes in in vitro studies is the 
inability to define the complex effect of lipids, metabolites and endogenous 
compounds by the portal vein on the liver as well as blood flow and subsequent 
xenobiotic metabolism in the liver.   
 
With longer incubation times, the recapitulation of microenvironments as well as the 
culture of many cell types, 3-dimensional (3-D) organotypic models offer a more 
representative and high-throughput system for analysing toxicity, metabolism, uptake 
and DDIs in comparison to current 2-dimensional models. However, cost and delicate 
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culture conditions currently hinder their use (237). Future possibilities include the 
combination of 3-D models with stem cells as well as the potential of pluripotent stem 
cells to provide a renewable source of organotypic cells. Whilst additional 
improvements are crucial, the advances in cell culture technologies and the potential 
to improve in vivo predictions is particularly encouraging. 
 
The primary focus of this thesis was to investigate nuclear receptor (NR)-mediated 
control of key hepatic and intestinal drug disposition genes in hepatic cell lines, 
cryopreserved primary human hepatocytes (Chapter 2 and others) and intestinal 
biopsies (Chapter 6). Whilst binding of NRs to their response elements governs the 
expression of cytochrome P450s (CYPs), ATP binding cassette transporters (ABCs) 
and organic anion transporting polypeptides (OATPs), this regulation is dependent 
upon the orchestration of NR co-regulators that facilitate NR activation or repression. 
For example, peroxisome proliferator-activated receptor-gamma co-activator 1-alpha 
(PGC1α) binds to pregnane x receptor (PXR), activating the NR, which then initiates 
the transcription of CYP3A4 (206, 207, 288, 292). In chapter 3, we demonstrated for 
the first time that PGC1α and growth arrest and DNA damage inducible 45-beta 
(Gadd45β) are required for CYP3A4 activity and expression in hepatic cells and 
manipulation of these NR co-activators allows the production of a more 
physiologically relevant phenotype. Many drugs have also been shown to induce (to 
varying amounts) the expression of key drug disposition genes mediated by the 
activation of PXR or constitutive androstane receptor (CAR) (Chapter 5) (146, 147, 
152, 381). Furthermore, the contribution by drug transporters to PK variability is 
becoming more apparent, with the US Food and Drug Administration (FDA) 
requiring rigorous in vitro transporter assays. Chapter 4 details the significance of 
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influx transporters in the hepatic uptake of drugs achieved by the optimisation and 
application of a method in primary human hepatocytes. Additionally, drug 
transporters and CYPs were analysed in intestinal biopsies to investigate the role of 
genetic variability and donor demographics, to further outline the importance of all 
factors and considerations to allow complete definition of PK phenotype (Chapter 6).  
 
Reasons why cell lines display variable phenotypes has been discussed previously, 
and include the lack of biological stress factors (e.g. xenobiotic insult, inflammatory 
proteins), absence of hepatic blood flow, artificial media and supplements, artificially 
high oxygen and unrestricted cell replication but the exact mechanisms are yet to be 
defined and require further analysis. Marked differences in drug disposition genes 
between Huh7 and HepG2 cell lines have been outlined previously (67, 89, 101, 105, 
246, 261, 274, 418). However, for the first time a comprehensive analysis of NR co-
regulator expression has been completed here. The reasons for the differences 
between the cell lines themselves and primary cells requires further investigation 
particularly looking at the protein expression of the co-regulators to define if the 
discrepancy is due to post-transcriptional, post-translational or transcriptional 
mechanisms. It is interesting to note, previous work has found ABCB1 is induced in 
transformed cell lines by non-transcriptional mechanisms (454).  
 
NRs act as a regulatory switch for drug disposition target genes that determine PK, 
though they are also involved in cell growth, differentiation and apoptosis (111). 
Hence, the low levels observed in hepatoma cell lines were to be expected but the 
causes, as yet, are to be characterised. The absence of certain CYPs and/or drug 
transporters could shunt the metabolism/transport of particular substrates into other 
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CYP/drug transporter pathways and requires further investigation. The hypothesis that 
alteration of NR co-regulator profiles in hepatoma cell lines may increase NR 
expression and subsequently improve PK predictions was determined here. This thesis 
provides novel evidence linking 2 co-activators (PGC1α and Gadd45β) to the activity, 
expression and inducibility of CYP3A4 in HepG2 cells. Interestingly, concentration-
dependent induction was not observed with single transfections. This implies transient 
transfection with NR co-regulators only partly rectifies the problem when generating 
a hepatocyte-like cell line. However, when combined into a complex transfection, a 
strong concentration dependent induction pattern was observed. The slight decrease in 
CYP3A4 activity but increased induction capability of the complex transfection poses 
many questions but it is tempting to speculate these differences are mediated through 
co-activator crosstalk to achieve an optimal effect. To further support this hypothesis, 
histone deacetylase 1 (HDAC1) mRNA expression was reduced to levels similar of 
primary human hepatocytes in complex transfected cells. Specific to protein 
expression, single transfections resulted in an increase of the other co-activator, this 
may be due to post-translational effects stabilising the protein with no change in 
mRNA but warrants further investigation and it would be useful to determine if this 
effect is specific to the co-activators in question. It is exciting to note, CYP3A4 
mRNA induction by rifampicin (RIF) in the complex transfected cells was similar to 
that observed in the primary human hepatocytes in Chapter 5. The generation of a 
stable cell line would be hugely beneficial but further analysis of the cells should 
include characterisation of hepatospecific genes (e.g. AldoB, PEPCK, OTC), cell 
growth, proliferation and effects of nutrition compared to a larger group of hepatocyte 
donors.  
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This work focused on co-regulators that have been linked to CYP3A4 activity, but 
with the significant substrate overlap between CYPs and drug transporters it was 
notable that the transfections had no effect on drug transporter expression. Following 
the success of these transfections it would be beneficial to identify co-regulators 
specific to drug transporters to allow cell line manipulation and the possibility of dual 
in vitro transporter and CYP analysis. The general strategy presented in Chapters 2 
and 3 may provide a means to explore such mechanisms in future work. 
 
The role for OATP1B1 has recently been demonstrated (and further confirmed in this 
thesis) as a significant factor in the uptake of the protease inhibitor, lopinavir as well 
as pitavastatin, rosuvastatin, olmesartan and valsartan (49, 50, 53). Early in vitro 
predictions of drug transport could improve the accuracy of PK predictions and 
success of lead compounds becoming successful therapies. In agreement with 
previous work (33, 34, 42, 45, 54, 56, 230, 261), the expression of drug transporters 
varies considerably between individuals and cell type (e.g. hepatic cells, Chapter 5 
and intestinal cells, Chapter 6), which is further influenced by drug transporter 
genetics. The OATP1B1*15 haplotype results in a 3.1-fold increase in plasma 
exposure of pitavastatin (328) hence early added detail could allow pre-clinical 
characterisation of potential DDIs. Application of the assay optimised in Chapter 4 to 
include a wider range of drug transporters (particularly those required for analysis by 
the FDA) is likely to have a broad importance in determining relative contribution 
that individual transporters play in drug disposition. A key strength of this approach is 
assessment of individual transporter function at physiologically relevant protein 
density on the backdrop of other relevant proteins, which may be important. 
 
 268 
A significant cause of drug failure is DDIs; applications such as those listed above 
could provide a platform for improved planning of drug regimens. Altering drug 
regimens may decrease DDIs but understanding the complete PK profile of existing 
drugs is essential. As previously described and presented in Chapter 5, RIF is a potent 
CYP3A4 inducer with a relatively short half-life whilst rifapentine (RPT) a potential 
RIF alternative has lower induction capabilities. However, RPT has a significantly 
longer half-life therefore any induction could be significantly exacerbated by the 
longer duration of action. As found in Chapter 5, RIF significantly increases ABCB1, 
OATP1B1 and CYP3A4 mRNA expression in primary human hepatocytes which in 
vivo would be predicted to correlate to a significantly altered PK profile to those 
previously predicted. RPT significantly induced ABCB1 suggesting contraindications 
with this rifamycin may be reduced, but as the drug is also a substrate for the 
transporter the minimum effective concentration of RPT may not be reached due to 
extensive efflux. Further analysis of the rifamycins in clinical studies is warranted to 
allow a complete PK picture to be determined. In addition, protein analysis of the 
observed in vitro induction is essential as well as determining free drug concentrations 
and the drug concentration at the site of action and/or within the specific metabolic 
tissue. 
 
Vitamin D can be used in combination with RIF-based tuberculosis treatment. 
However, as described previously, vitamin D induces CYP3A4 expression and 
activity (218, 415). Omitting vitamin D from the drug regimen may out weigh the 
benefits of the additional antimicrobicidal properties due to the additional CYP3A4 
induction potential. Similar to the method applied in Chapter 5, it would be interesting 
to determine the effect on CYP3A4 induction in primary human hepatocytes with and 
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without vitamin D supplemented RIF, as well as the antimicrobial effects in a clinical 
setting. 
 
PK is evidently influenced by genetic factors. Rather than concentrating solely on the 
genotype of ADME genes, the work herein considers polymorphisms in the regulators 
that mediate these genes (Chapter 6). For example, variability in the gene sequences 
of PXR as well as CYP3A4, OATP1B1 and ABCB1 have demonstrated the 
significance of PK variability (e.g. plasma exposure or drug-drug interactions) of 
HMG-CoA reductase inhibitors and antiretroviral drugs (49, 234, 438). In addition to 
CAR and PXR, recent studies have found vitamin D receptor (VDR) is significant in 
altering PK (88, 103, 123, 218, 402, 403, 406, 415, 417-420, 455, 456). VDR has 
>200 known polymorphisms, 5 of which were analysed in this thesis. A novel pattern 
for the polymorphism rs2228570 was found herein. The polymorphism produced 2 
distinct VDR expressing groups that were significantly correlated to high or low 
CYP3A4 expression (Chapter 6). This SNP may influence the efficacy of treatment of 
drug regimens by decreasing CYP3A4 expression in the intestine. This, coupled with 
a decrease in efflux drug transporter expression may negatively impact drug therapy. 
For example, a decrease in the expression of efflux proteins (demonstrated in Chapter 
6 with ABCB1), may increase the intracellular accumulation, accompanied with 
reduced metabolism may result in significant toxicity or DDIs. Furthermore, similar 
correlations were observed when VDR expression was compared to PXR and CAR 
expression, suggesting VDR SNPs may additionally complicate drug therapy. In 
contrast, an increase in influx transporters (for example, OATP1B1) with a decrease 
in CYP3A4 expression may contribute to significant adverse effects. The data 
presented here highlight the importance of the polymorphic nature of VDR. These 
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data suggest polymorphisms in the co-activators (identified in Chapter 2) should be 
considered to determine their effect on PXR and CAR expression. In addition, the 
overlap in target genes between CAR, PXR and VDR suggest the induction by the 
rifamycins in Chapter 5 may be a concerted effect of all 3 NRs. Genotyping of the 6 
primary human hepatocyte donors for VDR and VDR co-regulator SNPs may provide 
reasons for the high variability observed, notwithstanding that it is difficult to make 
meaningful conclusions on genetic analysis in so few individuals.   
 
Here, a positive correlation was observed between VDR expression and PXR or 
ABCB1 expression. In the intestine, drug induced activation (e.g. RIF) of CYP3A4 
and CYP24A1 by PXR has been found to decrease the expression of vitamin D3 and 
increase the hydroxylation of vitamin D3, respectively. However, drugs (e.g. RIF) can 
also induce VDR expression, which activates CYP3A4 expression and activity. Thus, 
PXR may play a dual role for VDR target genes and vice versa (154). However, this 
requires further analysis. It would be useful to identify the levels of VDR and VDR 
specific co-regulators between hepatic cell lines and primary human hepatocytes to 
determine if the contribution of the NR has a similar significance on drug disposition 
genes within the liver. 
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In summary, this thesis has focused on specific NR mechanisms and their 
interrelationship with pharmacological and PK parameters. Mechanisms regulating 
drug disposition genes have been outlined and further confirmed as fundamental 
parameters that are central in determining drug-drug interactions and individual PK 
(Figure 7.1). The bioavailability and absorption of drugs are critically regulated by 
uptake and efflux transporters that govern the disposition and efficacy profiles of 
orally administered drugs. During the course of this thesis an assay for determining 
the relative uptake of drugs by OATP1B1 and a cell line with a physiologically 
relevant CYP3A4 phenotype were developed to enable simple and relatively high 
throughput analysis. Novel associations between NR gene expression and 
polymorphisms were defined and the impact on drug disposition genes was also 
presented.  Generation of the models has allowed many questions to be answered but 
accordingly many questions have arisen and are yet to be resolved. Nonetheless, a 
solid platform has been constructed for future studies to further investigate these 
issues.  
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